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Substance use is a leading cause of morbidity and mortality that is under-identified 
in primary care settings. Screening for substance use in primary care requires an efficient and 
accurate approach. Exploring methods to collect sensitive and accurate data about substance use 
and related problems is important to inform research practice and clinical care. Using RCT data 
comparing computerized and therapist delivered brief intervention for substance use problems, 
the present study had a unique opportunity to compare computerized anonymous and 
confidential surveys to a confidential, interviewer-administered assessment in a sample of N = 
540 males and females at risk for heavy/problem alcohol and/or drug use and recruited through 
an urban primary care clinic. This study also compared self-reports of recent substance use to 
urine drug assay findings. Finally, the study identified correlates of any recent (past 30-day) use 
and days of alcohol and other drug use per week in the past 30 days. The sample was 39% male, 
78% African American, and had a mean age of 45.1 years. More participants self-reported 
alcohol use on the computerized, anonymous screen, including any recent (past 30-day) alcohol 
use, binge drinking, and problems associated with alcohol use. Any recent (past 30-day) illicit 
 vii 
 
 
  
 
drug use rates were highest on the confidential computerized survey, and quantity/frequency of 
alcohol use as well as frequency of illicit drug and prescription drug misuse were highest on the 
interviewer-administered assessment. Overall concordance rates between interviewer-
administered assessment and urine drug screening (UDS) were 72% or higher for each substance, 
driven by large subgroups with no use. Among participants with discordant use, marijuana and 
heroin / opiate use were the only substance with lower detection on UDS than self-report. 
Exploratory analyses examined psychosocial correlates of self-reported substance use. 
Anonymously screening for recent substance use followed by an interviewer-administered 
assessment provides the most parsimonious method to identify sensitive data about substance use 
and related behaviors in primary care. This approach has the potential to facilitate 
implementation of substance screening into demanding clinical environments. 
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A Comparison of Computer- and Interviewer-Administered Measures to Identify Heavy/Problem 
Alcohol and Other Drug Use in Primary Care Patients 
 
 
Substance misuse constitutes a major public health problem; one that costs the United 
States (U.S.) over $740 billion annually through health care costs, lost work productivity, and 
crime (NIDA, 2017). Substance misuse can result in a diagnosis of substance use disorder (SUD) 
or a person becoming addicted, necessitating evidence-based treatment services. However, of the 
estimated 21.2 million people age 12 and older (7.8%) in need of substance use treatment, many 
do not engage in requisite specialty treatment (Substance Abuse and Mental Health Services 
Administration [SAMHSA], 2019) and are under-recognized in medical settings (Edlund, 
Unutzer, & Wells, 2004; Rehm et al., 2016). In efforts to destigmatize and explain more fully the 
complexity of this chronic disease, the American Society of Addiction Medicine (ASAM) 
redefined addiction in 2019. The updated definition reads: 
Addiction is a treatable, chronic medical disease involving complex interactions among 
brain circuits, genetics, the environment, and an individual’s life experiences. People 
with addiction use substances or engage in behaviors that become compulsive and often 
continue despite harmful consequences. Prevention efforts and treatment approaches for 
addiction are generally as successful as those for other chronic diseases. (p 2).     
There is growing recognition that evidence-based treatment services can play important 
roles in the full spectrum of addiction care, with recent efforts focusing on the provision of brief, 
evidence-based nonpharmacologic therapy for SUDs, such as Screening, Brief Intervention, and 
Referral to Treatment (SBIRT) (Babor et al., 2017; Broyles et al., 2013; Jhanjee, 2014). 
Screening for substance use in adult primary care settings is recommended by the United States 
Preventive Services Task Force (USPSTF), ranking as the top 10 highest prevention priority for 
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adults in the U.S (USPSTF, 2018; USPSTF, 2019). The U.S. Surgeon General’s report on 
addiction recommends screening for other drug use as well as alcohol, which is the current 
approach of federally funded SBIRT programs (HHS, 2016; SAMHSA, 2020a).  
A key component of the SBIRT approach is the linking of screening and assessment 
results with appropriate early intervention services. The purpose of screening is to identify 
individuals whose levels, patterns, or consequences of substance use needs further assessment or 
referral to services based on risk level (SAMHSA, 2020a). Studies often use self-report to 
measure alcohol and drug use, but under-reporting is common. A growing body of literature has 
identified several factors that may affect the reliability and accuracy of self-reports, such as 
degree of anonymity, extent to which the behavior assessed is illicit or socially undesirable, the 
method by which data is collected (face-to-face interview or questionnaire), and whether 
biological verification is planned (Chermack et al., 2000; Bone et al., 2016; Fleming et al., 2007; 
Harrison & Hughes, 1997).   
Further, commonly used methods for screening and assessing substance use are designed 
with different purposes and vary widely in the time frame they capture; thus, each has specific 
strengths and weaknesses (Kaner et al., 2009; O’Conner et al., 2018). This variation in screening 
practices complicates the ability to clearly define best practices. Structured interview-
administered substance use screening and assessment approaches are thought to be most 
accurate, but they are challenging to implement in practice because they require staff time and 
training (Williams et al., 2011). Semi-structured, interviewer-administered instruments that use 
supplemental memory aids during the assessment process (e.g., Timeline-Follow-Back, TLFB) 
(Sobell & Sobell, 1992) to facilitate recall demonstrate excellent reliability and validity 
(Rosenbaum et al., 2006), but require staff time and training. Brief screening tools have been 
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developed to efficiently identify alcohol and drug use, but these do not provide enough 
information about the specific substances used, or the patient’s risk level, to guide clinical 
actions. Biologic measures also have limitations, including high cost, varying windows for 
detection of different drugs, and ease of collection (ASAM, 2017).  
Technology provides new possibilities for standalone or facilitated screening.  For 
example, Audio Computer-Assisted Interview (ACASI) technology allows for self-administered 
method that facilitate confidential administration, allowing patients to respond with lower threat 
of social desirability bias (Dolezal et al., 2012; Estes et al., 2010; Richter & Johnson, 2001). 
However, the impact of ACASI technology and degree of privacy (e.g., anonymous vs. 
confidential) on the way respondents answer questions across alcohol and illicit drug use 
outcomes, including prescription drug misuse, has largely been unexplored. Also, little is known 
about the agreement between interviewer-administered screening and assessment questionnaires 
and other questions on the frequency of substance use administered via ACASI. The process of 
validating self-report against self-report leaves opportunities for respondents to deny substance 
use in both conditions (Ondersma et al., 2012); however, substantial disagreement would 
indicate that studies using one method should not be compared to similar studies that used the 
other method, impairing the field’s ability to aggregate data across studies.   
The present study compares self-reports of alcohol and illicit drug use, and prescription 
drug misuse across different screening measures and methods of administration and across 
varying levels of privacy. This study also compares self-reports of recent substance use to urine 
drug toxicology findings. Data were part of a randomized clinical trial (RCT) comparing 
computerized and therapist delivered brief intervention for substance use problems. Participants 
were identified through an urban primary care clinic using an anonymous, computer-
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administered health screen (CAHS) with embedded questions about alcohol and other drug use.  
Data was collected on a diverse range of variables including patient demographics, drug and 
alcohol use, family history of substance use, living environment, and social supports.  
Participants (N=713) meeting criteria for heavy/problem substance use were randomized to one 
of four study arms: CAHS only (standard care true control), confidential, computerized 
assessment only intervention (CA), confidential, computerized assessment plus computer-
delivered brief intervention (CACI), or confidential, computerized assessment plus therapist-
delivered brief intervention (CATI).   
The present study was conducted with the baseline data for 540 individuals who 
completed the CAHS and were randomized to three of the four study arms. Those in the standard 
care control group were excluded as they did not complete the measures examined in the present 
study. This research directly compares an anonymous screen, confidential, computerized 
assessment, and confidential, interviewer-administered assessment. Other psychosocial and 
health disparity variables (e.g., age, gender, race, marital status, years of education, ethnicity, 
number of medical conditions) were also examined to identify of self-disclosure of any alcohol 
and other drug use as well as substance use per week in the past 30-days. 
The present study had four primary aims: 
I. Aim 1: To compare rates of participant self-disclosure of alcohol and illicit drug use and 
prescription drug misuse obtained by an anonymous, computer-administered health 
screen to those obtained by a confidential, computerized assessment and interviewer-
administered research assessment. Four hypotheses were tested: 
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a. Hypothesis 1: Participants will report more recent binge drinking days (past 30) 
on the anonymous, computer-administered screener (CAHS) compared to the 
confidential, interviewer-administered assessment (IARA).  
b. Hypothesis 2: Participants will report consuming, on average, more drinks per 
week over the past 30 days by anonymous, computer-administered screener 
(CAHS) compared to the confidential, computerized research assessment 
(CARA). The study also hypothesized that participants will report consuming, on 
average, more drinks per week by CAHS compared to the interview-administered 
assessment (IARA). 
c. Hypothesis 3: Participants will report, on average, more days of drug use per 
week over the past 30 days by anonymous, computer-administered screener 
(CAHS) compared to confidential, computerized assessment (CARA). The study 
also hypothesized that participants will report, on average, more days of drug use 
per week by CAHS compared to the interview-administered assessment (IARA). 
d. Hypothesis 4: Participants will report, on average, more days of prescription drug 
misuse per week by anonymous, computer-administered screener (CAHS) 
compared to confidential, computerized assessment (CARA). The study also 
hypothesized that participants will report, on average, more days of drug use per 
week by CAHS compared to the interview-administered assessment (IARA). 
II. Aim 2: Compare endorsement of alcohol and/or drug use related problems between the 
anonymous, computer-administered screener and confidential, computerized assessment.  
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a. Hypothesis 1: Participants will be more likely to score positive for problematic 
substance use on the anonymous, computer-administered screener compared to 
the confidential, computerized assessment. 
III. Aim 3: To compare agreement between self-report of recent drug use and biological 
measures (i.e., urinalysis). 
a. Hypothesis 1: Proportion of illicit drug use and non-medical prescription drug use 
will be higher by urine assay compared to self-report.  
IV. Aim 4: To identify correlates (e.g., age, gender, race, marital status, years of education, 
ethnicity, number of medical conditions, mental health-related conditions, etc.) of self-
disclosure of any alcohol and other drug use as well as substance use per week in the past 
30-days.  
Review of the Literature 
 
Epidemiology of Substance Use Disorders  
 
Substance misuse, defined as the use of alcohol or drugs in a manner, situation, amount, 
or frequency that could cause harm to the user or those around them (The U.S. Department of 
Health and Human Services [HHS], 2016) is a problem that affects millions of Americans (Grant 
et al., 2017; Rudd et al., 2016; Stahre et al., 2014). The economic, psychosocial and public health 
impact of increased mortality and morbidity is substantive (Esser et al., 2020; Gomes et al., 
2018; HHS, 2016; Johnson et al., 2014; Peacock et al., 2018; Rehm, 2020; Smith et al., 2015).   
The National Survey on Drug Use and Health (NSDUH) in 2018, the most recent year for 
which drug use data are available, found that 16.6 million Americans reported heavy drinking in 
the past month and 31.9 million people were users of at least one illicit drug (SAMHSA, 2019). 
Also, in 2018 an estimated 16.9 million Americans misused prescription drugs at least once in 
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the past year and nearly 20.3 million met diagnostic criteria for a substance use disorder (SUD) 
(alcohol or illicit drugs) (SAMHSA, 2019).  
Furthermore, binge-level drinking (defined as consuming five or more drinks on an 
occasion for men and four or more drinks on an occasion for women) contributes largely to  
alcohol-induced mortality among U.S. adults (Kanny et al., 2020; National Institute on Alcohol 
Abuse and Alcoholism [NIAAA], 2017), and significant increases in the prevalence of binge 
drinking have been observed in recent years (Grucza et al., 2018) with 1 in 4 people (67.1 
million) binge drinking in 2018 (SAMHSA, 2019). 
 The U.S. is also currently facing an opioid epidemic. In 2018, there was an estimated 2.0 
million people who had an opioid use disorder (SAMHSA, 2019). Also, in 2018, the Centers for 
Disease Control (CDC) estimated that 70% of drug overdose deaths involved an opioid. 
Synthetic opioids are of particular concern with overdose deaths from fentanyl increasing 10% 
from 2017 to 2018 (Scholl et al., 2019; Wilson et al., 2020).  
Receipt of Services for Substance Use 
There are myriad of nonpharmacological evidence-based interventions for the treatment 
of SUDs, ranging from individual and group psychotherapies, to self-control and social skills 
training, to aversion therapies (Hester & Squires, 2004). Please see Polak et al. (2020) for a 
comprehensive review of evidence-based behavioral and psychosocial interventions for the 
treatment of alcohol and other SUDs. Unfortunately, of the approximately 18.9 million people in 
need for substance use treatment in 2018, only 20% utilized any SUD treatment services, and 
only 13% received specialty treatment (SAMHSA, 2019). The vast majority (94.9%) of those 
who needed substance use treatment but did not receive specialty treatment did not think they 
needed treatment (SAMHSA, 2019). In general, reasons for not receiving substance use 
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treatment include not being ready to stop using, lack of health care coverage (SAMHSA, 2019), 
believing they don’t have a problem (Edlund et al., 2006; Edlund et al., 2009; Park-Lee et al., 
2017) or reporting reservations about seeking treatment (Cohen et al., 2006; Grant, 1997; Kim et 
al., 2017; Perron et al., 2009). 
Screening, Brief Intervention, and Referral to Treatment (SBIRT) 
 In 2003, SAMHSA launched a major initiative—SBIRT— a public health model 
designed to address substance misuse of all individuals presenting for care but not specifically 
seeking treatment for substance use (Madras et al., 2009).   
The major elements of SBIRT are 1) screening (identifying problematic substance use 
with standardized measures), 2) brief intervention for people who have problematic or hazardous 
substance use problems (provider and patient engage in evidenced-based counseling to raise 
patient’s awareness of substance use and its consequences and to elicit positive behavior 
change), and 3) referral to treatment for those with more severe substance use problems 
(Agerwala & McCance-Katz, 2012; Babor et al., 2007; Babor & Higgins-Biddle, 2001; Polak et 
al., 2020; SAMHSA, 2020a). 
SBIRT can be applied in a range of clinical settings, ranging from primary care clinics to 
hospital emergency departments, and varied community-based care centers. Together, this health 
network provides access to patient populations generally not seen in traditional SUD treatment 
facilities. Healthcare providers can implement SBIRT during routine medical visits by asking 
patients about their substance use and delivering brief intervention to those who screen at risk, 
with referral to treatment when warranted (Babor et al., 2007; Hargraves et al., 2017). 
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Effectiveness of Alcohol SBIRT in Primary Care 
A substantial number of systematic reviews and meta-analyses have demonstrated the 
effectiveness of SBIRT in primary care settings for people drinking in excess to established 
safety guidelines (Álvarez-Bueno et al., 2015; Cuijpers et la., 2004; Hettema et al., 2005; Jonas 
et al., 2012; Kaner et al., 2018; Moyer et al., 2002; Solberg et al., 2008). The effectiveness of 
SBIRT for those with more severe alcohol problems or alcohol dependence, however, is less 
clear (McCambridge & Satiz, 2017; Saitz, 2010; Saitz, 2013). 
Taken together, the findings summarized support moderate beneficial effect of screening 
and brief intervention for unhealthy alcohol use in adults. This evidence led the USPSTF to 
recommend screening and brief interventions to reduce unhealthy alcohol use by adults in 
primary care (Moyer, 2013; Reus et al., 2018; USPSTF, 2018). The USPSTF also recommends 
screening for unhealthy drug use in adults age 18 years or older, noting that screening should be 
implemented when effective treatment, including brief interventions, can be offered or referred 
(USPSTF, 2019; USPSTF, 2020). This recommendation statement replaces the 2008 USPSTF 
recommendation which concluded that the evidence at that time was insufficient to recommend 
screening and treatment for other drugs in adults. 
Effectiveness of Drug SBIRT in Primary Care 
Adapting SBIRT to target other drugs of abuse has been challenging. For screening, there 
is a need to target a range of drugs, including prescription drugs, not simply one substance. 
Further, the health consequences are less well-defined than for alcohol, and differ by class of 
drug. Finally, illicit drug use carries greater social stigma and greater fear of negative sanctions 
or consequences compared to heavy alcohol use. SBIRT outcomes, therefore, may be different 
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for other drugs compared to those targeting heavy and problem drinking (McCambridge & 
Rollnick, 2014; Saitz, 2014). 
SBIRT for other drugs of abuse has yielded mixed results, with some studies finding 
screening and brief intervention to be effective, with patient reductions in illicit drug use 
(Bernstein et al., 2005; Humeniuk et al., 2008; Humeniuk et al., 2012; Krupski et al., 2012; 
Madras et al., 2009). Others, however, have argued that negative findings predominate, with 
several RCTs finding the progression of brief intervention from efficacy to effectiveness for 
drugs other than alcohol has exceeded its evidence base (Bogenschutz et al., 2014; Hingson & 
Compton, 2014; Saitz et al., 2010; Saitz et al., 2014a; Roy-Byrne et al., 2014; Young et al., 
2014). Based on the current literature, dissemination of drug SBIRT has been limited, however, 
identifying and addressing illicit drug use and prescription drug misuse in primary care patients 
remains essential (Pace & Uebelacker, 2018; Tong et al., 2019). 
Estimate of Potential Cost Benefit 
Substance abuse is a serious disease that adversely affects U.S. economic vitality. It is 
estimated that alcohol, prescription opioids, and illicit drug abuse cost the U.S. $740 billion 
annually (Kasunic & Lee, 2014; NIDA, 2017). The cost of substance abuse treatment is 
approximately $11,600 per user, resulting in an economic burden of $224 billion, not including 
$84 billion lost in overall healthcare produced by the adverse outcomes of substance abuse 
(Florence et al., 2018; Sacks et al., 2015).  
Data suggest that primary care patients with SUDs often have multiple comorbidities 
associated with high clinical complexity and cost (Falk et al., 2008; Gerteis et al., 2014; Hayes et 
al., 2016; Korthuis et al., 2017; Saitz & Daaleman, 2017; Skinner et al., 2016). Patients with 
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chronic conditions and a co-occurring SUD are complicated to treat in primary care (Center for 
Behavioral Health Statistics and Quality, 2016; Graham et al., 2017). 
To promote SUD related care in primary care, SUDs have been re-conceptualized as 
chronic medical conditions in need of evidence-based screening and treatment (ASAM, 2019; 
Shapiro et al., 2013). SBIRT programs were included in the essential health benefits package as a 
part of the Affordable Care Act passed in 2010 (Moyer, 2013), and continuing to implement 
these evidence-based programs to identify at-risk users may mitigate the economic cost of 
specialized service provision. Economically, screening and brief interventions (SBI) have 
considerably lowered costs compared to conventional SUD treatment (Barbosa et al., 2015; Bray 
et al., 2014; Zarkin et al., 2015). A review by Bray et al., (2012) found costs for SBI for alcohol 
ranged from $0.51 to $601.50 per screen and from $3.41 to $243.01 per brief intervention. Other 
economic analyses on per-patient screening costs for alcohol and drug use is relatively limited, 
and data are needed with a focus on improving efficiency, such as computerized screening 
(Cowell et al., 2017).  
Therefore, with the support from Triple-Aim reforms and policy shifts toward value-
based care, allocating resources to investigate the magnitude of SUDs and associated 
comorbidities, and implementing screening and care-coordinating approaches for high-need, 
high-risk patients will help to improve health outcomes and reduce overall healthcare costs. 
Substance Use Screening and Assessment Measures  
Reliable and valid measures to identify individuals with heavy/problem substance use are 
an essential part of the public health armamentarium in the prevention and treatment of substance 
use disorders. Many standardized measures focus on quantity and frequency (QF) of use, with 
others targeting problems and consequences associated with use. Methods of administration also 
  
 
12 
 
 
vary, ranging from pencil-and-paper self-administered surveys and face-to-face interviews (IA) 
to computer/online self-administered and Audio Computer-Assisted Interviews (ACASI). The 
latter provides a user-friendly computer interface that guides people through a survey, using 
digitally recorded instructions, questions, and answers (Lavrakas, 2008). Variability also exists 
between alcohol and drug use screening and assessment. For example, reliance on self-report 
data via a broad array of measures is typical (Babor et al., 2000) but concurrent biological testing 
may also be used (Cone, 1997; Donovan et al., 2012). The window of assessment can vary from 
recent (typically past week or 30 days), to past 3 months, past year, and lifetime (any) use. The 
intention of these instruments’ ranges from assessment of general use, screening for problems, 
and facilitating diagnostic assessment. Intended use of a measure also plays a role. In particular, 
primary care settings require tools that are efficient and accurate to identify individuals at risk 
who would not necessarily be seeking treatment for a substance use disorder (Saunders et al., 
1993; SAMHSA, 2020a). However, other settings may require measures that provide detailed 
information about the specific substances used and the patient’s risk level to guide clinical 
actions or inform research effectiveness.   
In general, self-report remains a key metric for substance use screening, particularly in 
drug treatment programs and health care practices (Connors & Volk, 2004; Del Boca & Darkes, 
2003; Richter & Johnson, 2001; Sobell & Sobell, 2004), but also often in clinical research (Clark 
et al., 2016). Such measures are inexpensive, easy to administer, and widely accessible, 
especially when compared to biological measures such as urine or oral fluid testing. Self-report 
measures have also consistently demonstrated good accuracy in research studies. Table 1 
summarizes key characteristics of measures used in primary care settings looking separately at 
alcohol, other drugs, and alcohol and other drugs (see Babor & Kadden (2005) for a review). 
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Table 1. Commonly Used Substance Use Screening and Assessment Measures in Primary Care 
Settings. 
 
Test, Definition, and 
Citation 
 
Scoring 
 
Pros 
 
Cons 
Alcohol    
Alcohol Use Disorders 
Identification Test 
(AUDIT) (Babor et al., 
2001)  
-10 questions; 
scoring: (> 8) 
indicate alcohol 
abuse/ dependence  
-Identifies hazardous 
drinking & 
dependence 
-Lifetime/past year 
use 
-Sensitivity low in 
elderly populations 
 
Alcohol Use Disorders 
Identification Test – C 
(AUDIT-C) (Bush et 
al., 1998)   
-3 questions; 
scoring: positive 
scores equal > 3 
for women and > 4 
for men 
-Brief  
-Focuses on quantity, 
frequency, and 
pattern of drinking 
-Different scoring for 
men/women 
-Less sensitive and 
specific for recent use 
CAGE (Ewing, 1984) 
questionnaire; acronym 
for: Cut Down, 
Annoyed, Guilty, Eye-
opener 
-4 questions; 
scoring: Indication 
of alcohol 
problems  
(2) 
-Brief 
-Identifies potential 
alcohol problems 
-Lifetime assessment 
only; potential for 
falsification 
Michigan Alcoholism 
Screening Test (MAST) 
(Selzer, 1971) 
-24 yes/no 
questions: Probable 
alcoholism ( 5) 
-Identifies potential 
alcohol problems and 
dependence 
-Lengthy 
-Absence of early 
identification 
-Potential for 
falsification 
T-ACE (Sokol et al., 
1989) questionnaire; 
acronym for: 
Tolerance, Annoyance, 
Cut Down, Eye-opener 
-4 questions; 
scoring: Indication 
of alcohol 
problems  
(2) 
-Brief   
-Screens for risky 
drinking during 
pregnancy 
-Lifetime/current use 
-For women only 
 
Drugs    
Screen of Drug Use 
(SoDU) (Tiet et al., 
2015) 
-2 questions; 
scoring: positive if 
 7 days of drug 
use in past 12 
months and 2nd 
question is omitted 
(i.e., asking using 
drugs more than 
they meant to) 
-Easy interpretation 
-Days of drug use in 
the past 12 months 
-Identifies negative 
consequences of drug 
use 
 
-Direct obvious or 
face valid questions 
-Validated in 
Veteran’s Affairs 
population only 
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Drugs & Alcohol    
Alcohol, Smoking and 
Substance Involvement 
Screening Test 
(ASSIST) (WHO, 
2002); semi-structured 
interview 
8-57 questions; risk 
score for each 
substance (low-
moderate- or high) 
-Identifies risky 
alcohol/drug use and 
alcohol/drug 
problems 
-Lifetime & past 90-
day use 
-Strong diagnostic 
accuracy 
-Self-administered 
computerized version 
-Lengthy; structured 
interview  
-Complex scoring 
-Skip patterns 
 
CAGE-AID (Brown & 
Rounds, 1995) 
questionnaire, expanded 
CAGE to include 
alcohol and other drugs 
-4 questions; 
scoring: Probable 
alcoholism (> 2) 
-Brief  
-Identifies potential 
alcohol/drug 
problems 
- Lifetime assessment 
only; potential for 
falsification 
-More sensitive but 
less specific than the 
CAGE 
The Tobacco, Alcohol, 
Prescription 
medication, and other 
Substance use tool 
(TAPS) (McNeely et 
al., 2016) 
Two components: 
TAPS-1 – 4-item 
screen; any 
response other than 
‘never’ = positive. 
TAPS-2 – brief 
assessment; risk 
score for each 
substance (No use, 
problem use, 
higher risk) 
-Combines screening 
(frequency of use in 
the past 12-months) 
and brief assessment 
(past 3-month 
problem use) 
-Self-administered 
online or interviewer-
administered 
-Provides substance-
specific risk 
information on 
current use 
-Automatic generated 
risk levels for each 
substance class. 
-Less sensitive for 
prescription 
medications 
-Final score based on 
past 3-month 
use/problems. 
-English version only 
Timeline-Follow-Back 
(TLFB) (Sobell & 
Sobell, 1992) 
N/A -Focuses on quantity, 
frequency, and 
pattern of 
drinking/drug use 
-Estimates past 7 
days to 2 years of use 
-Use of supplemental 
memory aids 
-Lengthy 
-Retrospective 
estimates of use 
-Difficult to identify 
problems or 
dependence 
-Interview required 
                            
 
Alcohol Screening  
 
For alcohol, many instruments with good psychometric properties are available for the 
identification of at-risk or harmful drinking and associated problems (Connors & Volk, 2004; 
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O’Connor et al., 2018; Saitz, 2007; Sobel & Sobel, 2004). The better-known instruments are 
summarized below, highlighting their psychometric properties as well as their scientific and 
practical consideration for their use. 
Alcohol Use Disorders Identification Test (AUDIT) 
The 10-question AUDIT, developed by the World Health Organization (WHO), is widely 
recommended and is often considered the “gold standard” among alcohol screening measures 
(Babor et al., 2001). The AUDIT focuses on both at-risk drinking (current to past year) as well as 
alcohol-related consequences and problems. Questions also cover identification of heavy 
drinking (drinking more than 6 standard drinks on any one occasion) and common symptoms of 
alcohol dependence. The AUDIT’s psychometric properties are well established. Internal 
reliability has been consistently strong, with Chronbach’s alpha scores in the range of 0.80-0.94. 
At the recommended cut-off of 8, it is most effective in identifying subjects with at-risk, 
hazardous, or harmful drinking (sensitivity, 51%-97%; specificity, 78%-96%). Other studies 
report high internal consistency and reliability (r=.86) and good sensitivity but somewhat lower, 
specificity, for ICD-10 alcohol use disorders (Babor et al., 2001; Berner et al., 2007; de 
Meneses-Gaya et al., 2009). 
  Disadvantages of the AUDIT include length (10-items), with 2+ minute administration 
time and more complex scoring than other screeners. To address this, an abbreviated version, the 
Alcohol Use Disorders Identification Test – C (AUDIT-C, Bush et al., 1998) with 3 items was 
developed and tested. Focusing only on consumption and patterns of drinking (sensitivity 0.86, 
specificity 0.89 in men; sensitivity 0.73, specificity 0.91 in women) the AUDIT-C is particularly 
useful in screening for risky/hazardous drinking (Dawson et al., 2012). The USPSTF (2018) 
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considers the AUDIT-C as another instrument of choice for screening for unhealthy alcohol use 
in primary care settings. 
CAGE 
Developed in the late 1960s, the four-item CAGE (Ewing, 1984) screens for alcohol-
related problems. CAGE is a mnemonic that stands for Cut down, Annoyed, Guilty, and 
Eyeopener. The four CAGE questions are: 1) Have you ever felt you should Cut down on your 
drinking?, 2) Have people Annoyed you by criticizing your drinking?, 3) Have you ever felt bad 
or Guilty about your drinking?, and 4) Have you ever had a drink first thing in the morning to 
steady your nerves or get rid of a hangover (Eye-opener)? Each affirmative response receives 
one point with total scores ranging from zero to four. Typically, a score of ≥ 2 points on the 
CAGE is used as the cut-off for risk of problem drinking (Ewing, 1984). The CAGE is 
commonly used in primary care settings (Tan et al., 2018). The screener has good validity to 
screen for alcohol dependence in primary care patients (sensitivity, 43%-94%; specificity, 70%-
97%) (Fiellin et al., 2000). It also has demonstrated high test-retest reliability (0.80-0.95) (Dhalla 
& Kopec, 2007).  
A common criticism of the CAGE is that it is less sensitive for identifying non-dependent 
at-risk drinkers. Gender and ethnicity have also been found to affect its performance, with 
studies showing a sensitivity as low as 50% in adult white women and as low as 39% in at-risk 
groups ages 60 and over (Connors & Volk, 2004). The questionnaire should not precede 
questions on alcohol quantity or frequency as its sensitivity is dramatically improved by an open-
ended introduction (Steinweg & Worth, 1993). Finally, the CAGE asks about “lifetime” 
experience rather than current drinking, so a person who no longer drinks may screen positive 
unless the clinician directs the questions to focus on a more current timeframe; therefore, follow 
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up with the AUDIT of AUDIT-C is recommended for those who score positive on the CAGE 
(USPSTF, 2018). 
Michigan Alcoholism Screening Test (MAST) 
One of the first alcohol screening measures, the MAST (Selzer, 1971), consists of 24 yes-
no questions focused on the medical, social, family and legal consequences of alcohol use.   
Items are weighted (1 to 5 points) and summed, and reliability and validity have been established 
with cutoff scores for probable (> 4 points) and definite (> 5 points) alcoholism. The MAST 
provides a gross, general measure of lifetime problem drinking severity and has been used to 
guide choice of treatment modality as well as further inquiry into alcohol-related problems 
(Zung, 1982). 
 The MAST has been criticized because of its length, risk for underreporting or 
falsification, failure to discriminate between past and present drinking, and a focus on finding 
cases of alcohol dependence rather than early problem identification. Also, certain items on the 
Michigan Alcoholism Screening Test (MAST) fail to specify referent or provide drinking norms, 
which can confuse interpretation (Svikis et al., 1991). To address the issues of length, versions 
have been developed, including the 10-item Brief MAST (bMAST) (Pokorny et al., 1972) and 
the 13-item Short MAST (SMAST) (Selzer et al., 1975). Both increase feasibility of screening in 
clinical settings but still maintain a focus on identifying active dependence.   
T-ACE 
While alcohol use prevalence and comorbid conditions differ in men and women, efforts 
to develop sex/gender-specific screening instruments have focused predominantly on pregnant 
women (Kelpin et al., 2019). While a variety of screening measures for prenatal alcohol use are 
available (Burns et al., 2010; Svikis & Reid-Quiñones, 2003), the T-ACE is among those most 
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often used to identify prenatal drinking (Sarkar et al., 2010).  Developed by Sokol and colleagues 
(1989), the T-ACE retains 3 CAGE items (A, C and E), but replaces the G (feeling guilty) item 
with a question about Tolerance (How many drinks does it take to make you feel high?). In 
scoring the T-ACE, two points are assigned for the tolerance items when a woman reports 
needing more than two drinks to feel the intoxicating effects of alcohol or to feel “high.” The T-
ACE demonstrates good sensitivity and specificity for detecting risk consumption and AUD and 
has been used to screen for problem drinking in non-pregnant women as well (Kelpin et al., 
2019).  
Assessing Alcohol Quantity and Frequency 
Anther strategy for identifying individuals at risk for alcohol related problems is to 
examine quantity and frequency of use patterns. Patients with regular alcohol or other substance 
use are more likely to present for care with chronic and acute medical problems than patients 
who are not regular drinkers or drug users (Gupman et al., 2002). The past few decades have 
seen a growing literature describing a plethora of measures focused on quantity and frequency 
(QF) of alcohol use with psychometric evaluation across diverse study samples (Sobell & Sobell, 
2004). QF methods provide reliable and valid information about total consumption (quantity) 
and number (frequency) of drinking days (McKenna et al., 2018). All QF measures calculate 
“average” or “typical” consumption patterns (e.g., “How many days on average—in a specific 
time interval (e.g., per week, per month)—did you drink alcohol, and when you drank 
alcohol, on average how many beers did you drink?”). Most QF methods repeat these questions 
for each major alcoholic beverage type (i.e., beer, wine, distilled spirits) and then sum across 
beverage types (Sobell & Sobell, 2004). QF methods provide a quick and easy estimate of total 
amount consumed or total number of drinking days, but often do not describe the variability of a 
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respondent’s drinking (i.e., proportion of drinking occasions in which different numbers of 
drinks (e.g., 1–2, 5–9, ≥ 10) were consumed or different types of beverages were combined (e.g., 
beer and whiskey on the same day) (Room, 1990). 
The Graduated–Frequency (GF) Measure (Clark & Midanik 1982; Midanik 1994) was 
developed in response to this criticism. The GF Measure asks respondents to report the 
frequency of their drinking for different levels of drinking (e.g., 1–2 drinks or 3–4 drinks; highest 
level is most ever consumed) in a specific time interval for combined beverage types (Sobell & 
Sobell, 2004). The usual format consists of a question about largest amount followed by a 
question of frequency of use of applicable quantities falling below the maximum amount 
consumed (Del Boca & Darkes, 2003).   
Because a wide range of drinking patterns (e.g., daily drinking (i.e., alcohol use every day 
for a specified period) to sporadic heavy/problem drinking) are common in clinical populations 
(Wu et al., 2017), accurate assessment of such drinking is important. Unfortunately, QF methods 
to capture such drinking days (e.g., the Volume–Pattern Index and the GF Measure) result is a 
longer administration time. Recently, with the increased emphasis on brief methods to identify 
those at risk for alcohol problems, the QF approach has shifted to one or two question 
instruments (McNeely et al., 2015a; McNeely et al., 2015b; Saitz et al., 2014b; Seale et al., 2006; 
Smith et al.,2009). Brief QF items, or single-item screening questions (SISQs) typically take the 
following form, “How many times in the past year have you had X or more drinks in a day?” 
(where X is 5 for men and 4 for women), with an answer over one designated as positive (Smith 
et al., 2009; McNeely et al., 2015b), an indication of binge drinking (NIAAA, 2017). However, a 
positive answer has a sensitivity ranging from 0.34 to 0.89 [95% CI range, 0.25 to 0.92] for male 
participants and 0.28 to 0.91 [95% CI range, 0.21 to 0.93] for female participants for detecting 
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unhealthy alcohol use (O’Connor et al., 2018), but an even lower specificity (67-74%) for 
detecting current alcohol use disorder (McNeely et al., 2015b; Smith et al., 2009). Nonetheless, 
these one or two item instruments have been shown to offer clinicians something practical and 
easier to implement (McNeely et al., 2015a; McNeely et al., 2015b; Smith et al., 2009; Strobbe, 
2014). The single-question question QF screen is another instrument of choice recommended to 
quickly identify unhealthy alcohol use in primary care settings (USPSTF, 2018), however, 
administering an additional instrument (e.g., AUDIT, AUDIT-C) is essential for risk 
stratification and to guide care (McNeely et al., 2015a). 
Timeline-Follow-Back (TLFB) 
Originally designed to measure alcohol consumption in problem drinkers, the TLFB has 
long been the “gold standard.” Developed by Sobell and Sobell (1992), the TLFB combines 
characteristics of a semi-structured interview with that of a brief QF screener to accurately 
collect information about behaviors. The TLFB is typically administered by trained staff and is 
facilitated using memory aids, such as calendars and anchor dates. It can be administered by 
computer, telephone (Pedersen et al., 2012; Sobell et al., 1996), or as a paper-and-pencil survey.   
The TLFB retrospectively tracks daily use over a reference period ranging from 30 to 360 
days and across many variables (e.g., number of days of low- and high-risk drinking, number of 
days abstinent, days to relapse, mean drinks per drinking day, mean drinks per week, longest 
continuous abstinence period). This allows several dimensions of a person’s alcohol use to be 
separately examined: (a) variability (i.e., scatter); (b) pattern (i.e., shape); and (c) extent of use 
(i.e., elevation; how much), thus providing different and more precise information on individual 
use levels than indirect estimations (e.g., QF methods) (Sobell & Sobell, 1996; Sobell & Sobell, 
2004; Sobell & Sobell, 2000).   
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The TLFB has been used extensively in the research literature and has been found to have 
high test-retest reliability, with coefficients ranging from .79 to .96 over 30- to 90-day follow-up 
periods across a range of drinking populations (Sobell & Sobell, 2004). Many studies have 
compared QF methods to the TLFB for drinking and have concluded that the TLFB for drinking 
is superior to other QF methods in its ability to collect useful data (Lemmens et al., 1992; O’Hare 
et al., 1991; Saunders & Conigrave, 1990) and accurately categorize drinking levels (i.e., heavy 
drinker, moderate drinker) (Flegal, 1990).   
In terms of clinical applicability, the TLFB has been shown to have good psychometric 
characteristics, but the length of administration (e.g., 15 minutes to complete the TLFB for 90 
days and approximately 30 minutes for 12 months) and required training makes it impractical for 
medical settings such as primary care clinics (Fiellin et al., 2013). Further, some have found that 
the TLFB strengths may lie more in obtaining an overall summary of drinking patterns, rather 
than the number of drinks on a specific date (Hoeppner et al., 2010; Searles et al., 2000). 
Drug Use and Prescription Drug Misuse Screening and Assessment 
DAST 
In contrast to alcohol, fewer standardized measures are available (Smith et al., 2010). 
One measure is the DAST (Drug Abuse Screening Test) (Skinner, 1982), which consists of ten 
direct obvious questions about drug use and related problems that yields a quantitative score 
reflecting the severity of drug abuse. Since its inception, the DAST has been used as a clinical 
and research tool, though it was developed in addiction treatment rather than primary care 
settings (Smith et al, 2010). The DAST has moderate to high levels of test-retest, interitem, and 
item-total reliabilities as well as moderate to high levels of validity, sensitivity, and specificity 
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(McCann et al., 2000), especially for adults in general medical settings at risk for substance use 
disorders (Yudko et al., 2007).  The DAST is available in both 20-item and 10-item formats. 
DUDIT 
Another measure, the DUDIT (Drug Use Disorders Identification Test) (Berman et al., 
2005), an 11-item self-report questionnaire developed to screen individuals for drug problems, 
was developed in Sweden. Like the DAST and analogous to the AUDIT, the DUDIT assesses an 
individual’s illicit drug use and related consequences over the past year. Specifically, the DUDIT 
collects data in the following areas: (a) QF of drug use, (b) drug-related problems, and (c) drug 
dependence symptoms. Validated in both general and clinical populations (e.g., outpatient and 
residential treatment), the DUDIT was found to be a psychometrically instrument with high 
convergent validity (r = .85) when compared with the DAST-10, with a Cronbach’s alpha of .94. 
Also, when using the optimal cut-off score of 8, the DUDIT had sensitivity and specificity scores 
of .90 and .85, respectively (Hildebrand, 2015). A criticism of the DUDIT is that it has not been 
validated for applicability in general medical settings where the incidence of patients with SUD 
is typically lower than it is in specialty SUD treatment settings. 
SoDU 
The Screen of Drug Use (SoDU) is a misnomer, as it was validated in a cross-sectional 
study of 1283 veterans in primary care to detect drug use disorders (e.g., illicit drug use or 
prescription drug for non-medical purposes), and not use. The SoDU includes two questions, 
“How many days in the past 12 months have you used drugs other than alcohol?” (positive if 7 or 
more and skip the next item) and “How many days in the past 12 months have you used drugs 
more than you meant to?” (2 or more days meets criteria). The two-question screening 
instrument was 92.31% sensitive and 92.87% specific (Tiet et al., 2015). Although the SoDU 
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appears suitable as a screening instrument for drug use disorders, clinical personnel would need 
to engage patients in secondary-stage screening or other validated, detailed questioners to obtain 
additional data on drug use.   
Similar to single-item alcohol screeners, recommendations for instruments to be 
administered in primary care settings include the use of a validated SISQs for illicit drug use, 
“How many times in the past year have you used an illegal drug or used a prescription drug for 
non‐medical reasons?” (McKneely et al., 2015b; Smith et al., 2010), followed by a validated 
self-report questionnaire (Ghitza et al., 2013).  
Combined Alcohol and Drug Use Measures 
With polysubstance use as the norm, more screening measures now focus on screening to 
identify alcohol and/or drug use and quantify risk factors that are associated with actual or 
potential substance use disorders (Samet et al., 2007). However, assessment measures of this 
type tend to be quite long, require a significant amount of time to administer (e.g., 5-15 minutes 
of face-to-face interaction), and involve complex scoring systems. 
Several structured interview-based assessment measures collect QF data and focus on 
both drug and/or alcohol-related problems. One such measure is the Alcohol, Smoking and 
Substance Involvement Screening Test (ASSIST) (WHO, 2002). The ASSIST is a structured 
interview consisting of 8 questions covering alcohol and use of 10 psychoactive substances.  
Items cover lifetime use and frequency of use in the past-3 months, as well as various problems 
associated with the use of these substances. Responses produce a score and subsequent 
substance-specific risk stratification for each substance (e.g., low-moderate- or high-risk 
category) (WHO, 2002). Numerous studies have demonstrated good concurrent, construct, 
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discriminative, and predictive validity (WHO, 2002), as well as test-retest reliability of the 
ASSIST (Ali et al., 2002; Humeniuk et al., 2008; McNelly et al., 2014; Newcombe et al., 2005).   
The length and complexity of the ASSIST have hindered its implementation, especially 
in primary care settings. To further facilitate adoption, Ali and colleagues (2013) developed a 
short version of the ASSIST, termed the ASSIST-Lite, based on factor and item-response theory 
analyses of pooled data from previous ASSIST validation studies. This shortened version shows 
promising results in identifying problem substance users (sensitivity range: 0.8–1.0; specificity 
range: 0.7–0.8); however, additional research is needed to establish its clinical utility.   
In addition to alcohol, TLFB methods have subsequently been used to collect data on a 
host of other behaviors (e.g., episodes of violence, gambling behavior, and vocational activity) 
(Caetano et al., 2012; Svikis et al., 2012), including other drug use. Similar to the Alcohol-
TLFB’s operating characteristics, the TLFB can be used to obtain information on individual drug 
use levels more precisely than other indirect or direct estimations (Robinson et al.,2014). The 
TLFB has been evaluated and used with the following addictive behaviors: nicotine (Shiffman, 
2009), cannabis (Norberg et al., 2012), methamphetamine (Halkitis et al., 2009), opiates 
(Raistrick et al., 1994), prescription drugs (Sellers et al., 1990), cocaine (Ehrman & Robbins, 
1994), and polysubstance users (Staines et al., 2001). The TLFB has shown strong test-retest 
reliability across several substances (Fals-Stewart et al., 2000; Robinson et al., 2014) and diverse 
populations (Carey et al., 2004; Fals-Stewart et al., 2000; Levy et al., 2004; Sacks et al., 2003). 
The TLFB has also shown strong concurrent validity using biological measures (Hjorthøj et al., 
2012), other interviewer-administered instruments (Dennis et al., 2004; Fals-Stewart et al., 2000) 
and self-report instruments (Fals-Stewart et al., 2000; Sacks et al., 2003). 
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As mentioned previously, a major challenge to combined screening for specific 
substances is provider burden, which refers to the skills and time demanded of the measure. A 
relatively simple procedure that addresses this problem is the CAGE test adapted to include 
drugs (CAGE-AID). The CAGE-AID (Brown & Rounds, 1995) was found to be more sensitive 
but less specific than the CAGE (Brown & Rounds, 1995). This easy-to-use four-item test 
nevertheless requires further questioning if the patient scores positive. In addition, a brief 4-item 
patient self-administered Substance Use Brief Screen (SUBS) tool for primary care has been 
developed and validated. Analyses demonstrated high sensitivity and moderate-to-high 
specificity for detection of unhealthy use of tobacco, alcohol, and other drugs and indicated good 
discrimination (AUC 0.74-0.97) for all substance classes (McNeely et al., 2015a).   
Computer Surveys/Computer-Directed Substance Use Screening and Assessment  
To maximize reliability and validity and facilitate scoring (McCaul & Wand, 2017; 
Richter & Johnson, 2001), several instruments are available for computer administration. The 
second edition of Assessing Alcohol Problems: A Guide for Clinicians and Researchers, 
published by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) (Allen & 
Wilson, 2003) lists 28 computerized alcohol instruments, 21 of which are self-administered.  
Also, many drug use screening measures, such as the DAST and DUDIT, have been adapted for 
computer administration.   
Furthermore, several instruments can be administered as Audio Computer-Assisted 
Interviews (ACASI). Computerized-directed measures demonstrate comparable validity to 
traditional interview formats. For example, an ACASI version of the AUDIT was shown to be 
feasible, acceptable to patients, and equally good as an interviewer- or pencil-and-paper self-
administered version at detecting problem drinking among English speaking patients (Butler, 
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Chiauzzi et al., 2003). In addition, an ACASI version of the ASSIST was developed and 
produced scores similar to those obtained by the interview-administered ASSIST, demonstrating 
good psychometrics to measure substance use in primary care patients (Kumar et al., 2016; 
McNeely et al., 2014a; McNeely et al., 2016a; Wolff & Shi, 2015). 
Recently, McNeely and colleagues (2016b) developed the Tobacco, Alcohol, Prescription 
medication, and other Substance use (TAPS) tool, a two-stage brief instrument for substance use 
screening in primary care settings. This ACASI (or interviewer-administered) tool consists of a 
4-item screen (TAPS-1) asking about frequency of tobacco, alcohol, illicit drugs, and 
nonmedical use of prescription drugs, followed by a brief assessment of past 3-month problem 
use (TAPS-2) to generate a substance-specific risk level for individuals. The TAPS tool was 
compared to a computerized version of the Composite International Diagnostic Interview (CIDI) 
Substance Abuse Module (Cottler, 2000; Cottler et al., 1996; Robins et al., 1988).  
At a cutoff score of 1+ for problem use the TAPS Tool had sensitivity 0.93 (95% CI 
0.90–0.95) and specificity 0.87 (95% CI 0.85–0.89) for tobacco, and sensitivity 0.74 (95% CI 
0.70–0.78), specificity 0.79 (95% CI 0.76–0.81) for alcohol. For problem use of illicit and 
prescription drugs, sensitivity ranged from 0.82 (95% CI 0.76–0.87) for marijuana to 0.63 (95% 
CI 0.47–0.78) for sedatives, and specificity was 0.93 or higher. For identifying any SUD, 
sensitivity was lower, but a score of 2+ greatly increased the likelihood of having a SUD. In 
general, this screening tool demonstrated acceptable sensitivity and specificity for identifying 
primary care patients with problem substance use, with potential to also detect alcohol, tobacco, 
and marijuana use disorders (McNeely et al., 2016b). 
While the interviewer-administered and self-administered versions of the TAPS Tool 
performed similarly, when the tool’s first-stage screening component (TAPS-1) was validated in 
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primary care patients, disclosure rates for prescription medication misuse were 50% higher with 
the self-administered forma (Gryczynski, et al., 2017). A possible advantage of self-administered 
formats (particularly ACASI formats) is that participants are more reluctant to disclose substance 
use in a face-to-face interview compared to computerized tools (Butler et al., 2009). Self-
administered computer tools also have the potential to facilitate substance use screening in busy 
medical clinics and potentially streamline screening results into electronic medical records 
(Gryczynski, et al., 2017; McNeely et al., 2016b). 
Methods of Enhancing Validity of Self-Reported Substance Use  
There are notable limitations to the validity of self-report data of substance use. One such 
limitation is the underreporting of use. The under-reporting of substance use can be due to 
several factors, including poor recall, protection of personal data (confidential or anonymous) in 
research design and clinical practice, and social desirability bias (responding inaccurately to 
appear favorably) (McKenna et al., 2018; Rosenbaum et al., 2006).   
Social desirability bias may result in underreporting because substance use is often illegal 
or socially proscribed, stigmatizing, and potentially embarrassing to report (Andreae et al., 2016; 
Copeland, 1997; Corrigan et al., 2016; Digiusto & Treloar, 2007; Keyes et al., 2010; Kulesza et 
al.,2013; Mojtabai & Crum, 2013; Schomerus et al., 2010; Tourangeau & Yan, 2007). Research 
has consistently found higher rates of underreporting of illegal drug use as compared to those for 
licit substances like alcohol and tobacco use (Gelberg et al., 2015). Further, despite relatively 
uniform rates of substance abuse among racial and ethnic populations (SAMHSA, 2015), 
members of racial and ethnic minority groups are perhaps most adversely affected by stigma and 
are most likely to experience barriers that affect treatment services and outcomes for SUDs 
(Acevedo et al., 2018; Geurrero et al., 2013). Quantifying differences across race/ethnicity in 
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drug and alcohol use following screenings requires further investigation (Babor et al., 2007; 
Sahker et al., 2019).   
The TLFB method places emphasis on reducing forgetting and social desirability bias as 
a source of under-reporting. As mentioned previously, in a TLFB administration, interviewers 
work actively to address forgetting by facilitating recall events. The face-to-face, semi-structured 
format establishes trust and rapport and often mitigates social desirability bias. Despite these 
advantages, however, respondents often minimize their substance use reports to present 
themselves in a socially desirable manner (Richter & Johnson, 2001). This is consistent with 
other literature suggesting that respondents report higher rates of drug and alcohol use with a 
self-administered questionnaire than a face-to-face, provider-administered interview (Rosenbaum 
et al., 2006). 
Regarding protection of personal data – When collected for research purposes, 
information can be confidential or anonymous. Anonymous data are collected without personal 
identifiers that can link the information to the participant. When data is collected and held 
confidentially, the assessors and research staff can identify subjects and may have access to their 
data. When there are risks associated with disclosure of sensitive information, concerns about the 
confidentiality of data can impact disclosure of use (Sanker et al., 2003). For example, patients 
express concerns reporting their substance use in medical records and how that could potentially 
impact their job, insurance payments for medical care, or the care they receive from their 
providers (McNeely et al., 2018).   
Research suggests that disclosure of stigmatized behaviors, especially on self-
administered questionnaires, is enhanced when participants respond anonymously instead of 
confidentially. While many studies contrast anonymity with confidentiality across a range of 
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stigmatized health-related behaviors (e.g., HIV, mental health, psychosocial problems) (Bing et 
al., 2001; Bowling, 2005; Durant et al., 2002; Kessler et al., 2005; Kim et al., 2008; Ong & 
Weiss, 2000; Richman et al., 1999; Simões & Bastos, 2004; Simões et al., 2006), the number of 
studies focusing exclusively on alcohol and drug use is limited (Hormes et al., 2012; Richter & 
Johnson, 2001). Furthermore, methodological concerns arise given a relative lack of agreement 
over the notion about confidentiality and/or anonymity. For example, some researchers treat 
these as two exclusive constructs (e.g., Ong & Weiss, 2000; Scott, 2005) while others question 
whether anonymity and confidentiality are the same (Rogelberg et al., 2006).  
Several studies have focused on computerized modes of administration to counteract 
substance use-related stigma and address confidentiality concerns, demonstrating that 
computerized self-administered instruments generate higher rates of self-reported substance use 
(Beck et al.,2014; Delker et al., 2016; Lessler et al., 2000; McNeely et al., 2016a; NIMH, 2008; 
Perlis et al., 2004; van Griensven et al., 2006). Investigators posit that computerized data 
collection improves the accuracy of reports due to the provision of anonymity (Joinson, 2001; 
Newman et al., 2002) and enhanced perceived safety of disclosure (Brandimarte et al., 2012; 
Spear et al., 2016). Also, computerized-directed tools may yield health benefits for underserved 
populations by enhancing patient engagement, improving implementation of clinical guidelines, 
and inform patient care for those most vulnerable who have higher substance abuse and health 
risks.  
The notion that greater anonymity in computerized surveys results in higher self-
disclosure of sensitive behaviors, including substance use, is highlighted in a 2015 meta-
analysis (Gnambs & Kaspar, 2015). While evaluating disclosure of sensitive behaviors across 
self-administered paper–and–pencil and computerized survey modes in non-clinical settings, 
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computerized assessments resulted in significantly (p < .05) higher self-disclosure than paper-
and-pencil modes. This overall effect was replicated for several subgroups of different types of 
sensitive behaviors, including various forms of substance use (Ω =1.17). In particular, the use 
of heroin or cocaine resulted in larger differences in prevalence rates across survey modes as 
compared to less sensitive behaviors (predicted Ω =1.43), such as smoking or the consumption 
of alcoholic beverages (Gnambs & Kaspar, 2015). While research suggests increased self-
disclosure of sensitive behaviors in computerized surveys, future research on privacy 
perceptions and survey modes on self-disclosure of substance use is highly warranted. 
Adjuncts to Self-Report 
Since the assessment and evaluation of substance use are largely dependent on self-
reports, under-reporting is a significant threat to internal study validity. To test the validity of 
self-reported substance use, both clinicians and researchers have recommended the use of a self-
report measure in combination with biological testing (Center for Substance Abuse Treatment, 
1997; Cone, 1997; Donovan et al., 2012), especially in high-risk populations and those with high 
threats of stigmatization (Clark et al., 2016).   
Substance use testing can be completed on several biological matrices including urine, 
blood, hair, saliva, sweat, nails (toe and finger), and meconium (Moeller et al., 2017). Urine drug 
testing is the most well-established and supported biological matrix for detection of drug use in 
clinical settings (Moeller et al., 2008; Stefanidou et al., 2010). As such, it is the most commonly 
obtained specimen for drug testing, and to improve the accuracy of the assessments of drug use. 
A significant advantage of urine drug tests over other biological tests is the ability to conduct 
Point of Care Testing (POCT) in office settings. POCT allows for immediate results on site, 
allowing providers to review results with the patient in real-time. 
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Regarding alcohol, alcohol levels can be estimated through collection and analysis of 
breath, blood, and urine. Alcohol biomarkers include direct and indirect biomarkers (SAMHSA, 
2012; Jastrzębska et al., 2016). Indirect biomarkers (CDT, LFT & MCV) identify alcohol’s 
effects on organ systems or body chemistry. In contrast, Phosphatidylethanol (Peth) is a direct 
biomarker, meaning that it is only formed after someone has consumed alcohol.  
Phosphatidylethanol testing, known as Peth testing, is a highly reliable blood test allowing the 
detection of chronic excessive alcohol abuse over the previous 3-4 weeks. With a sensitivity and 
accuracy rate of over 99%, it is being widely adopted as a replacement to CDT, LFT & MCV 
testing which offers up to a 77% sensitivity rate (Viel et al., 2012). Although not recommended 
for routine screening, these methods have proven useful to increase the validity of self-report 
information in general (Babor et al., 2007).   
Research comparing biochemical verification results with self-reported data have 
primarily been conducted in substance use treatment settings and have demonstrated high rates 
of concordance (Basurto et al., 2009; Jain et al., 2006; Jain et al., 2013; Melnikov et al., 
2009; Schuler et al., 2009) while other studies have yielded mixed results (Clark, et al., 2016; 
Cone, 2012; Neale and Robertson, 2003). In general, a variety of self-report measures were used 
across these studies. 
The TLFB has gained popularity in cross sectional and prospective studies of drug use, 
and a 2012 systematic review and meta-analysis concluded that the TLFB is a valid measure in 
detecting illicit substance use in populations with substance use disorders (Hjorthøj et al., 2012).  
However, Nordeck et al. (2020) found mixed results in a study comparing the TLFB and oral 
fluid testing to detect substance use in adult primary care patients. Specifically, they found that 
marijuana use had higher detection using TLFB self-report, while cocaine, prescription opioids, 
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and heroin had higher detection using oral fluid testing. Additional research is needed in order to 
contribute to the literature on identifying substance use in primary care settings and to evaluate 
the concordance of TLFB compared to biological testing.  
Statement of Problem 
While much attention has been focused on brief interventions (BIs) and their effects on 
substance use, screening to identify persons at risk for heavy/problems alcohol or drug use has 
received much less attention. This is unfortunate as screening is an integral component of 
SBIRT, as it identifies the individuals likely to benefit from education or BI.   
The ability of screening tools to identify persons at risk for heavy/problem alcohol or 
other drug use varies greatly and can be impacted by types of questions asked and mode of 
administration. While differences between screening tools and modes of administration have 
been found, with self-administration and provisions of anonymity resulting in greater disclosure, 
the assumption in substance use research is that structured interview-administered substance use 
screening and assessment approaches are most valid. Research exploring the role of consent 
condition on disclosure in the context of computer-mediated and self-administered data 
collection in clinical settings is limited. Also, the accuracy and efficacy of screening, especially 
for illicit drug use and prescription drug misuse, necessitates more research given the insufficient 
evidence of the clinical utility of these instruments when applied in primary care practice 
settings.  
Moreover, previous studies suggest that in general, demographic characteristics such as 
age and gender (Beck et al., 2014; Bjarnason & Adalbjarnardottir, 2000; Dolezal et al., 2012; 
Ledgerwood et al., 2008; Vigil-Colet et al., 2015; Welte & Russell, 1993), race (Johnson & 
Fendrich, 2005; Ledgerwood et al., 2008; White et al., 2014), mental health-related conditions 
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(Baggio et al., 2015), and socioeconomic status (Welte & Russell, 1993) may be related to 
differential reporting of sensitive health behaviors. Whether these characteristics differentially 
affect reporting of substance use frequency in interviewer-administered vs. computer-mediated 
screening and assessments among primary care patients is largely unknown. Further, additional 
research is needed among those with comorbid SUD and medical disorders to be able to inform 
integrated screening and care-coordinating efforts (Freeman et al., 2014; Walter et al., 2017). 
The present study compares self-reports of alcohol, illicit drug use, and prescription drug 
misuse across an anonymous, computer-administered health screen (CAHS), confidential, 
computer-administered research assessment (CARA), and confidential, interviewer-administered 
research assessment (IARA) in males and females with heavy/problem substance use identified 
through an urban primary care clinic. This study also compares self-reports of recent substance 
use to urine drug assay findings. Data was part of a randomized clinical trial (RCT) evaluating a 
brief computerized Screening, Brief Intervention, and Referral to Treatment. This novel 
approach of comparing computerized anonymous and confidential surveys to a confidential, 
interviewer-administered assessment across alcohol and illicit drug use as well as prescription 
drug misuse will offer insight on the most parsimonious methods to collect the most sensitive 
and accurate data possible about substance use and related behaviors.   
Aims and Hypotheses 
The present study had four primary aims: 
I. Aim 1: To compare rates of participant self-disclosure of alcohol and illicit drug use and 
prescription drug misuse obtained by an anonymous, computer-administered health 
screen to those obtained by a confidential, computerized assessment and interview-
administered research assessment. Four hypotheses were tested: 
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a. Hypothesis 1: Participants will report more recent binge drinking days (past 30) 
on the anonymous, computer-administered screener (CAHS) compared to the 
confidential, interviewer-administered assessment (IARA).  
b. Hypothesis 2: Participants will report consuming, on average, more drinks per 
week over the past 30 days by anonymous, computer-administered screener 
(CAHS) compared to the confidential, computerized research assessment 
(CARA). The study also hypothesized that participants will report consuming, on 
average, more drinks per week by CAHS compared to the interview-administered 
assessment (IARA). 
c. Hypothesis 3: Participants will report, on average, more days of drug use per 
week over the past 30 days by anonymous, computer-administered screener 
(CAHS) compared to confidential, computerized assessment (CARA). The study 
also hypothesized that participants will report, on average, more days of drug use 
per week by CARA compared to the interview-administered assessment (IARA). 
d. Hypothesis 4: Participants will report, on average, more days of prescription drug 
misuse per week by anonymous, computer-administered screener (CAHS) 
compared to confidential, computerized assessment (CARA). The study also 
hypothesized that participants will report, on average, more days of drug use per 
week by CAHS compared to the interview-administered assessment (IARA). 
II. Aim 2: Compare endorsement of alcohol and/or drug use related problems between the 
anonymous, computer-administered screener and confidential, computerized assessment. 
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a. Hypothesis 1: Participants will be more likely to score positive for problematic 
substance use on the anonymous, computer-administered screener compared to 
the confidential, computerized assessment. 
III. Aim 3: To compare agreement between self-report of recent drug use and biological 
measures (i.e., urinalysis). 
a. Hypothesis 1: Proportion of illicit drug use and non-medical prescription drug use 
will be higher by urine assay compared to self-report measure.  
IV. Aim 4: To identify correlates (e.g., age, gender, race, marital status, years of education, 
ethnicity, number of medical conditions, mental health-related conditions, etc.) of self-
disclosure of any alcohol and other drug use as well as substance use per week in the past 
30-days. 
Methods 
Participants  
 
Present student participants were drawn from a parent randomized, controlled clinical 
trial (RCT) of SBIRT for heavy/problem alcohol or other drug use in a primary care patient 
sample. The study was approved by Virginia Commonwealth University’s Institutional Review 
Board under “Project COMP: A Randomized Clinical Trial,” protocol number HM13196 and all 
participants provided informed consent. Study recruitment occurred from November 2010 to 
December 2013, until the total sample was achieved. 
Parent Study RCT 
Phase 1 
 
In the parent study, Phase 1 participants were N=4,552 patients who completed an 
anonymous computer-administered health survey (CAHS) that focused on demographics and 
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general health and health risk behaviors including sleep, mood, diet and exercise, smoking and 
alcohol and other drug use.  
Phase 2 
Based on CAHS data who screened at risk for heavy problem alcohol or drug use, 
patients were invited to participate in the 4-arm RCT. The alcohol and drug use items to 
determine RCT eligibility were embedded within the larger health survey to minimize any 
stigma associated with completing a screener about substance use. 
RCT Inclusion Criteria 
For the parent RCT was as follows: between 18 – 70 years of age; not pregnant (by self-
report); residing in the clinic catchment area; able to speak and understand English; not enrolled 
in substance abuse treatment (inpatient, residential, outpatient, methadone maintenance, 
therapeutic community), and screened positive for heavy/problem alcohol and/or drug use. 
Further details about heavy/problem substance use are described below in the methods for the 
current study. 
Current Study 
 
Design and Procedures 
 
Patients were recruited from Virginia Commonwealth University Health System 
(VCUHS) (City of Richmond, Virginia and 33 surrounding counties) primary care and 
gynecology clinic waiting areas. They were approached by research assistances (Ras) who 
invited them to participate in CAHS. Those who expressed interest were escorted to a private 
area adjacent to the clinic waiting room. After obtaining informed verbal consent participants 
completed the 10-minute CAHS (Health Cheq) via Table computer.  
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Random Assignment 
Eligible patients who consented to the RCT (N=713) were randomized to one of four 
study arms, with stratification. Randomization to one of the four study conditions was 
determined by the computer, using participant survey data and internal algorithms, with 
stratification by gender; race (Caucasian or minority), and primary substance type (drug or 
alcohol). Current study participants were N = 540 individuals who completed the CAHS, met 
criteria for the RCT, and were randomized to either the CA, CACI, CATI arms of the study. 
Those in the TAU group were excluded as they did not participate in further baseline assessment 
means central to the current study hypotheses. 
Group 1. Treatment as usual (TAU) (standard care true control): Participants randomized 
to this arm completed no further research assessments until 3 & 6-months follow-ups. 
Group 2. Confidential, computerized assessment (CA) intervention only: Participants 
randomized to this arm were asked more detailed questions about their alcohol and drug use. 
Assessment items included additional standardized assessment measures (e.g., AUDIT, Babor et 
al., 2001), more detailed information about quantity and frequency of use with detailed 
characterization (using timeline-follow-back (TLFB) methods (Sobell & Sobell, 1992) in the past 
30 days. Drug items looked both generally (across all classes of drugs combined) and more 
specifically at drug classes prevalent in the City of Richmond (i.e., marijuana, cocaine, 
heroin/other opiates, sedative-hypnotics). Additional alcohol and other drug use questions 
focused on episodes of heavy use, problems associated with use (e.g., craving, preoccupation, 
loss of control, arguments with spouse, legal problems), efforts to quit or reduce use, family 
history of problems and personal history of substance use treatment (e.g., AA/NA, outpatient, 
residential, detoxification). 
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Group 3. Confidential, computerized assessment plus computer-delivered BI (CACI): 
Participants randomized to this arm completed the CA plus a computer-delivered BI that utilized 
a Motivation Enhancement System (MES). The MES included traditional motivationally-
oriented intervention components: feedback, pros and cons, willingness to change, and optional 
goal-setting. 
Group 4. Confidential, computerized assessment plus therapist-delivered BI intervention 
(CATI): Participants randomized to this arm completed the CA plus a single-session MI 
counseling session that focuses specifically on the same elements described above.  
After the computer and TLFB assessments, CA, CACI, and CATI participants were 
asked to provide a urine sample assayed for 6 drug classes (cocaine, amphetamines, marijuana 
(THC), opiates, methadone, and sedative/hypnotics). Baseline visit participation took between 5-
40 additional minutes (depending on group assignment). Patients were compensated for 
completing the assessments, with gift cards, and had the potential to earn $150 for completing all 
scheduled visits. 
Computerized Software Platform 
The computerized screening and assessment for the proposed study were developed using 
the Computerized Intervention Authoring System (CIAS), an authoring tool that allows creation 
or editing of internet-delivered interventions without the need of a programmer. The software 
features a high-quality synthetic text to speech engine that reads all questions and speaks aloud 
to the participant (using headphones); synchronous interactivity, natural language reflections, 
branching logic, a clean user interface, tailored SMS, and the ability to easily incorporate 
specific images, graphs, figures, text, or videos. CIAS was designed to be consistent with 
research from the Human-Computer Interaction literature suggesting that ethopoeia (the extent to 
  
 
39 
 
 
which software embodies lifelike attributes such as a voice, image, or personality) is related to 
greater engagement and better outcomes (e.g., Appel et al., 2012; Brave et al., 2005; Mumm & 
Mutlu, 2011); CIAS, therefore, uses an interactive and emotive three-dimensional narrator with 
multiple engaging animations. This narrator reads and speaks aloud and functions as an engaging 
guide throughout the intervention. 
For the parent and current study, the CAHS, computer-directed assessment, and 
computer-directed BI utilized CIAS. A mobile three-dimensional cartoon character, Peedy the 
Parrot, capable of over 50 specific animated actions (e.g., smile, wave, read a message, express 
concern, etc.) does the “talking” for the entire program. Peedy the Parrot acted as a narrator, 
reading each item aloud for the participant, guiding them throughout the survey, and providing 
occasional comic relief. Pleasing and relevant graphics changed with each screen to maintain 
interest. Participants could use either the touchscreen or keyboard/mouse to proceed through the 
survey, and participants listened to Peedy via headphones to ensure privacy. All answers were 
provided by choosing responses from a list or by touching a visual analog scale. The program did 
not require reading literacy.  
Alcohol and Other Drug Use Screening and Assessment Measures  
All screening and assessment measures are summarized in Table 2. Please see Appendix 
A for the TLFB used in the present study. Below is a detailed description of the alcohol, illicit 
drug, and prescription drug misuse screening and assessment measures.  
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Table 2. Baseline Screening and Assessment Measures. 
Domain Measure Anonymous, 
Computer-
Administered 
Health Screen 
Confidential, 
Computer-
Administered 
Research 
Assessment 
Confidential, 
interviewer-
Administered 
Research 
Assessment  
Demographic 
Characteristics 
Age, race, ethnicity, 
gender, marital status, 
education, employment, 
income, insurance 
coverage  
F   
 
 
 
 
Alcohol Use 
Q/F of typical recent (past 
30 days) use  
F   
Episodes of binge 
drinking 
F   
AUDIT  P  
Q/F of lifetime (heaviest) 
alcohol use 
 F  
Q/F of past 3 months use  F  
Timeline-Follow-Back 
(Q/F) 
 
  F 
 
 
 
 
Alcohol-
related 
Problems 
CAGE (men) F   
T-ACE (Women) F   
ASSIST (loss of control, 
problems, cravings) 
 P  
Efforts to quit or reduce 
drinking, family history of 
alcohol problems and 
personal history of alcohol 
treatment 
 P  
Brief Mast   P  
 
 
 
 
Illicit Drug 
Use 
Frequency of recent (past 
30 days) use (not drug-
specific) 
F   
Frequency of recent (past 
30 days) regular 
(3+x’s/week) use (drug 
specific) 
F F  
Frequency of lifetime use 
(drug specific) 
 P  
Frequency of use (drug 
specific) – past 3 months 
 F  
Peer influence on use  P  
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Timeline-Follow-Back 
(Q/F) 
  F 
 
Illicit Drug 
Use-related 
Problems 
CAGE-DRUG (men and 
women) 
F   
DAST  P  
Family history of drug 
problems 
P   
ASSIST (loss of control, 
problems, cravings) 
 P  
 
 
 
 
Prescription 
Drug Misuse 
Frequency of recent (past 
30 days) misuse 
F   
Lifetime use (drug 
specific) 
 P  
Episodes of heavy use 
(drug specific) 
 P  
Frequency of past 3-month 
use (drug specific) 
 P  
Reasons for misuse and 
source of drug 
 F  
Peer influence on drug use  P  
Timeline-Follow-Back 
(Q/F) 
  F 
Prescription 
Drug Misuse-
related 
Problems 
ASSIST (loss of control, 
problems, cravings) 
 P  
DAST  P  
 
Tobacco Use 
Quantity and frequency of 
recent and lifetime 
(heaviest ever) use 
F   
Fagerstrom Tobacco 
Dependence Questionnaire 
(FTD) 
 
P   
Physical and 
Emotional 
Health 
General health questions P   
Depression K10 F   
Anxiety K10 F   
Partner 
Violence 
PVS F   
F=Full Assessment 
P=Partial Assessment 
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CAHS Tools for Alcohol Use 
Screening measures included the 4-item CAGE (Ewing, 1998) for men and the 4-item T-
ACE (Sokol et al., 1989) and items from the 10-item Brief MAST (Pokorny et al., 1972). 
Problem alcohol use represents >2 score on the CAGE (for men) and T-ACE (for women). 
Participants were asked about quantity and frequency of typical recent (past-30 days) and binge 
drinking. This period of assessment is congruent with the TLFB assessment period (past 30 days) 
and thus enabled a comparable evaluation. 
CAHS Tools for Illicit Drug Use & Prescription Drug Misuse 
Screening included the standardized screening tool, the 4-item CAGE-AID, adapted for 
use of illicit drugs (CAGE-DRUG), with a cut-off of ≥ 1 (for both men and women) indicating 
problem substance use (Brown & Rounds, 1995), and subitems from the DAST (Skinner, 1982). 
Also, participants were shown a computer screen listing various classes of drugs (modified from 
the CIDI drug module) (Uston et al., 1997) and were asked to check all those they have used 
regularly (3+ days/week) in the past 30 days. The list included marijuana, cocaine, stimulants, 
inhalants, heroin, and hallucinogens. For those drugs endorsed, they were asked about their 
frequency of use in the past 30 days, including how many days they used as well as their average 
use per week. Various classes of prescription drugs (narcotics/analgesics, sedative-hypnotics) 
were included along with a list of common medications or drugs found within each class. 
Subsequent items asked about any category checked yes and focused on the frequency of recent 
use (past 30 days), use by prescription, and variations from such use (e.g., using greater amounts 
or using for longer periods than prescribed). Problems associated with prescription drug misuse 
was not assessed by the CAHS. Similar to CAHS tools for alcohol use, the past 30-day illicit 
drug use and/or prescription drug misuse period of assessment is congruent with the TLFB 
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assessment period (past 30 days) and thus enabled a comparable evaluation. Family history of 
drug use was also assessed.    
CARA Tools for Alcohol Use 
Assessment included subitems from additional standardized measures (e.g., AUDIT) 
(Babor et al., 2001), information about quantity and frequency of use, including lifetime 
(heaviest) alcohol and their average use per week in the past 3-months. Further assessment 
included subitems from the ASSIST (WHO, 2002) that referred to the past 3-month period and 
asked three questions focused on problems associated with alcohol use (e.g., loss of control, 
arguments with partner/family members related to drinking, craving or needing a drink). 
Response categories for these items were: almost all the time, sometimes, rarely, and not at all. 
Additional questions focused on efforts to quit or reduce drinking, family history of alcohol 
problems, and personal history of alcohol treatment (AA, outpatient, residential, detoxification). 
Participant perception of treatment was also surveyed.   
CARA Tools Illicit Drug Use & Prescription Drug Misuse 
For illicit drug use and prescription drug misuse, additional assessment focused on past 3-
month use, including how many days they used as well as their average use per week. Questions 
also focused on regular use, lifetime use, and episodes of heavy use/misuse. Items looked both 
generally (across all classes of drugs combined) and more specifically at drug classes prevalent 
in the City of Richmond (i.e., marijuana, cocaine, heroin/other opiates, sedative-hypnotics). Past 
3-month problematic use (e.g., loss of control, fights with partner/family members related to use, 
and cravings) was assessed using three subitems from the ASSIST (WHO, 2002) and focused 
separately for each illicit drug (i.e., marijuana, cocaine, amphetamines, inhalants, heroin, and 
hallucinogens) and/or prescription drug (i.e., sleep medicine, sedative and anxiety medicine, 
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stimulant medicine, and pain medicine) the participant self-reported using or misusing. Response 
categories for these items were: almost all the time, sometimes, rarely, and not at all. Additional 
questions focused on efforts to quit or reduce use/misuse, family history of drug problems, and 
personal history of drug treatment (NA, outpatient, residential, methadone maintenance, 
detoxification). Participant perceptions of such treatment experiences were assessed. Reasons for 
using drugs and peer influence on drug use were also assessed. 
IARA for Alcohol Use and Other Drug Use. 
Detailed information about quantity and frequency of alcohol use in the past 30 days was 
obtained using Timeline-Follow-Back (TLFB) methods (Sobell & Sobell, 1992), and detailed 
characterization of both past 30-day use of illicit drugs as well as prescription drug misuse was 
assessed using TLFB procedures.  
Urine Drug Assay.  
Participants were asked to provide a urine sample that was assayed for 6 drug classes 
(marijuana (THC), cocaine, amphetamines, opiates, oxycontin, and benzodiazepines). 
Information was collected about prescription medications that participants reported taking 
medically as prescribed and urine drug screens (UDS) for those medications were not counted as 
positive. 
In regard to the classification of UDS samples, positive opiate results could encompass 
both illicit substances (e.g., heroin) and non-medical prescription use (e.g., opiates, oxycontin) 
categories due to similar metabolic processes. For the present study, positive tests for opiates 
with self-reported heroin use (i.e., the heroin metabolite, 6-Monoacetylmorphine) absent of self-
reported non-medical prescription opiate use were classified as heroin-positive; tests positive for 
other opioids (codeine, oxycontin, oxycodone, hydrocodone) absent of self-reported heroin use 
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were classified as positive for non-medical prescription opioid use. Also, positive tests for non-
medical amphetamine and methamphetamine use were classified as amphetamine positive.  
Additional Baseline Assessment Measures 
Tobacco. Items from the NSDUH (SAMHSA, 2006) were used to briefly summarize 
quantity and frequency of recent and lifetime (heaviest ever) use. The items quantified lifetime 
cigarette smoking with questions such as: “Which statement best describes your smoking 
behavior over your lifetime?” with 3 response options (1 = 100 or more cigarettes and 3 = I have 
never smoked cigarettes). Also included were questions about lifetime and recent use (age of 
onset of use and daily smoking, years of daily smoking, efforts to quit, current interest in quitting 
or reducing tobacco use) (SAMHSA, 2006). Fagerstrom Test for Nicotine Dependence 
(Heatherton et al., 1991) was also used. These items assessed a range of current smoking 
behaviors including the number of cigarettes smoked per day, the amount of time after waking in 
the morning to first cigarette, and which cigarette would be the most difficult to give up. The 
Fagerstrom Test for Nicotine Dependence has demonstrated high reliability, as well as validity 
when using cotinine as a criterion variable (Pomerleau et al., 1994).   
Physical and Emotional Health. Participants were presented with a range of medical 
conditions related to addiction (e.g., chronic obstructive pulmonary disease (COPD), arthritis, 
hepatitis, liver disease, pancreatitis) and asked whether they had ever received a diagnosis for 
any of the listed conditions. They were also asked about the reason for their current medical visit 
(e.g., yearly check-up, new health problems, ongoing health problems) and, in general, how 
would they rate their overall health on a 5-point scale (1 = excellent and 5 = poor).  
Kessler Psychological Distress Scale (K10). Level of psychological distress was assessed 
using the Kessler Psychological Distress Scale (Kessler & Mroczek, 1992; Kessler et al., 2002). 
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This short dimensional measure includes 10 items to measure participants’ emotional state in the 
past 30 days, which are scored on a 5-point scale (1 = none of the time and 5 = all of the time) 
and identifies levels of distress. Scores of the 10 items are then summed, with higher scores 
indicating higher levels of psychological distress.      
Sleep Behavior. Sleep behavior was assessed using items from the Insomnia Severity 
Index (Bastian et al., 2001). Participants were asked to rate if they had difficulty falling asleep, 
staying asleep, or problems waking up too early on a 5-point scale (1 = none and 5 = very 
severe). The Insomnia Severity Index corresponds with the DSM-IV criteria for insomnia and 
measures perceptions of symptom severity, distress, and daytime impairment. The diagnostic 
validity of the measure has been well established in distinguishing individuals diagnosed with 
primary insomnia from good sleeper controls (sensitivity, 94%; specificity 94%) (Smith & 
Wegener, 2003). The use of prescription drugs for sleep was also assessed with an item from the 
Pittsburgh Sleep Quality Index (PSQI) asking participants if they took any medication to help 
them sleep in the past 30 days, and if so, how often did they take this medication as a sleep aid 
on a 4 point scale (1 = daily and 4 = less than twice per week) (Buysse et al., 1989). This 
measure has also demonstrated diagnostic validity in distinguishing good and poor sleepers 
(sensitivity, 89.6%; specificity, 86.5%).  
Partner Violence Screen (PVS). The 3-item Partner Violence Screen was included to 
assess two dimensions of partner violence: physical violence and perceived safety (Feldhaus et 
al., 1997). Physical violence was assessed by asking, “Have you been hit, kicked, punched, or 
otherwise hurt by someone within the past year?” with yes/no option. Two questions assessed 
perceived safety by asking, “Do you feel safe in your current relationship?” and “Is there a 
partner from a previous relationship who is making you feel unsafe now?” with yes/no options. 
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Three studies have assessed the sensitivity and specificity of the PVS (sensitivity, 35%-71%; 
specificity, 80%-94%) (Feldhaus et al., 1997; Mills et al., 2006; MacMillan et al., 2009), and 
although it has demonstrated a wide range of sensitivity, it serves as a brief screen for identifying 
partner violence in the primary care setting.  
Defining Heavy/Problem Substance Use 
 
To qualify for the RCT and the current study, participants had to meet criteria for 
heavy/problem alcohol and/or drug use. These were defined as follows: 
Heavy/problem alcohol use was defined as either: 1) 1) CAGE alcohol score ≥ 2 (men) or 
T-ACE score ≥ 2 (women) and self-reported consumption of > 14 drinks/week (men) or > 7 
drinks/week (women) in the past 30 days; or 2) Self-reported consumption of 5 or more drinks 
(men) or 4 or more drinks (women) on at least two occasions in the past 30 days.   
Heavy/problem drug use was defined as 1) CAGE drug score ≥ 1 and recent drug use 
(past 30 days); or 2) illicit drug use 2 or more days/week (past 30 days); or 3) misuse of 
prescribed medications (e.g., taking more than prescribed, using someone else’s prescription, 
getting medications from more than one health provider) on at least 2 occasions in the past 30 
days.  
Current Study Variables 
 
Variables for the current study included demographic variables (e.g., age, gender, race, 
ethnicity, employment, and marital status), alcohol and other drug use variables, and UDS 
results. The alcohol and other drug use variables were carefully selected and/or created out of 
existing alcohol and other drug use screening and assessment measures based on domains to be 
studied as well as psychometric properties. Table 3 lists the current study variables and the 
crosswalk between variables in the CAHS, CARA, and IARA. Past 30-day alcohol and binge 
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drinking as well as other drug use were also included to provide direct comparisons between the 
anonymous, computer-administered health screen and confidential, interview-administered 
research assessment, as past 30-day use was directly assessed by both methods. However, for 
past 30-day binge drinking and prescription drug misuse the anonymous, computer-administered 
health screen offered broader response options (e.g., 11-20 days, 21-29 days) and were 
reclassified as 15 and 25 days, respectively. Past 30-day alcohol and other drug use on the 
confidential, computer-administered research assessment was calculated by taking the mean of 
the self-reported average drinking days and/or other drug use (each drug was asked separately 
and included all those the participant reported using) per week in the past three months and 
multiplying by 4.29. 
 
Table 3. Crosswalk Between Screening and Assessment Study Variables. 
   Measure/Question 
Domain Anonymous, 
Computer-
Administered 
Health Screen 
 Confidential, 
Computer-
Administered 
Research Assessment 
 Confidential, 
interviewer-
Administered Research 
Assessment 
Alcohol 
Use – 
Weekly 
(7/days) 
During the past 
30 days, on 
average, how 
many drinks 
did you have 
each week? 
(asked 
separately for 
both females 
and males) 
 
 
 
 
X 
In an average week in 
the past 3 months, how 
many days per week did 
you typically drink? 
 
+ 
 
In the past 3 months, on 
the days when you did 
drink, how many drinks 
did you have? 
 
 
 
X 
Quantity of weekly use in 
past 30 days 
Binge Use During the past 
30 days, how 
many times 
have you had 
4/5 or more 
drinks per 
occasion? 
(asked 
  
N/A 
 Number of binge drinking 
days in the past 30 days 
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separately for 
both females 
and males) 
Illicit Drug 
Use – 
Weekly 
(7/days) 
During the past 
30 days, on 
how many days 
each week did 
you use 
recreational 
drugs? 
(not drug-
specific) 
 
X 
In an average week in 
the past 3 months, how 
many days per week did 
you typically use xxx? 
(drug specific) 
 
X 
Frequency of weekly drug 
use (drug specific) 
Prescription 
Drug 
Misuse – 
Weekly 
(7/days) 
In the past 30 
days, on how 
many days 
have you: 
Taken more 
pills, more 
often, etc. 
(not drug-
specific) 
 
 
X 
In an average week in 
the past 3 months, 
(“thinking about 
misuse”) how many 
days per week did you 
typically use xxx 
medicine? (drug 
specific) 
 
 
X 
Frequency of weekly 
misuse (drug specific) 
Alcohol-
related 
Problems 
(males) 
CAGE                           X ASSIST-3 items  N/A 
Alcohol-
related 
Problems 
(females) 
T-ACE             X ASSIST-3 items  N/A 
Drug-
related 
problems 
(males and 
females) 
CAGE-DRUG      X ASSIST-3 items  N/A 
 
 
The anonymous, computer-administered health survey directly asked for average weekly 
use for alcohol (i.e., quantity and frequency) and illicit drug use in the past 30 days. For 
prescription drug misuse, mean days of misuse per week was calculated by dividing past 30-day 
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use by 4.29. Days of alcohol and other drug use in the past 30 days were divided by 4.29 to 
calculate the average weekly use on the interviewer-administered research assessment. Mean 
days per week in the past three months was used to calculate average weekly use for alcohol and 
other drug use on the confidential, computer-administered research assessment. Drinks per week 
in the past 30-days were grouped the same across each measure (0 drinks, 1-2 drinks, 3-5 drinks, 
6-9 drinks, 10-15 drinks, 16-20 drinks, and 21 or more drinks).  
The T-ACE was modified by assigning only 1 point to the tolerance question while 
keeping positivity set at 2 or more of the possible 4 questions. The T-ACE was originally 
developed for a prenatal population to detect risk of fetal alcohol syndrome where a positive 
response to the tolerance question was sufficient for further inquiry. However, in a primary care 
clinic population, the modest increase in sensitivity resulting from lowering the threshold of 
positivity is not offset by the considerable drop in specificity (i.e., false positives) (McQuade, 
Levy, Yanek, Davis, & Liepman, 2000). 
The 3-Question ASSIST (ASSIST-3) questions for alcohol read, “In the past 3 months, 
how often did you experience a loss of control while you were drinking?” (ASSIST Q1); “In the 
past 3 months, how often did your drinking lead to problems like fights with family and 
friends?” (ASSIST Q2); and “In the past 3 months, how often did you have strong cravings for 
alcohol?” (ASSIST Q3). For illicit drug use, ASSIST questions read, “In the past 3 months, how 
often did you experience a loss of control while you were using (__________)?” (ASSIST Q1); 
“In the past 3 months, how often did your (__________) use lead to problems like fights with 
family and friends?” (ASSIST Q2); and “In the past 3 months, how often did you have strong 
cravings for (__________)?” (ASSIST Q3). 
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Similar to Tiet and colleagues (2015), the present study consolidated the ASSIST-3 
questions that assessed each category of illicit drug separately (i.e., marijuana, cocaine, heroin, 
amphetamines, inhalants, and hallucinogens) to assess all illicit drugs as a combined question. 
For every illicit drug the participant self-reported using regularly, ASSIST-3 responses were 
calculated to create a total ASSIST-3 score. The highest score (i.e., most severe value) for each 
question was summed. Therefore, if a participant reported high-risk for marijuana on one 
question but only moderate risk for cocaine, only the high-risk score was summed.  
Data Analysis 
 
Data Preparation and Missing Data 
Analyses for all study aims were computed with SPSS software, version 27.0 (SPSS, 
Armonk, NY). Prior to analysis, means, standard deviations and 95% confidence intervals (or 
medians and inter-quartile ranges) were estimated for each continuous variable, while 
frequencies, proportions, and 95% confidence intervals were computed for each categorical 
variable. Data were also examined for normality of distribution and the presence of outliers.  
Missing data was limited within the CAHS and CARA since the screening and 
assessment questions were delivered via CIAS with complex skip patterns based on participant 
responses. Missing data were also limited within the IARA given the face-to-face and semi-
structured format. Therefore, analyses were conducted to include all participants who were 
randomized to CA, CACI, CATI groups. The data was treated as is, with any case with missing 
values excluded from the analyses.  
Primary Analyses  
Aim 1: To address the first study aim comparing rates of recent (past 30-day) alcohol 
use, including binge drinking, illicit drug use (including marijuana, cocaine, methamphetamine, 
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heroin), and non-medical use of prescription drugs (including opioids, stimulants, and sedative-
hypnotics) across groups (e.g., CAHS by CARA, CARA by IARA, CAHS by IARA), sensitivity 
and specificity, positive predictive values (PPV), negative predictive values (NPV), and chance-
corrected Cohen’s kappa coefficient (κ) statistics were calculated. Kappa values ≤ 0 indicate no 
agreement, 0.01–0.20 as none to slight, 0.21–0.40 as fair, 0.41– 0.60 as moderate, 0.61–0.80 as 
substantial, and 0.81–1.00 as almost perfect agreement (Cohen, 1960). It has been suggested that 
k values of 0.50 or 0.60 are indicative of “acceptable” concordance (Grove et al., 1981). The 
interviewer-administered TLFB is the accepted “gold standard” against which the anonymous 
screener and computerized assessment (when applicable) are compared in order to reflect testing 
new modalities against the status quo.   
Interrater reliability across modes of administration for frequency of use (days during the 
past 30) as well as self-reported drinks per week (7/days) and frequency of weekly (7/days) illicit 
drug use and prescription drug misuse during the past 30 days was calculated using intraclass 
correlation coefficient (ICC) (Shrout & Fleiss, 1979) and their 95% confident intervals. The ICC 
(2,1) was based on a single-rater/measurement, consistency, 2-way random-effects model. 
Because we have randomly selected our raters (i.e., anonymous computer-administered screener, 
computerized assessment, interview-administered TLFB) from a larger population of raters with 
similar characteristics, a 2-way random-effects model was the model of choice. This 2-way 
random-effects model allowed us to generalize our reliability results to any raters who possess 
the same characteristics as the selected raters in this study. The selection of single-
rater/measurement was used because we plan to use the measurement from a single rater 
(interviewer-administered TLFB) as the basis of the actual measurement; therefore, “single rater” 
type was selected even though the reliability experiment involves 2 or more raters. Because the 
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CARA does offer a direct comparison of weekly alcohol and other drug use against the CAHS 
and IARA, the definition of relationship considered is “consistency” versus “absolute 
agreement.” Based on the 95% confident interval of the ICC estimate, values less than 0.5 are 
indicative of poor reliability, values between 0.5 and 0.75 indicate moderate reliability, values 
between 0.75 and 0.9 indicate good reliability, and values greater than 0.90 indicate excellent 
reliability (Koo & Li, 2016; Shrout & Fleiss, 1979). 
Hypothesis 1. The first hypothesis predicted that participants will report more binge 
drinking days in the past month (30 days) on the anonymous, computer-administered screener 
compared to the confidential, interviewer-administered assessment. To test this hypothesis, binge 
drinking days were compared for the two groups using paired sample t-tests. The effect size for 
the paired-samples t-test was calculated using Cohen’s d (Cohen. 1998). 
Hypothesis 2. The second hypothesis predicted that participants will report consuming, 
on average, more drinks per week over the past 30 days by anonymous, computer-administered 
screener (CAHS) compared to the confidential, computerized assessment (CARA). The study 
also hypothesized that participants will report consuming, on average, more drinks per week by 
CAHS compared to the interview-administered assessment (IARA). To test this hypothesis, 
drinks per week were compared for the three groups using paired sample t-tests. The effect 
size for the paired-samples t-test was calculated using Cohen’s d. 
Hypothesis 3. The third hypothesis predicted that participants will report, on average, 
more days of drug use per week over the past 30 days by anonymous, computer-administered 
screener (CAHS) compared to confidential, computerized assessment (CARA). The study also 
hypothesized that participants will report, on average, more days of drug use per week by CAHS 
compared to the interview-administered assessment (IARA). To test this hypothesis, days of drug 
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use per week were compared for the three groups using paired sample t-tests. The effect size for 
the paired-samples t-test was calculated using Cohen’s d. 
Hypothesis 4. The fourth hypothesis predicted that participants will report, on average, 
more days of prescription drug misuse per week by anonymous, computer-administered screener 
(CAHS) compared to confidential, computerized assessment (CARA). The study also 
hypothesized that participants will report, on average, more days of drug use per week by CAHS 
compared to the interview-administered assessment (IARA). To test this hypothesis, rates of 
prescription drunk misuse per week were compared for the three groups using paired sample t-
tests. The effect size for the paired-samples t-test was calculated using Cohen’s d. 
Aim 2: Aim 2 compared endorsement of alcohol and/or drug use related problems 
between the CAHS (CAGE, T-ACE, CAGE-DRUG) and CARA (ASSIST-3). 
First, descriptive statistics were calculated for problems related to alcohol use identified 
by the CAGE, T-ACE, and ASSIST-3 items. Descriptive statistics were also calculated for 
problems related to illicit drug use identified by the CAGE-DRUG as well as lifetime history of 
regular (3+ days/week) illicit drug use and subsequent ASSIST-3 scores. The CAGE-DRUG and 
ASSIST-3 items for illicit drug use were analyzed separately for males and females. 
Two-tailed independent t-tests were used to compare ASSIST-3 scores for participants 
endorsing each of the items (yes/no) of the CAGE, T-ACE, and CAGE-DRUG questions. The 
CAHS (i.e., CAGE-DRUG) did not measure problems associated with prescription drug misuse. 
For alcohol, the sample size was N = 159 for males. Excluded were N = 25 with missing 
data due to a programming error. N = 26 males who reported no alcohol use on both the CAHS 
and CARA and therefore were not asked both CAGE and ASSIST-3 items. For T-ACE, the 
sample size was N = 285 for this analysis. Excluded were women (N = 45) who denied alcohol 
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use on both the CAHS and CARA and therefore were not asked both CAGE and ASSIST-3 
items. 
For CAGE-DRUG (males), the sample size was N = 144. Excluded were N = 66 males 
who denied drug use on both surveys and therefore were not asked both CAGE and ASSIST-3 
items. For CAGE-DRUG (females), the sample size was N = 220, and excluded were N = 110 
women who reported no drug use on both the CAHS and CARA and therefore were not asked 
both CAGE and ASSIST-3 items. 
The ASSIST-3 total scores for alcohol and ASSIST-3 scores for illicit drug use were 
investigated for its ability to identify problematic alcohol and illicit drug use on the CAGE, T-
ACE, and CAGE-DRUG. The CAGE, T-ACE, and CAGE-DRUG was used as the reference 
measure. These tools have been widely used in primary care settings to assess substance use-
related problems (Brown & Rounds, 1995; Lanier & Ko, 2008; Sarkar et al., 2010; Tan et al., 
2018; USPSTF, 2018). Substance use-related problems were defined using the standard 
threshold of scoring positive on two or more CAGE/T-ACE items and scoring positive on one 
more CAGE-DRUG items (Steinbauer et al., 1998).  
Sensitivity, specificity, and the positive and negative predictive values (PPV and NPV) 
were calculated. The sensitivity and the specificity represent the proportion of participants whose 
CAGE, T-ACE, CAGE-DRUG score were correctly identified by the ASSIST-3 cut-points and 
the proportion of patients who do not have a problematic CAGE, T-ACE, CAGE-DRUG score 
and who have a negative ASSIST-3 total score (i.e., below the cut-points) respectively. The PPV 
represents the proportion of patients above the cut-points on the ASSIST-3 who had a 
problematic score on the CAGE, T-ACE, CAGE-DRUG, while the NPV shows the proportion of 
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patients who test negative on the ASSIST-3 who do not have a problematic score on the CAGE, 
T-ACE, CAGE-DRUG.  
 To generate a cut-point on the ASSIST-3 total score, binary logistic regression analyses 
and receiver operating characteristic (ROC) analysis were performed. The area under each curve 
(AUC) was examined (Hanley & McNeil, 1982) and the cut-point for the ASSIST-3 total score 
was based on maximizing the AUC. Excellent discrimination was considered an AUC of >.90, 
very good discrimination was considered an AUC of 0.8-0.9, acceptable discrimination was 
considered 0.7-0.8, poor discrimination was considered 0.6-0.7, while an AUC of 0.5-0.6 was 
considered poor discrimination (Meyers et al., 2017).  
Hypothesis 1. Participants will be more likely to score positive for problematic substance 
use on the anonymous, computer-administered screener (i.e., CAGE, T-ACE, CAGE-DRUG) 
compared to the confidential, computerized assessment (i.e., ASSIST-3). This hypothesis was 
tested using chi-square analyses. 
Aim 3: Aim 3 compared agreement between self-reports of recent drug use (marijuana, 
cocaine, heroin) or non-medical prescription drug use (opiates, benzodiazepines, amphetamines) 
on the TLFB and biological measures (i.e., urinalysis). The TLFB recorded only non-medical use 
of prescription medications. Those who did not provide a urine drug screen (UDS) (N = 26) or 
who’s illicit drug misuse data were missing (N =49) were excluded from the analysis. Also, type 
of prescription drug used was not initially assessed on the IARA due to parent study design. As 
such, these participants (N = 109) were also excluded from the analysis.   
Substances reported on the TLFB were matched with those detected on the urinalysis, 
and a binary variable was created for each substance, separately for both the TLFB and UDS. 
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Comparisons were made separately for self-reported non-medical prescription opiate use and 
heroin use as well as those with both prescription opiate and heroin use. 
Self-reported use on the TLFB and UDS results were compared for overall agreement. 
Participants were classified as concordant (positive) for each respective substance if the 
individual endorsed use for the identified substance on the IARA (i.e., the TLFB) and had a 
positive UDS result. Likewise, participants were classified as concordant (negative) if they 
reported no recent substance use and had a negative result on the UDS for each respective 
substance. Participants were classified discordant if the individual was TLFB positive only (i.e., 
self-reported use in combination with a negative UDS test) or UDS positive only (i.e., no self-
reported use in combination with a positive UDS test). Sensitivity, specificity, positive predictive 
values (PPV), and negative predictive values (NPV) were also calculated.  
The kappa (k) statistic (Cohen (1960)) was used to examine the concordance of self-
report and urinalysis results. While it has been suggested that k values of 0.50 or 0.60 are 
indicative of “acceptable” concordance (Grove et al., 1981), a combination of factors could 
potentially inflate the value of k. For example, underestimation/under-reporting of substance use 
by self-report, administering only one urinalysis tests during the 30-day interval covered by the 
TLFB, and potential for false-negatives with the UDS testing technique could potentially 
increase the apparent agreement between the two measures. Thus, in order to adjust for these 
factors, the conditional k statistic (cond. k) was also computed (Bishop et al., 1975). The cond. k 
indicates the degree to which self-reports agree with a positive urinalysis result and has been 
used to examine validity of self-reported drug use in several studies (Chermack et al., 2000; 
Sherman and Bigelow, 1992; Zanis et al., 1994). 
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Hypothesis 1: Proportion of illicit drug use and non-medical prescription drug use will be 
higher by urine assay compared to self-report measure. This hypothesis was tested using chi-
square analyses. 
Aim 4: Lastly, univariate logistic regression was used to identify correlates of self-
disclosure of any alcohol and other drug use as well as substance use per week in the past 30-
days, sampling from psychosocial and health disparity domains. Variables included: age; gender; 
race (e.g., White/Minority); ethnicity; marital status (married/unmarried); years of education ( 
12 yrs./< 12 yrs.); insurance coverage (private/government or state); employment status; anxiety; 
depression; psychological distress (moderate/severe) as measured by K10 total score (Andrews 
& Slade, 2001); sleep behavior (quality of sleep; taking sleep aids); and number of medical 
conditions (0/ 2). Significance was set at 0.05 for all univariate analyses; however, any 
variables reaching a significance level of <0.20, along with basic demographic variables, were 
subsequently included in a multivariate logistic regression model to examine their effect in 
combination. When multiple items from the same domain reached significance, only one 
predictor was selected for inclusion in the multivariate analysis to avoid multicollinearity. 
A multivariable logistic regression model, with backward elimination, was used to 
identify the most parsimonious model of correlates of self-reported substance use. The final 
model was achieved by eliminating covariates, one by one, that were not significant at the 0.05 
level. The Hossmer Lemeshow test was used to check goodness-of-fit of the logistic regression, 
as well as the R-squared value to determine how much of the variance was explained by the 
model. 
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Results 
 
Participant Flow through Study 
The consort diagram (see Figure 1) summarizes participant flow through the parent RCT 
and current study, as per the Standards of Reporting Trials guideline (Altman et al., 2001). A  
 
 
 
Figure 1. CONSORT Diagram of Study Recruitment and Enrollment. 
*Did not complete all baseline measures. 
 
total of N = 4552 primary care patients completed the CAHS/Health Cheq Survey. Of those, N = 
3214 did not meet inclusion criteria; of those who met parent RCT criteria, N = 625 elected not 
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to participate. A total of N = 713 provided informed consent and were randomized. A total of N 
= 172 were randomized to the Standard Care True Control group and did not complete all 
baseline measures. One participant (N=1) did not complete the three baseline assessments for the 
present study and was removed from analyses, totaling a sample size of N = 540 for the current 
study. 
Demographics 
Table 4 summarizes demographic characteristics for those who completed the 
anonymous, computer-administered health screen (CAHS) and went on to complete the  
 
Table 4. Participant Demographic Characteristics (N=540). 
 
Variable 
 
Percent (N) 
 
Mean ± SD 
Age (yrs.)  45.14 (11.01) 
Gender – Male  39% (210)  
Race 
    Black/African American     
    White      
    Other 
 
78% (421) 
18% (98) 
4% (21) 
 
Ethnicity 
    Hispanic 
 
3% (18) 
 
Employment* 
    Full Time 
    Part Time 
    On Disability 
    Retired 
    Unemployed 
    Student 
 
12% (49) 
13% (56) 
20% (83) 
3% (13) 
49% (206) 
3% (13) 
 
Marital Status* 
    Single/Never Married 
    In a Relationship 
    Married 
    Divorced/Separated 
    Widowed 
 
45% (187) 
21% (86) 
13% (53) 
20% (82) 
3% (12) 
 
*N=421 sub-sample for these variables.  
SD =standard deviation 
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confidential, computer-administered research assessment (CARA), and confidential, interviewer-
administered research assessment (IARA) (N=540). Almost two-thirds of the participants were 
female (61%). Mean age was 45.14 years (SD = 11.01) and the majority identified their race as 
Black/African American (78%). Nearly half reported being unemployed (49%) and a similar 
percentage were single/never married (45%).  
Overall Substance Use  
 
 The alcohol and other drug use characteristics for the overall sample are summarized in 
Table 5. As required for study eligibility, all participants met criteria for heavy/problem alcohol 
and/or drug use.  
 
Table 5. Baseline Substance Use for the Overall Sample (N=540). 
 
Substance Use and Problems 
Variable 
 
CAHS 
% (N) 
 
CARA 
% (N) 
 
IARA 
% (N) 
Alcohol Use 
Any Use (Past 30-Day) 
Any Binge Use (Past 30-Day) 
 
86% (465) 
71% (382) 
 
59% (320) 
-- 
 
79% (424) 
43% (232) 
Alcohol Problems 
T-ACE + (females N=330) 
CAGE + (males N=185)* 
 
39% (130) 
49% (90) 
 
-- 
-- 
 
-- 
-- 
Drug Use 
Any Illicit Drug Use 
(Past 30 Days) 
Any Prescription Drug 
Misuse (Past 30 Days) 
Type of Prescription Drug 
Misuse 
Higher Dosage than Prescribed 
More Often than Prescribed 
Using Someone Else’s 
Prescription 
Obtaining Same Prescription 
from Multiple Physicians 
 
37% (198) 
 
27% (144) 
 
 
 
15% (83) 
12% (62) 
13% (69) 
 
2% (10) 
 
 
53% (284) 
 
27% (145) 
 
 
 
-- 
-- 
-- 
 
-- 
 
47% (253) 
 
27% (145) 
 
 
 
-- 
-- 
-- 
 
-- 
Drug Problems 
CAGE-DRUG + 
 
39% (208) 
 
-- 
 
-- 
*N=25 males excluded due to computer branching error.  
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AIM 1: Rates of Any Recent Alcohol and Other Drug Use by Assessment Method (CAHS, 
CARA, or IARA) 
 
Any Recent (Past 30-Day) Alcohol Use. As shown in Table 6, rates of recent (past 30-
day) alcohol use by self-report ranged from 59% by confidential, computerized research 
assessment (CARA), to 79% by confidential, interviewer-administered research assessment 
(IARA), and 86% by anonymous, computer-administered health screen (CAHS). When the 
IARA (i.e., TLFB) was considered the gold standard, sensitivity for detecting alcohol use ranged 
from 0.70 for the CARA to 0.97 for the CAHS. The specificity of CAHS was moderate (0.54), 
with lower specificity for the CARA (0.21). Positive Predictive Values (PPV) were high for both 
the CAHS (0.89) and CARA (0.93) while Negative Predictive Values (NPV) were mixed, 
ranging between 0.42 and 0.84 for the CARA and CAHS, respectively. There was moderate 
agreement between both the CAHS and IARA (κ = 0.59) and fair agreement between the CARA 
and IARA (κ = 0.37). When the CARA was considered the gold standard, CAHS sensitivity was 
excellent (0.99) but specificity was fair (0.32). PPV was moderate at 0.68 and NPV was high at 
0.95, with fair agreement between the two assessments (κ = 0.34).  
 
Table 6. Any Recent (Past 30-Day) Alcohol Use by Assessment Measure (N=540). 
 Any Recent (Past 30-Day) Alcohol Use  
 CAHS IARA CAHS CARA CARA IARA 
Any Recent Use % (N) 86% (465) 79% (424) 86% (465) 59% (320) 59% (320) 79% (424) 
+ on Both 
Assessments % (N) 
 
76% (411) 
 
59% (315) 
 
47% (255) 
Sensitivity 0.97 0.99 0.70 
Specificity 0.54 0.32 0.21 
Positive Predictive  
Value (PPV) 
0.89 0.68 0.93 
Negative Predictive 
Value (NPV) 
0.84 0.95 0.42 
Kappa 0.59 0.34 0.37 
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Any Recent (Past 30-Day) Binge Drinking. Rates of self-reported binge drinking (past 
30-days) for the CAHS and IARA are shown in Table 7. The CARA did not measure this 
variable. Over two thirds of participants reported recent binge drinking on the CAHS compared 
to only 43% on the IARA. With the IARA (i.e., TLFB) as the gold standard, sensitivity and 
specificity for the CAHS was 0.91 and 0.45, respectively. The PPV (0.55) was moderate while 
the NPV (0.87) was high, and there was overall fair agreement between the CAHS and IARA (κ 
= 0.33). 
 
Table 7. Any Recent (Past 30-Day) Binge Drinking by Assessment Measure (N=540). 
 Any Recent (Past 30-Days) Binge Drinking 
 CAHS IARA 
Any Recent Use % (N) 71% (382) 43% (232) 
+ on Both 
Assessments % (N) 
 
39% (211) 
Sensitivity 0.91 
Specificity 0.45 
Positive Predictive  
Value (PPV) 
0.55 
Negative Predictive 
Value (NPV) 
0.87 
Kappa 0.33 
 
 
Any Recent (Past 30-Day) Illicit Drug Use. Rates of any recent (past 30-day) illicit 
drug use ranged from 37% by CAHS to 47% by IARA to 53% by CARA (see Table 8). With the 
IARA (i.e., TLFB) considered the gold standard, sensitivity for CAHS was 0.71 with higher  
 
Table 8. Any Recent (Past 30-Day) Illicit Drug Use by Assessment Measure (N=540). 
 Any Recent (Past 30-Day) Illicit Drug Use  
 CAHS IARA CAHS CARA CARA IARA 
Any Recent Use % (N) 37% (199) 47% (253) 37% (199) 53% (285) 53% (285) 47% (253) 
+ on Both  
Assessments % (N) 
 
34% (180) 
 
34% (184) 
 
42% (224) 
Sensitivity 0.71 0.65 0.89 
Specificity 0.94 0.95 0.79 
Positive Predictive  0.91 0.93 0.79 
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Value (PPV) 
Negative Predictive 
Value (NPV) 
0.79 0.71 0.89 
Kappa 0.66 0.58 0.67 
 
  
sensitivity for the CARA at 0.89. Conversely, specificity ranged from 0.79 to 0.94 for the CARA 
and CAHS, respectively. PPV was high at 0.79 for the CARA and even higher for CAHS (0.91), 
while NPV for the CAHS was 0.79 and 0.89 for the CARA. Kappa statistic for rater agreement 
was substantial between both the CAHS and IARA (κ = 0.66) and CARA and IARA (κ = 0.67). 
With CARA as the gold standard, sensitivity for the CAHS was at 0.65 with excellent specificity 
(0.95), and PPV was high at 0.93 with lower NPV at 0.71. There was moderate agreement (κ = 
0.58) between the two instruments. 
Any Recent (Past 30-Day) Prescription Drug Misuse. Table 9 shows rates of any 
recent (past 30-day) prescription drug misuse across the three assessments. Over one-fourth 
(27%) of participants reported any recent misuse on each measure. With the IARA (i.e., TLFB)  
 
Table 9. Any Recent (Past 30-Days) Prescription Drug Misuse by Assessment Measure (N=540). 
 Any Recent (Past 30-Day) Prescription Drug Misuse  
 CAHS IARA CAHS CARA CARA IARA 
Any Recent Use % (N) 27% (145)  27% (145) 27% (145) 27% (145) 27% (145) 27% (145) 
+ on Both 
Assessments % (N) 
 
18% (98) 
 
16% (83) 
 
17% (93) 
Sensitivity 0.68 0.57 0.64 
Specificity 0.88 0.84 0.87 
Positive Predictive  
Value (PPV) 
0.68 0.58 0.64 
Negative Predictive 
Value (NPV) 
0.88 0.84 0.87 
Kappa 0.56 0.42 0.51 
 
 
as the gold-standard, sensitivity ranged from 0.64 for the CARA to 0.68 for the CAHS. 
Specificity was 0.87 for the CARA and 0.88 for the CAHS. PPV ranged from 0.64 for the CARA 
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to 0.68 for the CAHS while NPV was high at 0.87 for CARA and 0.88 for CAHS. CAHS 
sensitivity was slightly lower (0.57) when the CARA was considered the gold standard, with 
specificity at 0.84. PPV remained moderate (0.58) while NPV remained high (0.84). Kappa 
statistic demonstrated moderate agreement between the CAHS and IARA (κ = 0.56), CAHS and 
CARA (κ = 0.42), and CARA and IARA (κ = 0.51).   
Frequency of Recent (Past 30-day) Alcohol and Other Drug Use 
Frequency of Past 30-Day Binge Drinking. As shown in Table 10, among those 
reporting any binge use, number of binge drinking days in the past 30 averaged 5.37 (SD = 7.77, 
median = 2.00, range = 30) on the CAHS and 3.52 on the IARA (SD = 7.10, median = 0.00, 
range = 30). Participants (N = 171) reported one or more binge drinking days only on the CAHS, 
while N = 21 reported one-plus days of binge drinking only on the IARA, and N = 211 reported 
1+ more days with binge use on both. The remainder (not in this analysis, N = 137) reported no 
alcohol use on either measure.    
Hypothesis 1. Participants will report more recent binge drinking days (past 30) on the 
anonymous, computer-administered screener (CAHS) compared to the confidential, interviewer-
administered assessment (IARA). As shown in Table 10, there was a significant difference in  
 
Table 10. Days of Recent (Past 30-Day) Binge Drinking by Assessment Measure (N=540).  
 
 
Survey 
Methods 
 
 
 
Mean ± SD 
 
 
Mean 
Difference 
95% CI of the 
Difference 
 
 
 
t (p-value) 
 
 
 
Cohen’s d 
 
Lower 
 
Upper 
CAHS 
x 
IARA 
5.37 ± 7.77 
 
3.52 ± 7.10 
 
1.85 
 
1.26 
 
2.44 
 
6.15 (< 0.001)* 
 
0.26 
*Denotes a statistically significant t-value (p < .05). 
SD = standard deviation. 
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mean binge drinking days for the CAHS compared to the IARA (t(539) = 6.15, p < 0.001), 95% 
CI [1.26, 2.44], Cohen’s d = 0.26, with more binge drinking days on the CAHS as compared to 
the IARA. These results support the hypothesized associations. 
Frequency of Past 30-Day Alcohol Use. Table 11 summarizes days of recent alcohol 
use across the three assessment measures. Among those reporting any alcohol use, mean number 
of drinking days in the past 30 ranged from 7.97 on the IARA (SD = 9.47, median = 4.00, range 
= 30) to 8.48 (SD = 9.57, median = 4.29, range = 40) on the CARA, and 10.10 on the CAHS (SD 
= 10.17, median = 6.00, range = 30). In the CAHS – IARA comparison, N = 53 participants 
reported number of days of use only on the CAHS, N = 12 reported one-plus days of use on the 
IARA, and N = 411 reported 1+ more days of use on both. The remainder (not in this analysis, N 
= 64) reported no alcohol use on either measure. In the CAHS – CARA comparison, N = 149 
participants reported number of days of use only on the CAHS, N = 4 reported one-plus days of 
use only on the CARA, and N = 315 reported 1+ more days of use on both. The remainder (not 
in this analysis, N = 72) reported no alcohol use on either measure. In the CARA – IARA 
comparison, N = 24 participants reported number of days of use only on the CARA, N = 128 
reported one-plus days of use on the IARA, and N = 296 reported 1+ more days of use on both. 
The remainder (not in this analysis, N = 92) reported no alcohol use on either measure. 
 
Table 11. Days of Recent (Past 30-Day) Alcohol Use by Assessment Measure. 
Days (Past 30) of Alcohol Use 
CAHS IARA CAHS CARA CARA IARA 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
10.10 ± 10.17 7.97 ± 9.47 10.13 ± 10.17 8.48 ± 9.57 8.48 ± 9.57 7.97 ± 9.47 
SD = standard deviation. 
 
Frequency of Past 30-Day Illicit Drug Use. Table 12 reflects the number of days 
participants reported using illicit drugs in the past 30. Average days of drug use ranged from 3.56 
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(SD = 5.04, median = 0.72, range = 30) on the CARA, to 5.02 (SD = 9.85, median = 0.00, range 
= 30) on the CAHS, and 6.19 (SD = 10.26, median = 0.00, range = 30) on IARA. In the CAHS – 
IARA comparison, N = 18 participants reported number of days of use only on the CAHS, N = 
73 reported one-plus days of use on the IARA, and N = 180 reported 1+ more days of use on 
both. The remainder (not in this analysis, N = 269) reported no illicit drug use on either measure. 
In the CAHS – CARA comparison, N = 14 participants reported number of days of use only on 
the CAHS, N = 100 reported one-plus days of use on the CARA, and N = 184 reported 1+ more 
days of use on both. The remainder (not in this analysis, N = 242) reported no illicit drug use on 
either measure. In the CARA – IARA comparison, N = 60 participants reported number of days 
of use only on the CARA, N = 29 reported one-plus days of use on the IARA, and N = 224 
reported 1+ more days of use on both. The remainder (not in this analysis, N = 227) reported no 
illicit drug use on either measure. 
 
Table 12. Recent (Past 30-Day) Illicit Drug Use by Assessment Measure (N=540). 
Days (Past 30) of Illicit Drug Use 
CAHS IARA CAHS CARA CARA IARA 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
5.02 ± 9.87 6.19 ± 10.26 5.02 ± 9.87 3.56 ± 5.04 3.56 ± 5.04 6.19 ± 10.26 
SD = standard deviation. 
 
Frequency of Past 30-Day Prescription Drug Misuse. Table 13 presents the number of 
days participants reported misusing prescription drugs in the past 30. Average days of drug use 
ranged from 1.71 on the CAHS (SD = 4.99, median = 0.00, range = 30) to 2.35 on the CARA 
(SD = 5.23, median = 0.00, range = 30), and 2.95 on the IARA (SD = 7.31, median = 0.00, range 
= 30). In the CAHS – IARA comparison, N = 46 participants reported number of days of use 
only on the CAHS, N = 47 reported one-plus days of use on the IARA, and N = 98 reported 1+ 
more days of use on both. The remainder (not in this analysis, N = 349) reported no prescription 
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drug misuse on either measure. In the CAHS – CARA comparison, N = 61 participants reported 
number of days of use only on the CAHS, N = 62 reported one-plus days of  
 
Table 13. Recent (Past 30-Day) Prescription Drug Misuse by Assessment Measure (N=540). 
Days (Past 30) of Prescription Drug Misuse 
CAHS IARA CAHS CARA CARA IARA 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
1.71 ± 4.99 2.95 ± 7.31 1.71 ± 4.99 2.35 ± 5.23 2.35 ± 5.23 2.95 ± 7.31 
SD = standard deviation. 
 
use on the CARA, and N = 83 reported 1+ more days of use on both. The remainder (not in this 
analysis, N = 334) reported no prescription drug misuse on either measure. In the CARA – IARA 
comparison, N = 52 participants reported number of days of use only on the CARA, N = 52 
reported one-plus days of use on the IARA, and N = 93 reported 1+ more days of use on both. 
The remainder (not in this analysis, N = 343) reported no prescription drug misuse on either 
measure. 
Past 30-Day Alcohol and Other Drug Use Reliability Comparisons. ICC estimates of 
interrater reliability agreement for frequencies of past 30-day alcohol and other drug use across 
the survey methods are summarized in Table 14. ICC for any recent (past 30-day) alcohol use  
 
Table 14. Intraclass Correlation Coefficients (ICC) for Past 30-Day Alcohol and Other Drug 
Use by Assessment Measure (N=540). 
Frequency Variable Survey Methods ICC 
 
Days of Recent Alcohol Use 
CAHS x IARA 0.75 [0.70, 0.79] 
CAHS x CARA 0.74 [0.69, 0.78] 
CARA x IARA 0.80 [0.76, 0.83] 
 
Days of Recent Binge 
Drinking 
 
 
CAHS x IARA 
 
0.72 [0.67, 0.76] 
 CAHS x IARA 0.85 [0.83, 0.88) 
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Days of Recent Illicit Drug 
Use 
CAHS x CARA 0.62 [0.54, 0.66) 
CARA x IARA 0.67 [0.61, 0.72] 
 
Days of Recent Prescription 
Drug Misuse 
CAHS x IARA 0.52 [0.44, 0.60] 
CAHS x CARA 0.43 [0.33, 0.52] 
CARA x IARA 0.53 [0.44, 0.60] 
*Values in square brackets indicate the 95% confidence interval for each ICC. 
 
demonstrated moderate interrater reliability between the CAHS and CARA (ICC (2,1) = 0.74) 
and good reliability for CAHS and IARA (ICC (2,1) = 0.75) and for CARA and IARA (ICC 
(2,1) = 0.80). ICC also demonstrated moderate reliability for recent (past 30-day binge drinking 
between the CAHS and IARA (ICC (2,1) = 0.72). ICC for past 30-day illicit drug use indicated 
moderate reliability between the CAHS and CARA (ICC (2,1) = 0.62 and between the CARA 
and IARA (ICC (2,1) = 0.67), while ICC demonstrated good reliability between the CAHS and 
IARA (ICC (2,1) = 0.85). ICC calculations indicated poor agreement between the CAHS and 
CARA (ICC (2,1) = 0.53), with reliability slightly rising between the CAHS and IARA (ICC 
(2,1) = 0.52) as well as between the CARA and IARA (ICC (2,1) = 0.53) for past 30-day 
prescription drug misuse. 
Mean Number of Drinks per Week During the Past 30 Days. The previous tables 
presented days of alcohol and other drug use (past 30 days). The following tables summarize 
average number of drinks per week of alcohol during the past 30 days as well as days of other 
drug use per week during the past 30 days. Means, standard deviations, and estimates of 
interrater reliability (ICC) for the number of self-reported drinks per week (7 days) across the 
three survey methods are summarized in Table 15. Number of drinks per week averaged from 
1.44 on the CARA (SD = 1.90), 2.21 on the CAHS (SD = 1.70), and 2.63 on the IARA (SD = 
3.16). ICC demonstrated moderate reliability between the CAHS and CARA (ICC (2,1) = 0.68), 
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while there was poor reliability between the CAHS and IARA (ICC (2,1) = 0.56) as well as 
between the CARA and IARA (ICC (2,1) = 0.55). Effect sizes between the CAHS and IARA 
were small (0.17), with larger effect sizes between the CAHS and CARA (0.42) and between the 
CARA and IARA (0.46). 
Hypothesis 2. Participants will report consuming, on average, more drinks per week over 
the past 30 days by anonymous, computer-administered screener (CAHS) compared to the 
confidential, computerized assessment (CARA). The study also hypothesized that participants 
will report consuming, on average, more drinks per week by CAHS compared to the interview-
administered assessment (IARA). As shown in Table 15, there was a significant average 
difference between the CAHS and IARA (t(539) = -3.50, p = 0.001, 95% CI [-0.66, -0.19], 
Cohen’s d = 0.15), between the CAHS and CARA (t(539) = 9.99, p < 0.001, 95% CI [0.61, 
0.91], Cohen’s d = 0.43), and between the CARA and IARA (t(539) = -9.50, p < 0.001, 95% CI 
[-1.43, -0.94], Cohen’s d = 0.41). Specifically, participants reported a greater number of drinks  
 
Table 15. Mean Drinks per Week During the Past 30 Days by Assessment Measure (N=540).  
  
 
Survey 
Methods 
 
 
 
Mean ± SD 
 
 
Mean 
Difference 
95% CI of the 
Difference 
 
 
 
t (p-value) 
 
 
 
Cohen’s d 
 
 
 
ICC 
 
Lower 
 
Upper 
 
Pair 1 
CAHS 
x 
IARA 
2.21 ± 1.70  
-0.42 
 
-0.66 
 
-0.19 
 
-3.50 (0.001)* 
 
0.15 
 
0.56  
[0.48, 0.63]  2.63 ± 3.16 
 
Pair 2 
CAHS 
x 
CARA 
2.21 ± 1.70  
0.76 
 
0.61 
 
0.91 
 
9.99 (<0.001)* 
 
0.43 
 
0.68  
[0.62, 0.73]  1.44 ± 1.90 
 
Pair 3 
CARA 
x 
IARA 
1.44 ± 1.90  
-1.19 
 
-1.43 
 
-0.94 
 
-9.50 (<0.001)* 
 
0.41 
 
0.55 
[0.47, 0.62]  2.63 ± 3.16 
*Denotes a statistically significant t-value (p < .05). 
*Values in square brackets indicate the 95% confidence interval for each ICC. 
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per week on the CAHS compared to the CARA, but greater number of drinks per week were 
reported on the IARA when compared to both the CAHS and CARA. These results support the 
hypothesized association between the CAHS and CARA but do not support the hypothesized 
association between CAHS and IARA. 
Illicit Drug Use (Days per Week) During the Past 30 days. Table 16 reflects the 
average days of drug use per week. Days of drug use per week ranged from 0.83 on the CARA 
(SD = 1.18) to 1.42 on the CAHS (SD = 2.38), and to 1.44 on the IARA (SD = 2.39). ICC 
demonstrated good reliability between the CAHS and IARA (ICC (2,1) = 0.86), while there was 
moderate reliability between the CARA and IARA (ICC (2,1) = 0.61) as well as between the 
CAHS and CARA (ICC (2,1) = 0.61). Effect sizes across each pair were small. 
Hypothesis 3. Participants will report, on average, more days of drug use per week over 
the past 30 days by anonymous, computer-administered screener (CAHS) compared to 
confidential, computerized assessment (CARA). The study also hypothesized that participants 
will report, on average, more days of drug use per week by CARA compared to the  
 
Table 16. Days of Illicit Drug Use per Week During the Past 30 Days by Assessment Measure 
(N=540).  
  
 
Survey 
Methods 
 
 
 
Mean ± SD 
 
 
Mean 
Difference 
95% CI of the 
Difference 
 
 
 
t (p-value) 
 
 
 
Cohen’s d 
 
 
Lower 
 
Upper 
 
ICC 
 
Pair 1 
CAHS 
x 
IARA 
1.42 ± 2.38  
-0.02 
 
-0.16 
 
0.12 
 
-0.32 (0.749) 
 
0.01 
 
 
1.44 ± 2.39 
0.86 
[0.83, 0.88] 
 
Pair 2 
CAHS 
x 
CARA 
1.42 ± 2.38  
0.59 
 
0.43 
 
0.76 
 
6.93 (< 0.001)* 
 
0.30 
 
 
0.83 ± 1.18 
0.61  
[0.54, 0.67] 
 
Pair 3 
CARA 
x 
IARA 
0.83 ± 1.18  
-0.61 
 
-0.77 
 
-0.45 
 
-7.60 (< 0.001)* 
 
0.33 
 
 
1.44 ± 2.39 
0.67 
[0.61, 0.72] 
*Denotes a statistically significant t-value (p < .05). 
Values in square brackets indicate the 95% confidence interval for each ICC. 
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interview-administered assessment (IARA). As shown in Table 16, paired sample t-tests found 
significant differences between the CAHS and CARA (t(539) = 6.93 p < 0.001, CI [0.43, 0.76], 
Cohen’s d = 0.30) and between the CARA and IARA (t(539) = -7.60 p < 0.001, CI [-0.77, -0.45], 
Cohen’s d = 0.33). No significant difference was found between the CAHS and IARA 
comparison (t(539) = -0.32, p = 0.749, CI [-0.16, 0.12], Cohen’s d = 0.01). Participants reported 
significantly more days of illicit drug use per week on the IARA and CAHS compared to the 
CARA. Results do not support the hypothesized association between the CAHS and IARA. As 
hypothesized, the CAHS found more days of illicit drug use per week than the CARA (t(539) = 
6.93 p < 0.001, CI [0.43, 0.76], Cohen’s d = 0.30). 
Prescription Drug Misuse (Days per Week) During the Past 30 Days. Table 17 
presents mean days of prescription drug misuse per week for the three administration methods 
with paired t-tests. Days of drug use per week ranged from less than half a day (Mean = 0.39) on  
 
Table 17. Days of Prescription Drug Misuse per Week During the Past 30 Days by Assessment 
Measure (N=540).  
  
 
Survey 
Methods 
 
 
 
Mean ± SD 
 
 
Mean 
Difference 
95% CI of the 
Difference 
 
 
 
t (p-value) 
 
 
 
Cohen’s d 
 
 
Lower 
 
Upper 
 
ICC 
 
Pair 1 
CAHS 
x 
IARA 
0.39 ± 1.16  
-0.29 
 
0.07 
 
-0.43 
 
-4.08 (< 0.001)* 
 
0.18 
 
 
0.68 ± 1.70 
0.52  
[0.44, 0.60] 
 
Pair 2 
CAHS 
x 
CARA 
0.39 ± 1.16  
-0.15 
 
-0.27 
 
-0.03 
 
-2.38 (0.018)* 
 
0.11 
 
 
0.54 ± 1.21 
0.43  
[0.33, 0.52] 
 
Pair 3 
CARA 
x 
IARA 
0.54 ± 1.21  
-0.14 
 
-0.29 
 
-0.00 
 
-2.01 (0.045)* 
 
0.08 
 
0.53 
[0.44, 0.60] 
 
0.68 ± 1.70 
*Denotes a statistically significant t-value (p < .05). 
*Values in square brackets indicate the 95% confidence interval for each ICC. 
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the CAHS (SD = 1.16) to 0.54 on the CARA (SD = 1.21), and to 0.68 on the IARA (SD = 1.70). 
ICC demonstrated poor reliability between the CAHS and CARA (ICC (2,1) = 0.43), while 
reliability slightly increased between the CAHS and IARA (ICC (2,1) = 0.52) and between the 
CARA and IARA (ICC (2,1) = 0.53). Effect sizes were small for CARA versus IARA (d = 0.08), 
for CAHS versus CARA (d = 0.11), and for CAHS versus IARA (d = 0.18).  
Hypothesis 4. Participants will report, on average, more days of prescription drug misuse 
per week by anonymous, computer-administered screener (CAHS) compared to confidential, 
computerized assessment (CARA). The study also hypothesized that participants will report, on 
average, more days of drug use per week by CAHS compared to the interview-administered 
assessment (IARA). As shown in Table 17, there was a significant average difference between 
the CAHS and IARA (t(539) = -4.08, p < 0.001, CI [0.07, -0.43], Cohen’s d 
= 0.18), between the CAHS and CARA (t(539) = -2.38, p = 0.018, CI [-0.27, -0.03], Cohen’s d = 
0.11), and between the CARA and IARA (t(539) = -2.10, p = 0.045, CI [-0.29, -0.00], Cohen’s d 
= 0.08). Participants reported, on average, less days of prescription drug misuse per week on the 
CAHS when compared to both the CARA and IARA, with participants reporting most days of 
prescription drug misuse on the IARA. Results do not support the hypothesized associations. 
Aim 2: Endorsement of Alcohol and/or Other Drug Use Related Problems by CAGE, T-
ACE, CAGE-DRUG, and ASSIST-3. 
 
Rates of alcohol-related problems as measured by the CAGE, T-ACE, and ASSIST-3 
(e.g., loss of control, fights with partner/family members related to use, and craving) are 
summarized below (Table 18 and 19). Both males and females were more likely to report 
problems related to feeling the need to cut down on their drinking on the CAGE/T-ACE and 
experiencing cravings on the ASSIST-3. 
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Table 18. Endorsement of Alcohol-Related Problems by CAGE and ASSIST-3 Items in Males (N 
= 159). 
 
 
CAGE 
 
Yes 
N (%) 
 
 
ASSIST 
 
Not at all 
N (%) 
 
Rarely 
N (%) 
 
Sometimes 
N (%) 
Almost all 
the time 
N (%) 
Cut down? 110 (69%) Loss of control? 99 (62%) 24 (15%) 29 (18%) 7 (4%) 
Annoyed? 68 (43%) Problems? 121 (76%) 17 (11%) 16 (10%) 5 (3%) 
Guilty? 70 (44%) Cravings? 85 (54%) 27 (17%) 32 (20%) 15 (9%) 
Eye-opener? 69 (43%)      
Summary Score N (%) 
0.      40 (25%) 
1.      29 (18%) 
2.      21 (13%) 
3.      30 (19%) 
4.      39 (25%) 
Summary Score N (%) 
0.    72 (45%)       5.    10 (6%) 
1.    22 (14%)       6.    8 (5%) 
2.    13 (8%)         7.    5 (3%) 
3.    13 (8%)         8.    1 (0.6%) 
4.    12 (8%)         9.    3 (2%) 
 
Table 19. Endorsement of Alcohol-Related Problems by T-ACE and ASSIST-3 Items in Females 
(N = 285). 
 
 
T-ACE 
 
Yes 
N (%) 
 
 
ASSIST 
 
Not at all 
N (%) 
 
Rarely 
N (%) 
 
Sometimes 
N (%) 
Almost all 
the time 
N (%) 
Tolerance 153 (54%) Loss of control? 208 (73%) 32 (11%) 39 (14%) 6 (2%) 
Annoyed? 77 (27%) Problems? 234 (82%)  22 (8%)   25 (9%) 4 (1%) 
Cut down? 148 (52%) Cravings? 188 (66%) 44 (15%) 41 (14%) 12 (4%) 
Eye-opener? 61 (21%)      
Summary Score N (%) 
0.      72 (25%) 
1.      83 (29%) 
2.      63 (22%) 
3.      38 (13%) 
4.      29 (10%) 
Summary Score N (%) 
0.    165 (58%)       5.    10 (4%) 
1.    32 (11%)         6.    13 (5%) 
2.    29 (10%)         7.    5 (2%) 
3.    17 (6%)           8.    1 (0.4%) 
4.    11 (4%)           9.    2 (0.7%) 
 
Table 20 shows rates of lifetime regular (3+ days/week) use and subsequent responses to 
ASSIST-3 items for the entire sample. For illicit drug use, rates of lifetime regular (3+ 
days/week) use were highest for marijuana (60%) and cocaine (35%), followed by heroin (12%), 
amphetamines (6%), hallucinogens (4%), and inhalants (1%). Similar to alcohol, participants 
were more likely to report problems related to cravings on the ASSIST-3.  
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Table 20. Frequency of Self-Reported Regular Illicit Drug Use and ASSIST Scores by Substance 
Type (N = 540). 
 
ASSIST 
Substance 
Type 
Regular Use*  
 
ASSIST 
Question 
 
 
Not at all 
% (N) 
 
 
Rarely 
% (N) 
 
 
Sometimes 
% (N) 
 
Almost all 
the time 
% (N) 
Yes 
% 
(N) 
No 
% 
(N) 
Marijuana 60% 
(323) 
40% 
(217) 
Loss of 
control? 
75% (242) 11% (37) 11% (36) 2% (8) 
   Problems? 89% (288) 7% (22) 3% (10) 0.9% (3) 
   Cravings? 54% (175) 14% (46) 19% (61) 13% (41) 
Cocaine 35% 
(190) 
65% 
(350) 
Loss of 
control? 
63% (119) 11% (20) 17% (32) 10% (19) 
   Problems? 79% (150) 8% (16) 9% (18) 3% (6) 
   Cravings? 57% (109) 13% (25) 23% (44) 6% (12) 
Heroin 12% 
(64) 
88% 
(476) 
Loss of 
control? 
66% (42) 16% (10) 9% (6) 9% (6) 
   Problems? 80% (51) 8% (5) 8% (5) 5% (3) 
   Cravings? 55% (35) 11% (7) 14% (9) 20% (13) 
Amphetamine 6% 
(30) 
94% 
(510) 
Loss of 
control? 
80% (24) 10% (3) 0% (0) 10% (3) 
   Problems? 83% (25) 10% (3) 3% (1) 3% (1) 
   Cravings? 77% (23) 3% (1) 13% (4) 7% (2) 
Hallucinogen 4% 
(23) 
96% 
(517) 
Loss of 
control? 
96% (22) 0% (0) 0% (0) 4% (1) 
   Problems? 91% (21) 4% (1) 0% (0) 4% (1) 
   Cravings? 91% (21) 4% (1) 4% (1) 0% (0) 
Inhalant 1% 
(5) 
99% 
(535) 
Loss of 
control? 
100% (5) 0% (0) 0% (0) 0% (0) 
   Problems? 100% (5) 0% (0) 0% (0) 0% (0) 
   Cravings? 100% (5) 0% (0) 0% (0) 0% (0) 
*Lifetime history of regular (3+ days/week) use. 
 
Overall, N = 126 (23%) reported marijuana as their primary problem drug, while 14%, 
4%, and 1% reported cocaine, heroin, and amphetamine as their primary problem drug,  
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respectively; N = 56 (10%) self-reported illicit drug use but denied problematic use problematic 
use of a specific drug. Over half of the sample (N = 285; 53%) self-reported recent (past 
30-day) illicit drug use on the CARA. Of those who reported recent illicit drug use, 
approximately three-fourths (N = 211; 74%) self-reported using one illicit drug. Over one-fifth 
(11%) self-reported using two different illicit drugs and 2% self-reported using three different 
illicit drugs (see Table 21). Zero participants self-reported using four illicit drugs and N = 1 self-
reported using five illicit drugs. Table 21 displays the response option (i.e., rarely, sometimes, 
almost all the time) count after summing each ASSIST-3 question among those who endorsed 
use of multiple illicit drugs, which were used to calculate participants’ total ASSIST-3 score. 
When adding across drugs, cocaine was the major confound for those endorsing use of multiple 
illicit drugs, and the total (sum) ASSIST-3 scores were largely comprised of ASSIST Q1-Q3 
scores for participants’ primary drug.   
 
Table 21. Response Option Count of ASSIST Questions by Primary Substance Type (N = 540). 
Number 
of Illicit 
Drugs 
 
% 
(N) 
 
Substance 
Type 
 
ASSIST 
Q1 Score 
 
ASSIST 
Q2 Score 
 
ASSIST 
Q3 Score 
 
% (N) 
Primary Drug 
 R1 R2 R3 R1 R2 R3 R1 R2 R3  
 
 
 
 
2 
 
 
 
 
11% 
(62) 
Marijuana 6 3 0 1 2 0 3 4 5 19% (12) 
Cocaine 10 11 10 6 9 4 6 19 9 60% (37) 
Heroin 3 1 1 2 1 1 2 3 2 11% (7) 
Amphetamine 1 0 1 0 1 0 0 1 1 3% (2) 
Inhalant 0 0 0 0 0 0 0 0 0 0% (0) 
Hallucinogen 0 0 0 0 0 0 0 0 0 0% (0) 
  ASSIST Q 
SUM 
20 15 12 9 13 5 11 27 17 -- 
 
 
 
 
 
 
 
 
Marijuana 0 2 0 0 1 0 0 1 1 18% (2) 
Cocaine 0 1 1 1 0 1 1 1 1 27% (3) 
Heroin 0 1 2 2 0 0 0 1 2 27% (3) 
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3 2%  
(11) 
Amphetamine 0 0 2 0 1 1 0 2 1 27% (3) 
Inhalant 0 0 0 0 0 0 0 0 0 0% (0) 
Hallucinogen 0 0 1 0 0 0 0 1 0 0% (0) 
  ASSIST Q 
SUM 
0 4 5 3 2 2 1 5 5 -- 
R1 = Rarely; R2 = Sometimes; R3= Almost All the Time 
 
Summarized below are the response rates to problematic illicit drug use as measured by 
the CAGE-DRUG and ASSIST-3, separately for males (Table 22) and females (Table 23).  
Similar to alcohol related problems, both males and females were more likely to report problems 
related to feeling the need to cut down on their drug use on the CAGE-DRUG and experiencing 
cravings on the ASSIST-3.  
 
Table 22. Endorsement of Drug-Related Problems by CAGE and ASSIST-3 Items in Males (N = 
144). 
 
 
CAGE 
 
Yes 
N (%) 
 
 
ASSIST 
 
Not at all 
N (%) 
 
Rarely 
N (%) 
 
Sometimes 
N (%) 
Almost all 
the time 
N (%) 
Cut down? 66 (46%) Loss of control? 74 (51%) 20 (14%) 34 (24%) 16 (11%) 
Annoyed? 46 (31%) Problems? 105 (73%) 18 (13%) 17 (12%) 4 (3%) 
Guilty? 61 (42%) Cravings? 48 (33%) 22 (15%) 51 (35%) 23 (16%) 
Eye-opener? 65 (45%)      
Summary Score N (%) 
0.      61 (42%) 
1.      8 (6%) 
2.      24 (17%) 
3.      22 (4%) 
4.      29 (20%) 
Summary Score N (%) 
0.    40 (28%)       5.    9 (6%) 
1.    13 (9%)         6.    13 (9%) 
2.    23 (16%)       7.    7 (5%) 
3.    12 (8%)         8.    2 (0.4%) 
4.    23 (16%)       9.    2 (0.4%) 
 
 
Table 23. Endorsement of Drug-Related Problems by CAGE and ASSIST-3 Items in Females (N 
= 220). 
 
 
CAGE 
 
Yes 
N (%) 
 
 
ASSIST 
 
Not at all 
N (%) 
 
Rarely 
N (%) 
 
Sometimes 
N (%) 
Almost all 
the time 
N (%) 
Cut down? 83 (38%) Loss of control? 147 (67%) 30 (14%) 29 (13%) 14 (6%) 
Annoyed? 61 (28%) Problems? 179 (81%)  20 (9%)   16 (7%) 5 (2%) 
Guilty? 75 (34%) Cravings? 100 (46%) 32 (15%) 51 (23%) 37 (17%) 
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Eye-opener? 91 (41%)      
Summary Score N (%) 
0.      95 (43%) 
1.      33 (15%) 
2.      34 (16%) 
3.      23 (11%) 
4.      35 (16%) 
Summary Score N (%) 
0.    95 (43%)       5.    8 (4%) 
1.    20 (9%)         6.    11 (5%) 
2.    24 (11%)       7.    5 (2%) 
3.    27 (12%)       8.    3 (1%) 
4.    23 (11%)       9.    4 (2%) 
 
Tables 24 – 27 compare the mean ASSIST scores by positive responses to each CAGE, 
T-ACE, and CAGE-DRUG question. For alcohol, participants scoring positive on each 
individual CAGE and T-ACE item had significantly higher ASSIST-3 scores compared with 
participants for whom scored negative on the same individual CAGE and T-ACE item (Table 24 
and 25). For males endorsing illicit drug use problems, a similar pattern was found, however, 
nonsignificant differences were found for participants scoring positive on CAGE-DRUG 
question one compared to ASSIST question one and for participants scoring positive on CAGE-
DRUG questions one and two compared to ASSIST question two (Table 26). For females, 
nonsignificant differences were found for participants scoring positive on CAGE-DRUG 
question one compared to ASSIST question two (Table 27).
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Table 24. Comparison of Mean ASSIST-3 Screening Test with Alternative Alcohol CAGE Cut-Off Scores in Men (N=159). 
ASSIST Q1 = loss of control; ASSIST Q2 = problems; ASSIST Q3 = cravings. 
 
 
Table 25. Comparison of Mean ASSIST-3 Screening Test with Alternative Alcohol T-ACE Cut-Off Scores in Men (N=285). 
ASSIST Q1 = loss of control; ASSIST Q2 = problems; ASSIST Q3 = cravings. 
 
ASSIST 
Score 
Mean 
CAGE 
+1 
 CAGE 
+2 
 CAGE 
+3 
 CAGE 
+4 
 
 
Yes 
 
No 
t-value 
(p-value) 
 
Yes 
 
No 
t-value  
(p-value) 
 
Yes 
 
No 
t-value  
(p-value) 
 
Yes 
 
No 
t-value 
(p-value) 
ASSIST 
Q1 
0.82 0.15 -4.11 
(<0.001) 
1.00 0.19 -6.04 
(<0.001) 
1.12 0.29 -6.19 
(<0.001) 
1.33 0.43 -5.84 
(<0.001) 
ASSSIT  
Q2 
0.50 0.13 -2.59 
(0.010) 
0.61 0.13 -3.94 
(<0.001) 
0.71 0.17 -4.51 
(<0.001) 
0.90 0.25 -4.76 
(<0.001) 
ASSIST 
Q3 
1.04 0.30 -4.06 
(<0.001) 
1.22 0.38 -5.48 
(<0.001) 
1.32 0.50 -5.28 
(<0.001) 
1.54 0.63 -5.03 
(<0.001) 
ASSIST 
Sum 
2.35 0.58 -4.31 
(<0.001) 
2.83 0.70 -6.25 
(<0.001) 
3.14 0.96 -6.44 
(<0.001) 
3.77 1.30 -6.27 
(<0.001) 
 
ASSIST 
Score 
Mean 
TACE 
+1 
 TACE 
+2 
 TACE 
+3 
 TACE 
+4 
 
 
Yes 
 
No 
t-value 
(p-value) 
 
Yes 
 
No 
t-value  
(p-value) 
 
Yes 
 
No 
t-value  
(p-value) 
 
Yes 
 
No 
t-value 
(p-value) 
ASSIST 
Q1* 
0.56 
 
0.11 -4.24 
(<0.001) 
0.82 0.14 -7.91 
(<0.001) 
1.03 0.27 -7.35 
(<0.001) 
1.34 0.35 -6.80 
(<0.001) 
ASSSIT  
Q2* 
0.38 0.06 -3.49 
(<0.001) 
0.56 0.07 -6.44 
(<0.001) 
0.78 0.15 -7.13 
(<0.001) 
1.00 0.21 -6.23 
(<0.001) 
ASSIST 
Q3* 
0.72 0.11 -5.29 
(<0.001) 
0.98 0.23 -7.83 
(<0.001) 
1.27 0.35 -8.20 
(<0.001) 
1.66 0.45 -7.62 
(<0.001) 
ASSIST 
Sum 
1.66 0.28 -5.22 
(<0.001) 
2.36 0.43 -9.04 
(<0.001) 
3.07 0.77 -9.23 
(<0.001) 
4.00 1.01 -8.37 
(<0.001) 
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Table 26. Comparison of Mean ASSIST-3 Screening Test with Alternative CAGE-DRUG Scores in Males (N=144). 
ASSIST Q1 = loss of control; ASSIST Q2 = problems; ASSIST Q3 = cravings. 
 
Table 27. Comparison of Mean ASSIST-3 Screening Test with Alternative CAGE-DRUG Scores in Females (N=220). 
ASSIST Q1 = loss of control; ASSIST Q2 = problems; ASSIST Q3 = cravings. 
 
ASSIST 
Score 
Mean 
Drug CAGE 
+1 
 Drug CAGE 
+2 
 Drug CAGE 
+3 
 Drug CAGE 
+4 
 
 
Yes 
 
No 
t-value 
(p-value) 
 
Yes 
 
No 
t-value  
(p-value) 
 
Yes 
 
No 
t-value  
(p-value) 
 
Yes 
 
No 
t-value 
(p-value) 
ASSIST 
Q1* 
1.08 
 
0.75 -1.80 
(0.074) 
1.16 0.71 -2.51 
(0.013) 
1.37 0.71 -3.62 
(0.001) 
1.55 0.79 -3.47 
(0.001) 
ASSSIT  
Q2* 
0.52 0.34 -1.28 
(0.204) 
0.55 0.33 -1.59 
(0.111) 
0.73 0.29 -3.19 
(0.005) 
0.86 0.34 -3.21 
(0.011) 
ASSIST 
Q3* 
1.61 0.97 -3.62 
(<0.001) 
1.61 1.04 -3.19 
(0.002) 
1.67 1.16 -2.68 
(0.006) 
1.86 1.21 -2.92 
(0.004) 
ASSIST 
Sum 
3.22 2.07 -2.90 
(0.004) 
3.32 2.09 -3.15 
(0.002) 
3.76 2.16 -4.01 
(<0.001) 
4.28 2.34 -4.06 
(<0.001) 
 
ASSIST 
Score 
Mean 
Drug CAGE 
+1 
 Drug CAGE 
+2 
 Drug CAGE 
+3 
 Drug CAGE 
+4 
 
 
Yes 
 
No 
t-value 
(p-value) 
 
Yes 
 
No 
t-value  
(p-value) 
 
Yes 
 
No 
t-value  
(p-value) 
 
Yes 
 
No 
t-value 
(p-value) 
ASSIST 
Q1* 
0.70 
 
0.45 -1.91 
(0.051) 
0.88 0.38 -3.99 
(<0.001) 
1.02 0.44 -4.15 
(0.001) 
1.14 0.49 -3.89 
(0.005) 
ASSSIT  
Q2* 
0.35 0.24 -1.15 
(0.252) 
0.47 0.19 -2.96 
(0.006) 
0.57 0.21 -3.41 
(0.006) 
0.77 0.22 -4.46 
(0.003) 
ASSIST 
Q3* 
1.34 0.82 -3.33 
(0.001) 
1.49 0.84 -4.21 
(<0.001) 
1.72 0.90 -4.90 
(<0.001) 
1.83 0.98 -4.11 
(<0.001) 
ASSIST 
Sum 
2.38 1.52 -2.77 
(0.006) 
2.84 1.41 -4.66 
(<0.001) 
3.31 1.54 -5.23 
(<0.001) 
3.74 1.68 -5.05 
(<0.001) 
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Table 28 shows the sensitivity, specificity, PPV, NPV, and AUC for the ASSIST-3 
assessing for problem alcohol and/or illicit drug use in the past 3-months. In some cases (as 
shown in Table 24 – 27; Figures 2-5), in which marginally higher values would have resulted in 
a different cut-point but the AUCs were similar, the cut-point matching the other substances was 
chosen in order to simplify interpretation of the test. The optimal cut-points on the ASSIST-3 for  
 
 Table 28. Problem Alcohol and Illicit Drug Use by CAHS and CARA. 
  
+CAGE 
% (N) 
 
+ASSIST 
% (N) 
+CAGE/ 
ASSIST 
% (N) 
 
 
Sen.1 
 
 
Spec.2 
 
 
PPV3 
 
 
NPV4 
 
 
AUC5 
 
 
2 
Alcohol 
(Males 
N = 159) 
 
57% (90) 
 
55% (87) 
 
38% (60) 
 
0.67 
 
0.61 
 
0.69 
 
0.58 
 
0.72 
 
11.59* 
Positive on CAGE 2 (ASSIST-3 Cut-Point = 1) 
  
+T-ACE 
% (N) 
 
+ASSIST 
% (N) 
+T-ACE/ 
ASSIST 
% (N) 
 
 
Sen.1 
 
 
Spec.2 
 
 
PPV3 
 
 
NPV4 
 
 
AUC5 
 
 
2 
Alcohol 
(Females  
N = 285) 
 
46% (130) 
 
42% (120) 
 
39% (87) 
 
0.67 
 
0.79 
 
0.73 
 
0.74 
 
0.76 
 
60.40* 
Positive on T-ACE 2 (ASSIST-3 Cut-Point = 1) 
 
 
 +CAGE-
DRUG 
% (N) 
 
 
+ASSIST 
% (N) 
+CAGE-
DRUG/ 
ASSIST 
% (N) 
 
 
 
Sen.1 
 
 
 
Spec.2 
 
 
 
PPV3 
 
 
 
NPV4 
 
 
 
AUC5 
 
 
 
2 
Illicit Drug 
Use (Males 
N = 144) 
 
58% (83) 
 
63% (91) 
 
43% (62) 
 
0.75 
 
0.53 
 
0.68 
 
0.60 
 
0.65 
 
11.15* 
Positive on CAGE-DRUG 1 (ASSIST-3 Cut-Point = 2) 
 
 
 +CAGE-
DRUG 
% (N) 
 
 
+ASSIST 
% (N) 
+CAGE-
DRUG/ 
ASSIST 
% (N) 
 
 
 
Sen.1 
 
 
 
Spec.2 
 
 
 
PPV3 
 
 
 
NPV4 
 
 
 
AUC5 
 
 
 
2 
Illicit Drug 
Use (Females 
N = 220) 
 
57% (125) 
 
48% (105) 
 
32% (71) 
 
0.68 
 
0.53 
 
0.57 
 
0.64 
 
0.62 
 
9.55* 
Positive on CAGE-DRUG 1 (ASSIST-3 Cut-Point = 2) 
1Sen. = Sensitivity; 2Spec. = Specificity; 3PPV = Positive Predictive Value; 4NPV = Negative Predictive Value;  
 AUC = 5Area Under the Curve 
*Denotes a statistically significant 2 value (p < .05). 
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detecting “problem use” for alcohol was 1 for both males (Figure 2) and females (Figure 3), 
while the cut- point on the ASSIST for detecting “problem use” for illicit drug use was 2 for 
males (Figure 3) and females (Figure 4). The AUC demonstrated acceptable discrimination 
between the CAGE and ASSIST-3 (0.72) and between the T-ACE and ASSIST-3 (0.76) but 
demonstrated poor discrimination between the CAGE-DRUG and ASSIST-3 for both males 
(0.65) and females (0.62). All AUC values were statistically significant (p < .05).  
For males, when the CAGE was considered the reference standard, sensitivity and 
specificity was 0.67 and 0.79 for detecting “problem use” for alcohol ASSIST-3 thresholds. The 
PPV was 0.69 and NPV was only slightly greater than 50% chance classification (0.58). For 
females, when the T-ACE was considered the reference standard, sensitivity was 0.67 with 
higher specificity (0.79). PPV (0.73) and NPV (0.74) were similar. When the CAGE-DRUG was 
considered the reference standard for detecting “problem use” for illicit drug use, ASSIST-3 
sensitivity and specificity was 0.75 and 0.53 for males and 0.68 and 0.53 for females. PPV and 
NPV for males were 0.68 and 0.60, respectively, while PPV and NPV for females were 0.57 and 
0.64, respectively. 
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Figure 2. ROC curve for CAGE+ predicting ASSIST-3 alcohol-related problems in males. 
Optimal cutoff score of 1 is indicated by a circle. The diagonal line indicates the theoretical ROC 
curve for AUC = .50. 
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Figure 3. ROC curve for T-ACE+ predicting ASSIST-3 alcohol-related problems in females. 
Optimal cutoff score of 1 is indicated by a circle. The diagonal line indicates the theoretical ROC 
curve for AUC = .50. 
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Figure 4. ROC curve for CAGE-DRUG+ predicting ASSIST-3 illicit drug-related problems in 
males. Optimal cutoff score of 2 is indicated by a circle. The diagonal line indicates the 
theoretical ROC curve for AUC = .50. 
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Figure 5. ROC curve for CAGE-DRUG+ predicting ASSIST-3 illicit drug-related problems in 
females. Optimal cutoff score of 2 is indicated by a circle. The diagonal line indicates the 
theoretical ROC curve for AUC = .50. 
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Hypothesis 1. Participants will be more likely to score positive for problematic substance 
use on the anonymous, computer-administered screener (i.e., CAGE, T-ACE, CAGE-DRUG) 
compared to the confidential, computerized assessment (i.e., ASSIST-3). Participants were more 
likely to score positive on the CAGE compared to the ASSIST-3 for both males (2 (1, N = 159) 
= 11.59 p = 0.001) and females (2 (1, N = 285) = 60.40 p < 0.001), supporting the hypothesized 
associations. Males were more likely to score positive for illicit drug-related problems on the 
ASSIST-3 compared to CAGE-DRUG (2 (1, N = 144) = 11.15 p = 0.001), which does not 
support the hypothesized association. However, females were more likely to score positive for 
illicit drug-related problems on the CAGE-DRUG compared to the ASSIST-3 (2 (1, N = 220) = 
9.55 p < 0.001), which supports the hypothesized association. 
Aim 3: Agreement Between Self-Reports of Recent (Past 30-Day) Drug Use and Non-
medical Prescription Drug Use by Urinalysis and IARA. 
 
For the present analyses, positive tests for opiates with self-reported heroin use (i.e., the 
heroin metabolite, 6-Monoacetylmorphine) absent of self-reported non-medical prescription 
opiate use were classified as heroin-positive (N=54); tests positive for other opioids (codeine, 
oxycontin, oxycodone, hydrocodone) absent of self-reported heroin use were classified as 
positive for non-medical prescription opioid use (N = 83). Also, positive tests for amphetamines 
and methamphetamines (N=8) were classified as amphetamine positive.  
Table 29 shows rates of recent (past 30-days) substance use by personal interview 
(IARA) and UDS. Marijuana was most prevalent, with approximately one-third (N = 154) of 
participants self-reporting recreational use, followed by cocaine use (14%; N = 64). Positive 
UDS rates were 30% for marijuana and 20% for cocaine, with 89% overall concordance rate 
(i.e., agreement between self-reported use on the TLFB and UDS results) for cocaine use and 
85% for marijuana use. Both k and cond. k values indicate acceptable concordance.  IARA  
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Table 29. Concordance of TLFB Self-Reported Illicit & Non-medical Prescription Drug Use to 
UDS results. 
  
 
+IARA 
% 
(N) 
 
 
+UDS 
% 
(N) 
Concor- 
dance 
Positive 
% 
(N) 
Concor- 
dance 
Negative 
% 
(N) 
Overall 
Concor- 
dance 
% 
(N) 
 
 
 
 
Sens.1 
 
 
 
 
Spec.2 
 
 
 
 
PPV3 
 
 
 
 
NPV4 
Marijuana  
(N = 465) 
33% 
(154) 
30%  
(141) 
24%  
(113) 
61% 
(283) 
85% 
(396) 
.80 .87 .73 .91 
    k=0.66 
    cond. k=0.62 
         
Heroin / Opiates 
(N = 405) 
    k=0.25 
    cond. k=0.22 
24% 
(97) 
20% 
(83) 
9% 
(37) 
65% 
(262) 
74% 
(299) 
.45 .81 .38 .85 
Opiates 
(N = 405) 
    k=0.12 
    cond. k=0.12 
20% 
(79) 
20% 
(83) 
6% 
(24) 
66% 
(268) 
72% 
(292) 
.29 .83 .30 .82 
Cocaine 
(N=465) 
    k=0.59 
    cond. k=0.49 
14% 
(64) 
20% 
(91) 
11% 
(51) 
78% 
(361) 
89% 
(412) 
.56 .97 .80 .90 
Heroin 
(N = 405) 
    k=0.32 
    cond. k=0.21 
4% 
(18) 
13% 
(54) 
3% 
(13) 
86% 
(347) 
89% 
(360) 
.24 .99 .72 .89 
Benzodiazepines 
(N = 405) 
    k=0.19 
    cond. k=0.12 
4% 
(17) 
16% 
(65) 
3% 
(10) 
81% 
(330) 
84% 
(340) 
.15 .98 .59 .86 
Amphetamines 
(N = 405) 
    k=0.19 
    cond. k=0.12 
0.5% 
(2) 
2% 
(8) 
0.2% 
(1) 
97% 
(393) 
97% 
(394) 
.13 1.00 .50 .98 
1Sen. = Sensitivity 
2Spec. = Specificity  
3PPV = Positive Predictive Value 
4NPV = Negative Predictive Value 
 
 
sensitivity for detecting marijuana was 0.80 and 0.56 for cocaine. The specificity of was high for 
each drug, ranging from 0.87 for marijuana to 0.97 for cocaine. The Positive Predictive Value 
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(PPV) was high for cocaine (0.80) and slightly lower for marijuana (0.73), and Negative 
Predictive Values (NPV) were high for each drug ranging from 0.90 for cocaine to 0.91 for 
marijuana.  
For the N = 405 with substance specific non-medical prescription drug use information, 
including urine assay-opiate results, approximately one-fourth (N = 97) self-reported either using 
heroin or non-medical opioid medication, while less than 5% (N = 18) self-reported only heroin 
use. Rates of reported recent non-medical benzodiazepine and non-medical amphetamine use 
were 4% and 0.5%, respectively. Positive UDS rates were 20% for heroin / opiates and opiates, 
13% for heroin, 16% for benzodiazepines, and 2% for non-medical amphetamine use.  
Overall concordance rates for each substance type ranged from 97% for non-medical 
amphetamine use, 89% for heroin use, 84% for non-medical benzodiazepine use, 74% for heroin 
/ opiate use, and to 72% for non-medical opiate drug use. However, the low value of both k and 
cond. k indicates that positive concordance was poor (see Table 29). IARA sensitivity for 
detecting heroin / opiates was 0.45, 0.29 for non-medical opiate use, 0.24 for heroin, 0.15 for 
non-medical benzodiazepine use, and 0.13 for non-medical amphetamine use. The specificity of 
was high for each drug, ranging from 0.81 for heroin / opiates to 1.00 for amphetamines. The 
PPV for opiates (0.30) and heroin / opiates (0.38) was moderate, with higher PPVs for both 
amphetamines (0.50) and benzodiazepines (0.59), and even higher PPV for opiates (0.72). 
Negative Predictive Values (NPV) were high for each drug ranging from 0.82 for opiates to 0.98 
for non-medical amphetamine use.  
For the sample based on illicit drugs, urinalysis yielded higher rates of cocaine use than 
self-report; however, the TLFB yielded higher rates of marijuana use compared to urinalysis. For 
the sample based on prescription drug use, urinalysis generally yielder higher rates than self-
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report. The only case in which self-reported use was higher than that detected by urinalysis was 
for reports of heroine / opiate use.  
In order to examine discordant results on the TLFB and the UDS, individuals were 
considered positive for each substance if they either reported use on TLFB or had a positive OFT 
result. Table 30 displays the discordance between the TLFB and UDS across each substance.  
 
Table 30. Discordance Between TLFB and UDS results for marijuana (N = 182), heroin / 
opiates (N = 143), opiates (N = 138), cocaine (N = 104), benzodiazepines (N = 72), heroin (N = 
59), and amphetamines (N = 9). 
 +IARA 
-UDS 
% 
(N) 
-IARA 
+UDS 
% 
(N) 
Total Discordance 
% 
(N) 
Marijuana  
 
23% 
(41) 
15% 
(28) 
38% 
(69) 
Heroin / Opiates 
 
42% 
(60) 
32% 
(46) 
74% 
(106) 
Opiates 40% 
(55) 
43% 
(59) 
82% 
(113) 
Cocaine 
 
13% 
(13) 
38% 
(40) 
51% 
(53) 
Benzodiazepines 
 
10% 
(7) 
42% 
(30) 
51% 
(37) 
Heroin 8% 
(5) 
69% 
(41) 
78% 
(46) 
Amphetamines 
 
11% 
(1) 
78% 
(7) 
89% 
(8) 
 
Among the subsample of participants with any positive marijuana (N = 182), heroin / opiate (N = 
143), opiate (N = 138), cocaine (N = 104), benzodiazepine (N = 72), heroin (N = 59), and 
amphetamine (N = 9) use, total discordance rates between the two measures were 38% for 
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marijuana, 74% for heroin / opiates, 82% for opiates, 51% for cocaine and benzodiazepines, 78% 
for heroin, and 89% for non-medical amphetamine use.  
Hypothesis 1: Proportion of illicit drug use and non-medical prescription drug use will 
be higher by urine assay compared to self-report measure. Rates of cocaine (2 (1, N = 465) = 
170.41, p < 0.001), heroin (2 (1, N = 405) = 56.71, p < 0.001), non-medical benzodiazepine (2 
(1, N = 405) = 23.93, p < 0.001), non-medical amphetamine (2 (1, N = 405) = 23.75 p < 0.001), 
and opiate (2 (1, N = 405) = 5.95, p = 0.015) use were higher on the UDS compared to IARA, 
supporting the hypothesized association. Rates of marijuana (2 (1, N = 465) = 202.02, p < 
0.001) and heroin / opiates (2 (1, N = 405) = 23.80, p < 0.001) use were higher on the IARA 
compared to UDS results. These results do support the hypothesized associations.  
Aim 4: Multivariable Analysis  
All of the independent variables included in the multivariate analysis to identify 
correlates of any recent (past 30-day) alcohol and other drug use are summarized in Table 31.  
  
Table 31. Variables Included in Multivariable Logistic Regression. 
Demographics Medical 
Age3,5,6,7,8,9,10,11,12,15,16,17,19 Anxiety1,2,3,4,5,6,7,8,9,10,11,12,13,14,18,19,20 
Gender2,7,9,12,13,14,16,20 Depression1,3,4,6,7,8,9,10,11,12,14,16,17,18,19,20 
Race1,3,4,6,9,10,11,18,19 Psychological Distress (K10)1,4,6,7,8,9,9,10,11,13,14,15,16,17,19,20 
Ethnicity13,14 2+ Medical Conditions2,5,9,10,11,12,13,14,18,19,20 
Education2,4,5,9,10,11,12,13,14,15,16,17,18   COPD High Blood Pressure 
Insurance2,4,5,7,8,11,13,14,16   Liver Disease Pancreatitis 
Employment3,5,7,8,16   Hepatitis High Cholesterol 
Marital Status1,4,7, 10,14   Heart Disease Chronic Pain 
Quality of Sleep6,9,15,17 
Sleep Problems1,2,4,7,8,9,10,11,13,14,16,18,19,20 
Taking Sleep Aids4,7,9,10,11,14,16,18,19,20 
  Migraines 
  Arthritis 
Asthma 
 
Variables selected for any recent alcohol use: CAHS1, CARA2, IARA3 
Variables selected for any recent binge drinking: CAHS4, IARA5 
Variables selected for any recent illicit drug use: CAHS6, CARA7, IARA8 
Variables selected for any recent illicit drug use: CAHS9, CARA10, IARA11 
Variables selected for mean number of drinks per week: CAHS12, CARA13, IARA14 
Variables selected mean days of illicit drug use per week: CAHS15, CARA16, IARA17 
Variables selected mean days of prescription drug misuse per week: CAHS18, CARA19, IARA20 
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Based on a classification threshold predicted probability of target group membership of 0.5, 
models for any recent (past 30-day) alcohol and binge drinking by assessment measure were 
statistically significant. The Nagelkerke pseudo R2 suggested that the model(s) accounted 
between approximately 5% and 6% of the total variance in any recent (past 30-day) alcohol and 
between 5% and 7% in any recent binge drinking (see Table 32). 
Classification success for the cases based on a classification cutoff value of 0.5 for 
predicting any recent (past 30-day alcohol use) was moderately high for the CAHS and IARA, 
with overall prediction success rates of 88% and 80%, respectively; prediction success rate for 
the CARA was less at 63%. For any recent (past 30-day) binge drinking, the CAHS correctly 
classified 74% of participants while the IARA only correctly classified 56%.   
As shown in Table 32, significant predictors of any recent (past 30-day) alcohol use were 
taking sleep aids in the past 30 days and being from a racial minority group for the CAHS; 
having government insurance and being female were significant predictors for the CARA, while 
endorsing symptoms of depression and being unemployed were significant predictors for the 
IARA. Having >12 years of education and being from a racial minority group were associated 
with any recent (past 30-day) binge drinking on the CAHS, while being older age, having 
government insurance, and having >12 years of education were all associated with any recent 
(past 30-day) binge drinking on the IARA. No other predictors exerted a unique effect on any 
recent (past 30-day) alcohol use or binge drinking (all ps >.05). 
Table 33 shows that, based on a classification threshold predicted probability of target 
group membership of 0.5, models for any recent (past 30-day) illicit drug use and prescription 
drug misuse by assessment measure were statistically significant. The Nagelkerke pseudo R2 
suggested that the model(s) accounted between approximately 8% and 16% of the total variance 
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in any recent (past 30-day) illicit drug use and prescription drug misuse. Classification success 
for the cases based on a classification cutoff value of 0.5 for predicting any recent (past 30-day) 
illicit drug use was moderate, with an overall prediction success rate of 66% for the CAHS, 61% 
for the CARA, and 59% for the IARA. Overall classification prediction success rate was higher 
for any recent (past 30-day) prescription drug misuse with 76%, 74%, and 73% rates for the 
CAHS, CARA, and IARA, respectively.  
Significant predictors for any recent (past 30-day) illicit drug use were endorsing 
moderate-severe psychological distress and being older age on the CAHS, while trouble staying 
asleep in the past 30 days, being older and female, and endorsing moderate-severe psychological 
distress were associated with any recent (past 30-day) illicit drug use on the CARA. Trouble 
falling asleep in the past 30 days, being older, and endorsing moderate-severe psychological 
distress were associated with any recent illicit drug use on the IARA (see Table 33). Significant 
predictors for any recent (past 30-day) prescription drug misuse were taking sleep aids, having 
>12 years of education, being older age, and having 2+ medical conditions on the CAHS. 
Trouble falling asleep in the past 30 days, having 2+ medical conditions, being married, and 
being older age were all associated with any recent past prescription drug misuse on the CARA, 
while trouble falling asleep in the past 30 days and endorsing symptoms of anxiety were 
significant predictors on the IARA. No other predictors exerted a unique effect on any recent 
(past 30-day) illicit drug or prescription drug misuse (all ps > .05) (see Table 33). 
All of the independent variables summarized in Table 31 were also used to identify 
correlates of alcohol QF and frequency of other drug use per week in the past 30 days. The 
overall model(s) significantly predicted both alcohol and other drug use per week during the past 
30 days. Together, these predictors accounted between 7% and 8% of the variance in alcohol use 
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per week (see Table 34) during the past 30 days, between 8% and 11% of the variance in illicit 
drug use per week, and between 5% and 10% in prescription drug misuse (see Table 35).  
Being female and endorsing symptoms of anxiety were significant predictors of alcohol 
use per week during the past 30 days on the CAHS, while being female, >12 years of education, 
and having government insurance were significant predictors of alcohol use per week during the 
past 30 days on the CARA. Trouble staying asleep in the past 30 days, being female, endorsing 
symptoms of anxiety, having >12 of education, and being married were significant predictors of 
alcohol use per week on the IARA (see Table 34).  
As shown in Table 35, being older, having >12 years of education, and endorsing 
moderate-severe psychological distress were associated with illicit drug use per week during the 
past 30 days on the CAHS; trouble staying asleep in the past 30 days, being older and female, 
having >12 years of education, and endorsing moderate-severe psychological distress were 
significant predictors on the CARA, while being older and having >12 years of education were 
significant predictors on the IARA. Taking sleep aids in the past 30 days and having 2+ medical 
conditions were associated with prescription drug misuse per week on the CAHS, while trouble 
falling asleep and taking sleep in the past 30 days, being older, having 2+ medical conditions, 
and endorsing moderate-severe psychological distress were significant predictors on the CARA. 
Taking sleep aids in the past 30 days and endorsing symptoms of anxiety were significant 
predictors of prescription drug misuse per week on the IARA. No other predictors exerted a 
unique effect on days of alcohol or other drug use per week during the past 30 days (all ps > .05).
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Table 32. Multivariable Logistic Regression by Assessment Measure for Alcohol (N=540). 
 
Substance Use 
Variable 
 
Assessment 
Measure 
 
 
Covariate 
 
 
B 
 
Standard 
Error 
 
 
p-value 
95% CI for Odds Ratio   
 
Lower 
 
Exp(B) 
 
Upper 
Nagelkerke 
R2 
Model χ2 
 
 
 
Any Recent 
(Past 30-Day) 
Alcohol Use 
CAHS 
                            
 
Sleep Aids 
Race 
0.73 
-0.69 
0.32 
0.34 
0.024 
0.039 
1.10 
0.26 
2.07 
0.50 
3.89 
0.97 
0.05 10.29* 
 
CARA 
 
 
Sleep Problems 
Insurance 
Gender 
Education 
 
0.45 
-0.57 
-0.45 
-0.46 
0.25 
0.27 
0.23 
0.24 
0.069 
0.031 
0.047 
0.054 
0.97 
0.34 
0.41 
0.40 
1.57 
0.56 
0.64 
0.63 
2.54 
0.95 
1.00 
1.01 
 
0.06 
 
16.94* 
IARA 
 
Depression 
Employment 
0.58 
0.85 
0.25 
0.35 
0.021 
0.015 
1.09 
1.18 
1.79 
2.35 
2.94 
4.67 
0.06 15.06* 
 
Any Recent 
(Past 30-Day) 
Binge Drinking 
CAHS 
 
 
 
Race 
Education 
-0.76 
0.81 
0.30 
0.25 
 
0.011 
0.001 
0.26 
1.39 
0.47 
2.25 
0.84 
3.66 
0.07 18.06* 
 
IARA 
 
Age 
Insurance 
Education 
-0.02 
0.59 
0.50 
0.01 
0.27 
0.23 
0.046 
0.029 
0.034 
0.96 
1.06 
1.04 
0.98 
1.80 
1.64 
1.00 
3.06 
2.60 
 
0.05 
 
13.24* 
*Denotes a statistically significant χ2 (p < .05). 
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Table 33. Multivariable Logistic Regression by Assessment Measure for Other Drugs (N=540). 
*Denotes a statistically significant χ2 (p < .05). 
 
Substance Use 
Variable 
 
Assessment 
Measure 
 
 
Covariate 
 
 
B 
 
Standard 
Error 
 
 
p-value 
95% CI for Odds Ratio   
 
Lower 
 
Exp(B) 
 
Upper 
Nagelkerke 
R2 
Model 
χ2 
Any Recent 
(Past 30-Day) 
Illicit Drug 
Use 
 
CAHS 
Sleep Quality 
K10 
Age 
0.35 
-0.62 
-0.03 
0.19 
0.20 
0.01 
0.071 
0.002 
<0.001 
0.97 
0.37 
0.95 
1.41 
0.54 
0.97 
2.05 
0.80 
0.99 
 
0.09 
 
*34.93 
 
CARA 
Sleep Problems 
Gender 
K10 
Age 
-0.58 
0.65 
-0.64 
-0.03 
0.24 
0.23 
0.24 
0.01 
0.016 
0.004 
0.009 
0.006 
0.35 
1.23 
0.33 
0.95 
0.56 
1.91 
0.54 
0.97 
0.90 
2.97 
0.86 
0.99 
 
0.10 
 
*29.50 
 
 
IARA 
 
Sleep Problems 
K10 
Age 
 
-0.48 
-0.58 
-0.03 
 
0.25 
0.24 
0.01 
 
0.054 
0.014 
0.006 
 
0.38 
0.35 
0.95 
 
0.62 
0.56 
0.97 
 
1.01 
0.89 
0.99 
 
0.08 
 
*23.83 
 
 
 
 
 
Any Recent 
(Past 30-Day) 
Prescription 
Drug Misuse 
 
 
CAHS 
Sleep Quality 
Sleep Aids 
Education 
2+ Medical 
Age 
0.43 
-0.75 
-0.54 
-1.07 
-0.03 
0.24 
0.25 
0.25 
0.29 
0.01 
0.074 
0.002 
0.030 
<0.001 
0.026 
0.96 
0.29 
0.36 
0.19 
0.95 
1.54 
0.47 
0.59 
0.34 
0.98 
2.47 
0.76 
0.95 
0.61 
1.00 
 
 
0.14 
 
 
*40.97 
 
 
 
CARA 
 
Sleep Problems 
Anxiety 
2+ Medical 
Marital 
Age 
K10 
 
-0.78 
-0.46 
-0.62 
-1.06 
-0.04 
-0.47 
 
0.31 
0.26 
0.28 
0.35 
0.01 
0.26 
 
0.012 
0.074 
0.023 
0.002 
0.002 
0.070 
 
0.25 
0.38 
0.31 
0.18 
0.95 
0.37 
 
0.46 
0.63 
0.54 
0.35 
0.97 
0.62 
 
0.84 
1.05 
0.92 
0.69 
0.99 
1.04 
 
 
 
0.16 
 
 
 
*47.19 
 
 
IARA 
 
Sleep Problems 
Anxiety 
Insurance 
 
-1.11 
-0.82 
0.54 
 
0.34 
0.25 
0.33 
 
0.001 
0.001 
0.102 
 
0.17 
0.27 
0.90 
 
0.33 
0.44 
1.71 
 
0.64 
0.72 
3.25 
 
 
0.11 
 
 
*29.77 
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Table 34. Multivariable Linear Regression by Assessment Measure for Alcohol (N=540). 
*Mean Days of Alcohol Use per Week During the Past 30 Days 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Substance Use 
Variable 
 
Assessment 
Measure 
 
 
Covariate 
 
 
B 
 
 
SE 
B 
 
 
 
 
 
t 
 
 
p-value 
95% CI for B    
 
R2 
 
Lower 
 
Upper 
 
F 
 
p-
value 
 
 
 
 
 
*Alcohol 
 
 
CAHS 
 
 
 
CARA 
 
 
 
 
 
IARA 
 
 
Gender 
Anxiety 
 
Sleep Problems 
Gender 
Education 
Insurance 
 
Sleep Problems 
Gender 
Anxiety 
Marital 
Education 
-0.65 
-0.53 
 
0.40 
-0.58 
-0.62 
-0.59 
 
0.72 
-0.82 
-0.75 
1.21 
-0.80 
0.17 
0.17 
 
0.24 
0.21 
0.23 
0.26 
 
0.36 
0.32 
0.32 
0.51 
0.34 
-0.19 
-0.15 
 
0.09 
-0.14 
-0.14 
-0.12 
 
0.11 
-0.13 
-0.12 
0.12 
-0.12 
-3.91 
-3.16 
 
1.71 
-2.76 
-2.71 
-2.31 
 
2.00 
-2.60 
-2.30 
2.36 
-2.33 
<0.001 
0.002 
 
0.089 
0.006 
0.007 
0.022 
 
0.046 
0.010 
0.022 
0.019 
0.020 
-0.98 
-0.86 
 
-0.06 
-1.00 
-1.07 
-1.09 
 
0.01 
-1.44 
-1.39 
0.20 
-1.47 
-0.32 
-0.20 
 
0.87 
-0.17 
-0.17 
-0.09 
 
1.42 
-0.20 
-0.11 
2.22 
-0.13 
5.89 
 
 
 
6.51 
 
 
 
 
 
5.81 
<0.001 
 
 
 
<0.001 
 
 
 
 
 
<0.001 
 
0.08 
 
 
 
0.07 
 
 
 
 
 
0.08 
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Table 35. Multivariable Linear Regression by Assessment Measure for Other Drugs (N=540). 
*Mean Days of Illicit Drug Use per Week During the Past 30 Days 
**Mean Days of Prescription Drug Misuse per Week During the Past 30 Days 
 
Substance Use 
Variable 
 
Assessment 
Measure 
 
 
Covariate 
 
 
B 
 
 
SE 
B 
 
 
 
 
 
t 
 
 
p-value 
95% CI for B    
 
R2 
 
Lower 
 
Upper 
 
F 
 
p-value 
 
 
 
 
 
 
*Illicit Drug 
 
CAHS 
 
 
 
 
CARA 
 
 
 
 
IARA 
Age 
Education 
K10 
 
Sleep Problems 
Age 
Gender 
Education 
K10 
 
Sleep Quality 
Education 
Age 
-0.06 
-0.55 
0.47 
 
0.29 
-0.02 
-0.35 
-0.27 
0.26 
 
-0.42 
-0.55 
-0.06 
0.01 
0.25 
0.25 
 
0.14 
0.01 
0.13 
0.14 
0.14 
 
0.24 
0.25 
0.01 
-0.28 
-0.11 
0.09 
 
0.10 
-0.20 
-0.14 
-0.10 
0.10 
 
-0.08 
-0.11 
-0.27 
-5.84 
-2.24 
1.91 
 
1.99 
-3.99 
-2.74 
-2.00 
1.90 
 
-1.75 
-2.20 
-5.55 
<0.001 
0.025 
0.056 
 
0.047 
<0.001 
0.006 
0.046 
0.058 
 
0.080 
0.028 
<0.001 
-0.08 
-1.03 
-0.01 
 
0.00 
-0.04 
-0.60 
-0.54 
-0.01 
 
-0.89 
-1.04 
-0.08 
-0.04 
-0.07 
0.96 
 
0.57 
-0.01 
0.10 
-0.01 
0.52 
 
0.05 
-0.06 
-0.04 
 
14.64 
 
 
 
 
 
6.92 
 
 
 
12.36 
 
<0.001 
 
 
 
 
 
<0.001 
 
 
 
<0.001 
 
0.10 
 
 
 
 
 
0.09 
 
 
 
0.08 
 
 
 
 
**Prescription 
Drug 
 
CAHS 
 
 
 
 
 
CARA 
 
 
 
 
IARA 
Sleep Aids 
+ Medical 
Race 
Education 
 
Sleep Problems 
Sleep Aids 
Age 
2+ Medical 
Race 
K10 
 
Sleep Aids 
Anxiety 
0.37 
0.30 
-0.27 
0.24 
 
0.25 
0.25 
-0.01 
0.40 
-0.24 
0.32 
 
0.38 
0.55 
0.13 
0.13 
0.16 
0.14 
 
0.12 
0.10 
0.01 
0.11 
0.13 
0.11 
 
0.15 
0.16 
0.14 
0.11 
-0.08 
0.09 
 
0.09 
0.11 
-0.10 
0.16 
-0.08 
0.12 
 
0.11 
0.16 
2.87 
2.25 
-1.68 
1.78 
 
2.09 
2.44 
-2.23 
3.54 
-1.80 
2.79 
 
2.51 
3.52 
0.004 
0.025 
0.094 
0.076 
 
0.037 
0.015 
0.026 
<0.001 
0.072 
0.005 
 
0.012 
<0.001 
0.12 
0.04 
-0.59 
-0.03 
 
0.01 
0.05 
-0.02 
0.18 
-0.49 
0.09 
 
0.08 
0.24 
0.62 
0.56 
0.05 
0.51 
 
0.48 
0.46 
-0.00 
0.62 
0.02 
0.54 
 
0.68 
0.85 
 
5.74 
 
 
 
 
 
9.70 
 
 
 
 
13.09 
 
<0.001 
 
 
 
 
 
<0.001 
 
 
 
 
<0.001 
 
 
0.05 
 
 
 
 
 
0.10 
 
 
 
 
0.05 
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Discussion 
  
From a public health perspective, primary care settings offer an excellent opportunity to 
identify and address patient substance use and related problems. For large scale implementation, 
however, efficient tools are needed that are both valid and reliable. The present study compared 
computerized anonymous and confidential surveys to a confidential, interviewer-administered 
assessment in a primary care sample of heavy/problem alcohol and/or drug using males and 
females. This study also compared self-reports of recent substance use to urine drug assay 
findings. Finally, this study identified correlates of any recent (past 30-day) use as well as 
correlates of recent alcohol quantity-frequency and other drug use frequency per week in the past 
30 days. 
 Any recent (past 30-day) alcohol/drug use (i.e., illicit drug use and/or prescription drug 
misuse) as well as recent alcohol quantity-frequency and other drug use frequency were 
measured by all three methods of administration. The computerized, anonymous survey and 
interviewer-administered assessment also measured frequency of recent binge drinking, while 
the computerized, anonymous survey and computerized, confidential survey measured problem 
alcohol and/or drug use.  
Overall, prevalence of any substance use were higher by anonymous computer survey 
than those found by the other two methods of administration. Specifically, any recent (past 30-
day) alcohol use was highest on the computerized, anonymous survey while rates of any recent 
(past 30-day) illicit drug use were highest on the confidential, computerized assessment. Rates of 
binge drinking were significantly higher on the computerized, anonymous survey compared to 
interviewer-administered assessment; and rates of alcohol and/or drug use related problems were 
significantly higher on the anonymous computerized survey versus confidential computerized 
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survey. Quantity-frequency of alcohol use and frequency of prescription drug misuse per week 
were significantly higher on the interviewer-administered assessment compared to the other two 
methods of administration. While frequency of illicit drug use per week was highest on the 
interviewer-administered assessment, significant differences were only found when compared to 
the computerized, confidential survey. 
Sample Representativeness 
It is important to recognize that the present study looked only at individuals who 
qualified for a RCT targeting heavy/problem alcohol and/or illicit drug use or prescription 
medication misuse. Primary care patients who were not at risk are absent from the sample. 
Further, of those who met RCT criteria, only 53% gave informed consent and participated in the 
clinical trial. Previous research by members of our research team found RCT consenters differed 
from non-consenters on a variety of measures. Specifically, RCT participants were more likely to 
endorse prescription drug misuse and problems related to drug use. They also endorsed a greater 
number and more severe psychosocial and mental health problems (Kelpin et al., 2018). As a 
result, the representativeness of the present study sample and generalizability of present study 
findings to broader patient groups (e.g., all primary care patients) must be made with caution.  
Anonymous Survey vs. Personal Interview (CAHS and IARA) 
Any Recent Alcohol Use and Binge Drinking 
For alcohol, participants were more likely to report recent alcohol use by CAHS than by 
IARA (i.e., the TLFB). For any recent use, the difference was modest (86% by CAHS and 79% 
by IARA), as was the difference in number of days of recent alcohol use. For binge drinking, 
however, the difference was more striking, with nearly twice as many participants reporting any 
recent binge drinking by anonymous survey (71% on CAHS) as compared to personal interview 
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(43% by IARA). This difference was also seen in the number of recent binge drinking days 
reported, with a mean of 5.37 days on the CAHS compared to 3.52 days on the IARA.  
A similar pattern was reported by Gryczynski, et al (2017) in a multi-site study of adult 
primary care patients. They found an anonymous tablet-based alcohol screen yielded higher self-
reported alcohol use than a subsequent interviewer-administered version of the same questions 
(48% vs. 37%; p < 0.001). Interestingly, this pattern was not seen when the interviewer mode of 
administration preceded the computer-based survey (e.g., all ps > 0.05). For the present study, 
the anonymous, computerized survey was always administered prior to the personal interview, as 
it was the screener that determined RCT eligibility.  
Similarly, in a research study with postpartum women, Beatty et al., (2014) found that 
those randomly assigned to an anonymous consent condition disclosed significantly more 
alcohol and drug use than those completing traditional confidential consent procedures. 
Underreporting of alcohol and drug use is of particular concern in pregnant women, where fear 
of adverse societal or legal consequences is often elevated (Grekin et al., 2010). The current 
study suggests similar under-reporting of heavy/binge may not be limited to postpartum women.  
In the field of alcohol research, the TLFB has long been considered the most reliable and 
valid method of assessment for quantity and frequency of alcohol use (Sobell & Sobell, 2003; 
Sobell & Sobell, 2008; Sobell et al., 2001; Sobell et al., 2003). The TLFB is rarely used in 
routine clinical practice (e.g., as a screening tool) as it is too time consuming and requires more 
staff training than other measures (McPherson & Hersch, 2000). In the present study, when the 
TLFB (IARA) was considered the reference standard, anonymous survey (CAHS) sensitivity 
was high for both any recent alcohol use and binge drinking, while specificity was unacceptably 
low for both any alcohol (0.54) and binge drinking (0.45).  
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A recent systematic review evaluating the accuracy of unhealthy alcohol screening tests 
in general primary care populations found that brief screening instruments (e.g., SASQ, AUDIT-
C) reported sensitivity and specificity between 0.73 and 0.10; For the AUDIT-C, while 
sensitivity was similar, the range of reported specificity was wider. Most studies used structured 
diagnostic interviews as reference standards, with the TLFB sometimes being used in 
combination with the interviews. All of these studies were conducted largely in primary care 
settings and participants were administered a brief screener to identify excess use, followed by 
assessment with a more detailed instrument with greater specificity (e.g., the AUDIT) (O’Conner 
et al., 2018).  
Interestingly, when O’Conner and colleagues (2018) looked separately at a sub-sample of 
adults with heavy use episodes (e.g., binge drinking) in the past month, PPVs ranged between 
55-76% and NPVs ranged between 88-96%, results similar to the present study that found a PPV 
of 55% and NPV of 87%. In general, however, these studies evaluated the accuracy of screening 
tests in general primary care populations with a broad range of drinking disorders and patient 
characteristics, making it difficult to infer whether the test performs equally well in each group.  
Similarly, what cannot be gleaned from present study findings, is whether the TLFB was, 
in fact, more valid than the CAHS in identifying alcohol and binge drinking or if alternatively, 
participants were more willing to admit to recent alcohol and binge drinking when queried 
through an anonymous, computer-delivered survey as compared to an in-person, face-to-face 
interview.  
Notwithstanding the CAHS identified half as many non-binge drinking days (29%) as the 
IARA (57%), the anonymity, as well as method of administration, may have also resulted in 
higher self-disclosure of unhealthy use. Research suggests that heavy alcohol use is highly 
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stigmatized (Bazzi & Saitz, 2018) and that computerized surveys lead to significantly more 
reporting of socially undesirable behaviors than comparable surveys administered on paper 
(Gnambs & Kaspar, 2015) and during face-to-face interviews (Butler et al., 2009). In the CAHS 
modality, questions about unhealthy alcohol use were self-administered without an interviewer, 
allowing patients to respond privately and thus reducing the threat of social desirability bias 
(Davis et al., 2010; Estes et al., 2010; Richter & Johnson, 2001). As such, participants may 
have been tempted to give more importance to periods of lower alcohol consumption during 
the IARA. Further, order effect may have contributed to differences in response rates. Research 
suggests the orders in which are presented may affect how respondents answer subsequent 
questions (Strack, 1992). Again, for the present study, the anonymous, computerized survey was 
administered prior to the personal interview. 
Additionally, offering certain option choices may affect test characteristics, albeit only to 
a small degree (Roy et al., 2009). For example, the present study asked, “During the past 30 days 
how many times (i.e., days) have you had 5 or 4 [males or females, respectively] more drinks per 
occasion?” while the TLFB recorded daily alcohol quantity and frequency without option 
choices. Interesting, previous research has validated a computerized single-question screener 
against a past-30 day TLFB for identifying unhealthy alcohol use among adults in primary care 
(“How many times in the past year have you had X or more drinks in a day?”, where X is 5 for 
men and 4 for women) (McNeely et al., 2015b), demonstrating the validity of a clinically 
useful computerized brief screener.  
Also, noteworthy, the categorization of binge episodes on the CAHS provided a less-
than-perfect comparison to the TLFB. For example, days greater than 10 were categorized 11-
20, 21-29, and every day (30 days) on the CAHS versus a continuous record of each day on the 
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TLFB. While the absolute difference is small (e.g., using TLFB data as the standard, the 
difference between methods in reports of binge drinking between 11-29 days was 8% on the 
IARA and 6% on the CAHS), the difference may be meaningful given the relatively large sample 
size of 540 participants. 
Other methodological issues also deserve consideration. For example, was the definition 
of “a standard drink” adequately communicated during CAHS administration and did 
participants remember to consider beer and wine as alcoholic beverages (not just hard liquor)? 
Participants were offered a visual aid with standard drink definitions, but these definitions did 
not appear on the computer screen each time questions were asked. In contrast, TLFB 
interviewers routinely provided drink definitions (see Appendix A), and the TLFB was 
administered only to people RAs knew would be positive for alcohol and/or other drug use. RA’s 
expected no completely negative cases, and interviewers could remind participants as they 
worked actively to assist with accurate recall (Sacks et al., 2003). 
Alcohol Quantity and Frequency 
For quantity-frequency of alcohol use per week (average drinks per week), a different 
pattern was observed, with participants reporting a greater number of drinks per week on the 
IARA (2.63) when compared to the CAHS (2.21). While past studies (Roy et al., 2008; Sobell & 
Sobell, 2003; Sobell et al., 2003) comparing quantity-frequency and daily estimation (DE) 
measures, such as the TLFB, have found relatively similar reports for aggregate drinking 
variables, quantity-frequency measures typically are not able to capture sporadic and atypical 
drinking patterns. Consequently, quantity-frequency measures compared with DE measures 
usually underestimate consumption. Further, in clinical trial data, the correlation between the 
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quantity-frequency and TLFB (using a 30-day recall period) is less robust (NIAAA, 2018), as 
most screening instruments assess for past year use (O’Connor et al., 2018). 
In the present study, the agreement between quantity-frequency on the CAHS and the 
IARA (i.e., the TLFB) was moderate to good; however, more drinks per week were reported on 
the IARA vs. CAHS while more unhealthy/heavy alcohol use was reported on the CAHS when 
compared to the IARA. This combination of results has not been compared in previous studies.  
The reasons for this discrepancy are not known and could relate to the different levels of 
data protection or due to the TLFB’s sensitivity to sporadic and unpatterned drinking (Sobell & 
Sobell, 1992; Sobell & Sobell, 2003; Staudt et al., 2018). Further, determining quantity of 
alcohol use is complex. For example, respondents might think vaguely about recent drinking or 
they might carefully try to recall the number of drinks consumed. Subsequently, participants 
calculate their average number to format tentative answers in terms of the response options 
provided, or not provided in the case of the TLFB. Participants then decide what answer to 
choose based on social desirability bias. Collectively, this resulted in a much poorer crosswalk 
between quantity overall compared to the crosswalk between days of use and days of binge 
drinking in the past 30 days. 
Interestingly, research reviewing the accuracy of quantity-frequency alcohol screening 
tests in primary care found a wide range of reported sensitivities and specificities (Fiellin et al., 
2000). For example, one study found a sensitivity of 47% and a specificity of 96%, with the use 
of MAST scores as the reference standard, and a quantity cutoff score of 4 or more drinks per 
day (Cry & Wartman, 1988). Fleming and Barry (1991) found sensitivities of 50% and 20% with 
specificities of 87% and 97%, with the use of a cutoff of 7 and 20 drinks per week, respectively. 
In another study, there was a gradual decrease in sensitivity (100%-21%) with a corresponding 
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increase in specificity (43%-97%) as the number of drinks consumed per week increased from 0 
to 24 or more (Buchsbaum et al., 1995). While this review took into account demographic and 
clinical (e.g., severity of alcohol problem) factors, these data suggest using formal screening 
instruments may perform better than quantity-frequency questions. 
Of note, quantity-frequency of alcohol use per week was taken from the 30-day TLFB. 
The concordance between longer versus shorter assessment windows has been a subject of prior 
research (Carey et al., 2004; Hoeppner et al., 2010; Roy et al., 2008; Sobell et al., 2001; Toll et 
al., 2008; Vakili et al., 2008) but rarely investigated in non-substance-related treatment-seeking 
individuals. Research shows that participants report more drinking on the repeated TLFB-7 than 
on the standard TLFB-30, and those discrepancies between methods increased as the length of 
recall increased, suggesting that using shorter recall periods may yield more accurate data (Vakili 
et al., 2008).  
Lastly, all consented participants in the present study were administered the TLFB 
assessment regardless of their CAHS results. This prevented workup bias (Reid et al., 1995), 
which occurs when participants preferentially receive the criterion standard evaluation based on 
positive, as opposed to negative, results on a screening test. When participants screen positive 
and preferentially receive the criterion standard evaluation, the sensitivity of the test can be 
falsely elevated because of the incorrect exclusion of participants (false negatives) from 
analyses. In addition, most, if not all, studies examining the accuracy of alcohol screening 
measures do so among general primary care samples and not among those with very heavy use. 
While the present study’s sample included those with heavy/problem alcohol use, it also included 
those with heavy/problem illicit drug and/or prescription drug misuse. Because alcohol screening 
identifies patients with dependence (Saitz, 2010), it would be reasonable to argue that the 
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accuracy of the present study’s screening tools would increase if the sample only included 
heavy/problem drinkers. 
Other Drugs 
For illicit drugs, when CAHS was compared to IARA, more participants also reported 
any recent drug use by personal interview (47% by IARA) than by anonymous, computerized 
survey (37% on CAHS). For prescription drug misuse, both the CAHS and IARA found 27% of 
participants reported one or more days of drug misuse in the past 30 days. The mean number of 
days of illicit drug use and prescription drug misuse in the past 30 were highest on the IARA. 
Participants also reported more average illicit drug use (1.44 by IARA and 1.42 by CAHS) and 
prescription drug misuse per week (0.68 by IARA and 0.39 by CAHS, p < 0.001) by personal 
interview; however, the difference between the CAHS and IARA for illicit drug use per week 
were nonsignificant. 
Interestingly, reliability was low in detecting use of prescription drug misuse in the 
present study, however, even though the difference between the CAHS and IARA was 
statistically significant, with participants reporting the most days of prescription drug misuse on 
the IARA, in absolute terms the difference was minuscule. The relatively low reliability of 
screening for this substance class could be due to confusion among participants about what 
constitutes non-medical use (McNeely et al., 2014b). Also, there was no visual aid offered for 
illicit or prescription medications, and certain prescription drugs (e.g., sedatives and hypnotics) 
purchased on the street may have been mixed with illicit non-prescription drugs to create 
inconsistent recordings during the IARA. 
When the IARA was considered the gold standard for assessment of illicit drug use, 
  
 
108 
 
 
CAHS sensitivity and specificity was 0.71 and 0.95, and CAHS’s high PPV (0.91) is desirable, 
implying that false positive outcomes are minimized. For prescription drug misuse, CAHS 
sensitivity and specificity were slightly lower. In a recent systematic review assessing the 
accuracy of different screening tools (e.g., SUBS, TAPS, ASSIST, DAST) in adult primary care 
patients found the sensitivity of direct tools for detecting unhealthy use of any drug (including 
illicit drugs and prescription drug misuse) in the past month or year ranged from 0.71 to 0.94 
(95% CI, 0.62-0.97), and specificity ranged from 0.87 to 0.97 (95% CI, 0.83-0.98). Screening 
tools had higher sensitivity for detecting unhealthy illicit drug use related to any drug (most of 
which was cannabis), cannabis, heroin, and stimulants than for detecting illicit drug use related 
to prescription drug misuse, including opioids or sedatives (range, 0.38-0.96 [95% CI, 0.29-
0.99]) but specificity was comparable (range, 0.79-1.00 [95% CI, 0.71-1.00]) (Patnode et al., 
2019; Patnode et al., 2020; USPSTF, 2020). One likely reason for the lower sensitivity in the 
present study is that many of the studies examining screening tools for other drug use assess use 
in the past three months. Research has shown that self-report rates of drug use increase when the 
recall window is widened to 90 days (Rendon et al., 2017).  
While prevalence rates are similar to those found in other high-risk primary care 
populations (Saitz et al., 2014a), present study findings were unexpected as research has found 
computerized screening as well as provision of anonymity increases disclosure of substance use 
(Beck et al., 2014; Durant et al., 2002; Tourangeau & Yan, 1997). Further, research indicates that 
participants are more likely to disclose risky behaviors when assessed by Audio Computer-
Assisted Self Interview (ACASI) format than by interviewer-administration (Dolezal et al., 
2012; Estes et al., 2010; Perlis et al., 2004; Newman et al., 2002). A study examining audio 
ACASI versus facet-to-face interviewing found that the ACASI respondents were more likely to 
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report intranasal heroin use and smoking marijuana than face-to-face interviewing respondents 
(Perlis et al., 2004). Whereas this study examined interviewer-administered and computer-
assisted modalities, their population included injecting drug users entering drug treatment 
programs, and the authors assessed for each illicit drug separately over the past six months. 
Nonetheless, this study highlights how greater privacy in ACASI conditions could have reduced 
social desirability bias, leading to greater and more accurate reporting of drug use (White et al., 
2007).  
The illegal status of drugs may underlie this distinction, where misuse of alcohol is more 
socially normative, especially in non-treatment settings. Relatedly, a major advantage about the 
interviewer-administered TLFB modality is that the face-to-face, interviewer-administered, semi-
structured format establishes trust and rapport between interviewer and participant (Bowling, 
2005; Rosenbaum et al., 2006), overcoming social desirability bias. Further, interviewers were 
not blinded to the study’s inclusion criteria when they administered the TLFB, which could have 
impacted the interview. Even within surveys, differences in interviewer styles and presentation 
may influence validity. 
Notably, willingness to disclose substance use can also be influenced by awareness of 
confirmatory biological testing (Nordeck et al., 2020). In the present study, participants agreed in 
the RCT consent to urine drug testing after completing the CAHS. This was done purposefully, 
to obtain responses that were not potentially biased by knowledge of subsequent testing, given 
the primary purposes of the parent study. Contrary to expectations, however, participants may 
have been more likely to provide accurate information after knowing their use could be 
discovered via confirmatory testing. This may also suggest that ensuring confidentiality is likely 
to maximize the truthfulness of self-reported drug use (Harrison & Hughes, 1997; Hjorthøj et al., 
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2012; Magura & Kang, 1996; Shupp et al., 2020), as there are fewer consequences associated 
with illicit substance under research conditions. As a consequence, however, this finding might 
not apply to clinical assessment settings and may not generalize to less severe forms of use found 
among patients attending primary care clinics. 
Nevertheless, these findings in general add to the existing literature supporting the use of 
the TLFB for dichotomous detection of substance use, and for frequency of such use (Hjorthøj et 
al., 2012; Martin-Willet et al., 2020; Metrik et al., 2018; Patnode et al., 2019; Patnode et al., 
2020). 
Anonymous vs. Confidential Survey (CAHS and CARA) 
For alcohol, participants were more likely to report any recent (past 30-day) alcohol use 
by CAHS than by CARA. A similar pattern was observed for days of alcohol use in the past 30 
days as well as average drinks consumed per week in the past 30 days. When the CARA was 
considered the gold standard, CAHS sensitivity was high for any recent alcohol use but 
specificity was unacceptably low, and reliability was moderate for both days of alcohol use in the 
past 30 and average drinks consumed use per week. One factor contributing to this finding may 
be variability in question wording as well as the window of assessment (week vs. month). 
However, CAHS had a high PPV (0.95) and moderate NPV (0.68), implying that false positive 
outcomes are minimized, and the false negative outcomes associated with moderate NPV is 
acceptable given the CAHS acted as a screening tool while the CARA offered a more detailed 
assessment of alcohol use. 
Since actual alcohol use is unknown, we cannot determine if one computerized survey is 
more valid than the other. Given higher rates by anonymous vs. confidential surveys, it is 
possible participants were more willing to admit to recent alcohol use when no personal 
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identifying information had been collected. Similar to Beatty et al., (2014) who found 
participants disclosed significantly more alcohol use in an anonymous vs. traditional consent 
condition, Hormes and colleagues (2012) found an anonymous questionnaire yielded 
significantly (p<.05) higher rates of alcohol use compared to confidential survey in a sample of 
HIV positive primary care patients. 
Whereas several computerized screening programs have been developed to identify 
alcohol use, research examining anonymous versus confidential computerized surveys is limited. 
Nevertheless, present study findings parallel those of previous studies in terms of the clear 
influence of anonymity on disclosure (Lau et al., 2003; Ong and Weiss, 2000). 
Findings were mixed when comparing rates of other drug use. Interestingly, the highest 
rate of any recent (past 30-day) illicit drug use was reported on the CARA, and rates of 
prescription drug misuse were identical for both surveys. However, days of drug use and average 
days per week in the past 30 were higher on the CAHS compared to the CARA. In contrast, days 
of prescription drug misuse and average days of misuse per week in the past 30 were higher on 
the CARA (all ps <.05).  
While these results were unexpected, they mirrored results reported by Beatty et al., 
(2014), who found that the presence of a certificate of confidentiality yielded increased 
disclosure of drug use compared to traditional confidentiality. Responding under confidential 
research conditions in the present study, with IRB consent language assuring protection against 
medical or legal consequences, may have provided some measure of comfort concerning the 
risks of drug use disclosure. 
 Further, consistent order effects and knowledge of biological testing could have 
influenced the truthfulness of their responses, particularly for other drug use. Finally, the CARA 
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provided a much more detailed assessment of alcohol and other drug use compared to the CAHS 
and also included a longer window of assessment (i.e., past three months). This provided a less 
sensitive comparison of past 30-day other drug use compared to the CAHS, and research 
suggests the validity of self-report measures of other drug varies when assessed for recent and 
more distal use (Cólon et al., 2002; Harrison & Hughes, 1997; Rendon et al., 2017), with validity 
increasing when the recall window is widened to 90 days. The influence of questions occurring 
earlier in the CAHS with subsequent, albeit differently worded, questions on the CARA could 
also account for the differences in self-reports (McNeely et al., 2014b). Interestingly, results 
obtained in the present study contradict conclusions drawn by researchers examining the role of 
confidential versus anonymous self-reports of substance use in other populations (e.g., younger 
adults; Moore & Ames, 2002; O’Malley et al., 2000), suggesting that findings may be unique to 
this patient group and setting.  
Computerized Confidential Survey and Personal Interview (CARA and IARA) 
 Results were much more consistent when comparing the CARA and IARA, albeit 
findings contradicted hypotheses predictions. For alcohol, recent use and average drinks 
consumed per week in the past 30 days were higher on the IARA compared to the CARA; mean 
days of alcohol use in the past 30 were higher on the CARA, though, these differences were 
modest. For other drugs, mean days of drug use in the past 30 and frequency of drug use and 
prescription drug misuse were higher on the IARA compared to the CARA (all ps > 0.05). In 
contrast, any recent drug use was highest by CARA versus IARA and any recent prescription 
drug misuse was identical for both measures.  
 Interestingly, when the IARA was considered the gold standard for assessment of illicit 
drug use, the CARA had the highest sensitivity (0.89) and specificity (0.94). The higher 
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sensitivity and specificity for the CARA is likely related to the more detailed assessment of each 
illicit drug used in the past 3-months. Although it is desirable to have tests with high sensitivity 
and specificity, this result may not be of particular importance considering the length of the 
confidential, computerized assessment (Trevethan et al., 2013), which may not be useful in 
clinical practice settings. 
While previous work has examined interviewer-administered and computer-assisted 
modalities in heterogeneous samples of patients, determining agreement between these two 
modalities has received less attention in the area of substance use in primary care settings. 
Moreover, while the TLFB has been validated in multiple formats, to date very few systematic 
comparisons have been conducted between computerized assessment and an interviewer-
administered TLFB for substance use.  
One study comparing interviewer-administered TLFB versus ACASI format questions 
about frequency of illicit drugs found the ACASI modality reflected more days used than TLFB 
(Delker et al., 2016). Specifically, they found a mean of 10.2 days by ACASI versus 8.7 days by 
TLFB. They also found the difference was greatest among younger participants. Similar to the 
present study, Delker and colleagues (2016) found that while statistically significant the 
magnitude of the discrepancy was marginal.  
In contrast to the present study, Delker et al., (2016) assessed frequency of use during the 
prior 30 days by primary drug and included a sample of HIV-infected drug users. Substance use 
can have major consequences among HIV patients, which may have contributed to under-
reporting on the interviewer-administered TLFB. Also, while the present study focused on the 
participants’ primary drug on the TLFB, the CARA included all drugs the participant self-
reported using, which may negatively skewed the distribution. 
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The present study expected that participants will report higher rates of alcohol and other 
drug use with a computerized self-administered assessment than interviewer-administered 
assessment (Beck et al., 2014; Butler et al., 2009; Delker et al., 2016; Lessler et al., 2000; 
McNeely et al., 2016a; Newman et al., 2002; van Griensven et al., 2006), however, several 
studies examining the effects of computerized self-administered surveys (CASI) have generated 
contradictory findings. Some comparisons of CASI with face-to-face interviewing have 
concluded that participants report more socially undesirable behavior in the face-to-face 
interview modes than with CASI (Tourangeau & Yan, 1997), while others have found little or no 
difference between CASI and face-to-face interviews (Islam et al., 2014; Williams et al., 2000). 
However, in particular, these studies include samples of injecting drug users from a Hepatitis B 
Acceptability and Vaccination Incentive Trial (HAVIT) (Islam et al., 2014) and drug users from 
an HIV reeducation risk study (Williams et al., 2000); participants may have been less motivated 
to conceal substance use from interviewers given incentives for study participation. 
  Similar results were found by McNeely and colleagues (2016a) who evaluated the 
concordance of an audio computer-assisted self-interview version of the Alcohol, Smoking, and 
Substance Involvement Screening Test (ACASI ASSIST) with the previously validated 
interviewer-administered ASSIST in primary care patients. The authors found the ACASI 
ASSIST demonstrated excellent concordance (92–99%) with the ASSIST in identifying 
moderate to high-risk substance use, though, reporting of alcohol and illicit drug use on the 
ACASI ASSIST. More reporting of illicit drug use CARA vs. IARA was also found in the 
present study, which is consistent with multiple prior studies showing that self-administered 
instruments generate higher rates of reporting of stigmatized behaviors (Kim et al., 2008). 
Similar to the present study, McNeely et al., (2016) summed ASSSIT responses for each 
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substance and also aggregated responses into two summary categories: ‘prescription drugs’ 
(prescription opioids, sedatives, and stimulants) and ‘illicit drugs’ (all other drugs, excluding 
tobacco and alcohol). However, their sample included a general medical population and 
relatively few had high-risk use of any substance. Further, participants completed both 
instruments in sequence, which has the potential to bias responses. 
Possible explanations for the present study findings may include limited retrospective 
recall (Bowling, 2005; Killeen et al., 2004) on the CARA as it assessed for lifetime and past 3-
month use. In contrast, the CARA preceded the TLFB and may have acted as a memory prompt, 
leading to increased reporting of substance use during subsequent TLFB administration. To 
eliminate this potential bias, future research should engage a cross-over design, in which half of 
the participants complete a CARA first while the other half begin with interviewer-
administration.  
Other factors contributing to these findings may be due to differences in measurement 
and terminology among the instruments (Bowling, 2005). For example, questions on the CARA 
focused on regular alcohol and other drug use in the past 3-months while the TLFB (IARA) 
focused on past 30-day quantity-frequency of use (Sobell, 2003), allowing only approximate 
comparability. Also, the TLFB allows interviewers to provide additional instructions and 
clarifications as needed. Further, participants responded under confidential research conditions in 
both formats, with the knowledge that the results would not enter their medical record and they 
were protected from legal of other consequences. One advantage of the TLFB is that the face-to-
face, interviewer-administered, semi-structured format establishes trust and rapport between 
interviewer and participant (Rosenbaum et al., 2006). 
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Overall, differences between the present study and others are likely to reflect the 
characteristics of the sample, for example, whether the sample is in treatment or out of treatment, 
and the prevalence of use in the sample. Again, while it is unclear whether one modality is more 
valid than the other, results from the present study indicate that the interviewer-administered 
quantity-frequency measure produced more self-disclosure of alcohol and other drug use 
compared to the CARA. However, it is not known how patients’ willingness to disclose 
substance use might change under real-world practice conditions.  
Discrepancies Between Self-Reported Alcohol and Other Drug Use 
Significant CAHS and IARA discrepancies in reports of recent alcohol and other drug 
use frequencies by some participants warrant further study. Some participants reported 30 days 
of other use on one measure but reported zero days of use on the other and vice versa. In general, 
these participants reported similar rates on the CARA or endorsed inconsistent use of other 
substances across measures, and many with discrepant prescription drug misuse data were 
recently in a controlled environment. There were also discrepancies between some participants 
reporting different frequencies of days of alcohol use and binge drinking in the past 30 days on 
the CAHS. Generally, these participants also underreported their frequency of binge drinking on 
the IARA, suggesting again the anonymity, as well as method of administration, may have 
resulted in higher self-disclosure of unhealthy use.  
While some discordance between methods is expected related to methodological 
differences or random measurement error, social desirability bias likely contributed to the 
observed discordance. Participants may misreport substance use due to stigma or a desire to 
avoid further discussing their use (Davis et al., 2010). Furthermore, randomized controlled trials 
suggest that repeated screening leads to lower reported consumption on later screens 
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(McCambridge & Day, 2008; Moos, 2008; Kypri et al., 2007). The present study had a consistent 
order of administration, with provision of anonymity decreasing as participants progressed across 
the CAHS, CARA, and IARA. Further, participants could have experienced respondent fatigue 
(Lavrakas, 1998), especially if the individual participated in the RCT after a length medical 
appointment.  
However, participants may also be more motivated to report substance use in subsequent 
surveys if they feel it is relevant to their health (Bradley et al., 2011). For example, participants 
became aware of the intervention/treatment focus of the parent study during confidential consent 
procedures and may have been more honest with their use during the IARA if interested in 
addressing their use. For example, previous research by members of our research team found 
those consenting to the RCT endorsed a range of mental health conditions and greater sleep 
disturbance than those who chose not to participate (Kelpin et al., 2018). This finding may reflect 
the association between help-seeking and medical comorbidity (Aikens & Rouse, 2005; Hall & 
Farrell, 1997). Greater awareness of the need for help among clients with comorbidities might 
make them more motivated to seek services, including those provided through a clinical trial.  
Also, the primary purpose of the CAHS was to identify those at risk for heavy/problem 
substance use, this was not made explicit during recruitment. Instead, it was described as an 
anonymous general health and risk behaviors survey. This was done in part, to minimize social 
desirability. Therefore, the survey included questions that did not pertain to substance use. 
Research efforts were made to mask the primary purpose of the screener, however, may have 
become less successful over time, as the clinic became aware of an ongoing RCT that involved 
substance use. Patients could converse in the waiting area and this may have influenced how they 
responded to the substance-related survey items.  
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While the number of cases with discrepant data were small compared to the larger sample 
(e.g., 3-7 cases per comparison), these data highlights that measuring frequency of alcohol and 
other drug use can be vulnerable to under-reporting or misreporting likely due to different levels 
of data protection and social desirability bias as well as other factors that are unpredictable based 
on this study. 
Identifying Alcohol and/or Other Drug Use Related Problems 
The present study examined the concurrent validity of the ASSIST-3 in comparison to the 
CAGE, T-ACE, and CAGE-DRUG. The optimal cut-points on the ASSIST-3 for detecting 
alcohol-related problems on the CAGE/T-ACE and for detecting illicit drug use-related problems 
on the CAGE-DRUG were 1 and 2, respectively. The ASSIST-3 was found to have acceptable 
sensitivity and specificity to detect alcohol-related problems in both males and females. The 
ASSIST-3 had good sensitivity but poor specificity for detecting illicit drug use-related problems 
in males, and the ASSIST-3 had acceptable sensitivity but poor specificity for detecting drug 
use-related problems in females.  
The present study also compared positive scores for problematic substance use on the 
CAHS (i.e., CAGE, T-ACE, and CAGE-DRUG) by CARA (i.e., ASSIST-3). In general, both 
males and females were more likely to score positive for alcohol-related problems on the CAHS 
compared to the CARA. These results were in the predicted direction. While females were more 
likely to score positive for illicit drug use-related problems on the CAHS, males were more 
likely to score positive on the CARA. 
The existent literature supports the usefulness of screening for both alcohol and drug use 
disorders and their antecedents in primary care (Pilowsky & Wu, 2012; USPSTF, 2018; 
USPSTF, 2020), and the present study offers insight on the performance of a modified ASSIST 
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to screen for substance use-related problems. While sensitivity, specificity, PPVs, and NPVs 
were mixed, the ASSIST-3 could prove useful by identifying individuals with current alcohol 
and/or drug use and problems. In contrast to the CAGE, T-ACE, and CAGE-DRUG, the 
ASSIST-3 inquiries about specific substances and assesses for current problems. It is much 
briefer and easier to score than the full ASSIST and has the potential to lead to actionable results 
based on the scores, such that individuals who score positive need an assessment for 
treatment. However, additional refinement and validation against alternative criterion measures 
(e.g., the full ASSIST; AUDIT, CIDI; TAPS Tool; DAST; DUDIT; Inventory of Drug Use 
Consequences (InDUC) (Tonigan & Miller, 2002)) will be important before it can be broadly 
recommended as a screener for substance use-related problems. 
For example, the ASSIST-3, in contrast to the CAGE, T-ACE, and CAGE-DRUG and in 
keeping with the format of the ASSIST, has three items for each substance and an ordinal 
response format rather than a binary (yes/no). Based on previous literature the ASSIST-3 
questions were consolidated (McPherson & Hersch, 2000; Tiet et al., 2008; Tiet et al., 2015) and 
each category of drug (e.g., marijuana, cocaine, heroin) was assessed as a combined question, 
with the final score (i.e., for illicit drugs) based on the highest value for each question. This 
format as opposed to dichotomous (yes or no) responses provides information about the specific 
substances used and severity of problems to guide clinical actions. However, this format likely 
limited the sensitivity and specificity of the ASSIST-3.  
Similar to Steinbauer and colleagues (1998), normal cut-points were used for the CAGE 
(2), T-ACE (2), and CAGE-DRUG (1) questionnaires. Using different cut-points for the 
reference standards could have also impacted results. For example, while the Consensus Panel 
recommends that the primary care clinicians lower the threshold to one positive answer to cast a 
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wider net and identify more patients who may have substance abuse disorders (Center for 
Substance Abuse Treatment, 1997), the present study included a unique sample of individuals 
who met criteria for heavy/problem substance use. Lowering, or rising the threshold cut-points 
may have led to an underestimation of CAGE sensitivity but would have likely excluded a large 
number of individuals and limit the ability to draw some comparisons between the CAGE, T-
ACE, CAGE-DRUG and ASSIST-3. 
This is first study to examine the concurrent validity of a modified ASSIST focused 
exclusively on problems. While the ASSIST-3 was likely a better assessment of current 
substance use-related problems compared to the CAGE, T-ACE, CAGE-DRUG, the present 
study did not provide additional criterion measures to compare. Further, there is limited ability to 
draw comparisons with other instruments that screen for substance use-related problems, because 
only the ASSIST, ASSIST-Lite, and the TAPS Tool (a modified version of the ASSIST-Lite) 
provide substance-specific results. 
In comparison to the TAPS Tool (Schwartz et al., 2017), the ASSIST-3 underperformed. 
The TAPS Tools, compared to the WHO ASSIST, had favorable sensitivity and specificity at a 
cut-point of 2 to detect high risk use of tobacco, alcohol, marijuana, stimulants (prescription and 
cocaine/methamphetamine combined) and opioids (prescription opioids and heroin combined), 
but its sensitivity was unacceptably low in detecting moderate risk use of stimulants (cocaine, 
prescription stimulants) opioids (heroin, prescription opioids), and sedatives at a cut-point of 1. 
While Schwartz and colleagues (2017) conducted their research anonymously, participants were 
included all primary care patients while the present study looked at a unique higher risk 
subgroup that enrolled in a RCT. Also, the TAPS Tool’s items mapped onto the WHO ASSIST 
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classifications. These factors likely contributed to the differences in sensitivity and specificity 
between the ASSIST-3 and TAPS Tool. 
It is possible that the accuracy of the ASSIST-3 also reflects differences between the 
timeframe of the reference standard measure and the ASSIST-3. The ASSIST-3 screens for 
problems in the past 3 months (vs. lifetime with the CAGE, T-ACE, and CAGE-DRUG). As a 
result, the ASSIST-3 could fail to identify individuals who had problem use in the past (e.g., 
concern expressed by friends or relatives, and failed attempts to control, cut down, or stop using) 
that had not continued into the most recent 3-month period. However, by focusing on current 
use, the ASSIST-3 has the potential to identify individuals who are most in need of clinical 
intervention, which is important in primary care settings. In contrast, participants who did not 
use the substance in the past 3 months would have a zero score on the ASSIST-3.  
This is also the first study to compare an anonymous versus confidential self-
administered computerized screening tool. Endorsement of “problem use” for alcohol and other 
drug use was higher on the CAHS compared to the CARA. One likely reason for this is finding 
is that participants are more reluctant to disclose substance use-related problems in a confidential 
vs. anonymous survey. However, and like mentioned before, another likely reason for this 
finding is that participants who reported lifetime substance use denied used in the past 3 months 
would not be identified by the ASSIST-3. 
Interestingly, and in contrast with previous research (Kypri et al., 2005), a greater 
proportion of females screened positive for at-risk alcohol use relative to males. The ASSIST-3 
also performed best when compared to the T-ACE for alcohol (AUC = 0.76). One likely reason 
for this finding is that the present study had a larger sample of females compared to males. The 
present study also used a modified version of the T-ACE (by assigning only 1 point to the 
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Tolerance question). Present study results concerning alcohol-related problems in women are 
similar to a cross-sectional study examining prevalence of symptoms alcohol abuse (McQuade et 
al., 2000) in a hospital-based outpatient clinic. The authors, who also modified the T-ACE by 
assigning only 1 point to the Tolerance question, found that the T-ACE was more effective than 
either the CAGE or the AUDIT in identifying patients who meet diagnostic criteria (sensitivity) 
and distinguishing patients who do not meet criteria (specificity). One important limitation of this 
finding, however, is that these results cannot compare directly to clinic data.  
While males were more like to score positive on the ASSIST-3 vs. the CAGE-DRUG, the 
ASSIST-3 outperformed the CAGE-DRUG in males compared to females. Research shows that 
dependence on or harmful use of illicit drugs is generally higher in men (National Institute on 
Drug Abuse [NIDA], 2020) compared to women, though, women are at greater risk for a variety 
of medical and psychosocial consequences (Polak et al., 2015). However, research is limited and 
mixed on gender differences in screening for drug use and related problems in primary care. The 
single-item screen (How many times in the past year have you used an illegal drug or used a 
prescription medication for non-medical reasons?) developed by Smith and colleagues (2010) 
was found to be less specific for the detection of a current drug use disorder in men compared to 
females, but the difference was small. The Substance Use Brief Screen (SUBS), which screens 
for all clinically relevant classes of substances (tobacco, alcohol, illicit drugs, prescription drugs 
used nonmedically), had statistically significant lower sensitivity and higher specificity among 
females for detecting unhealthy use of any drug (McNeely et al., 2015a). Future studies should 
examine how well screening tools perform by gender, especially tools screening for illicit drug-
use related problems. 
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The USPSTF currently recommends screening for drug use in primary care, and the 
USPSTF review found no evidence addressing harm from drug screening. Continuing to screen 
in primary care is important as it reduces stigma and invites substance use to be viewed as an 
important and treatable health problem. Notwithstanding, any screening tool assessing for risk 
associated with unhealthy alcohol or drug use or comorbid conditions only reveal information 
signaling the need for further assessment. Therefore, brief screening tools that inquire about 
recent use of specific substances and goes beyond simple endorsement of use (e.g., TAPS Tool, 
ASSIST-LITE, AUDIT-C) can lead to more actionable results versus tools like the CAGE, T-
ACE, CAGE-DRUG, or single substance screeners such as the AUDIT for alcohol (Bradley et 
al., 2003) that provide less data on problematic use.  
Agreement Between Self-Reported Recent (past 30-day) Other Drug Use and Urinalysis 
Overall prevalence of positive UDS results and endorsement of use on the TLFB 
included: marijuana (30% positive UDS, 33% positive TLFB), cocaine (20% positive UDS, 14% 
positive TLFB), heroin / opiates (20% positive UDS, 24% positive TLFB), opiates (20% positive 
UDS, 20% positive TLFB), benzodiazepines (16% positive UDS, 4% positive TLFB), heroin 
(13% positive UDS, 4% positive TLFB and amphetamines (2% positive UDS, 0.5% positive 
TLFB). The overall concordance between self-reported use on the TLFB and positive UDS 
results ranged from 72% for non-medical opiate use to 97% for non-medical amphetamine use; 
however, non-medical amphetamine use was not highly prevalent and the congruence of self-
report and urine test data can be inflated if drug use is not highly prevalent in a sample (Harrison, 
1997).  
These findings are fairly consistent to those of a systematic review and meta-analysis 
examining the validity of the TLFB for illicit drugs in comparison to biological measures 
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(Hjorthøj et al., 2012). The included studies almost exclusively used urine as a biological 
measure and involved subjects with a diagnosis of alcohol or illicit substance use disorder. The 
authors found that the percent agreement between self-report and biological measures ranged 
from 87.3%-90.9% for marijuana, 79.3%-84.1% for cocaine, and 94.0 for opiates, evidencing the 
validity of the TLFB in detecting illicit substances in populations with substance use disorders. 
Further, Hjorthøj and colleagues (2012) found sensitivity and specificity were 0.60 and 0.42 for 
marijuana, 0.69 and 0.9 for cocaine, 0.88 and 0.96 for amphetamines, and 0.64 and 1.00 for 
opiates. In the present study, sensitivity (0.80) and specificity (0.87) were higher for marijuana, 
and while the sensitivity was much lower for cocaine and opiates in the present study, specificity 
and NPV were high for each drug, highlighting the TLFB’s ability to validly detect true 
negatives.  
The different sensitivity, specificity, and rates of agreement between the present study 
and that of Hjorthøj and colleagues (2012) are likely due to length of recall. In the review by 
Hjorthøj et al., (2012), the length of recall (i.e., the number of days of recall assessed by the 
TLFB) varied in many studies from the actual number of days used for validation with UDS 
samples. For instance, if the potential detection window for a substance in UDS was only five 
days, some studies only used the last five days of TLFB for comparison. However, Hjorthøj and 
colleagues (2012) as well as Rendon et al., (2017) found the agreement rate increased as the 
length of recall increased, suggesting that utilizing the full TLFB increased validity. As such, in 
the present study, the length of recall was the past 30-days regardless of detection window for a 
substance in the UDS.  
Notwithstanding, this may have contributed to the low concordant opiate, heroin / opiate, 
and heroin self-report and urinalysis given the relatively short detection window of opiates (e.g., 
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1-4 days; ASAM, 2017). Present study results are similar to that of Chermack and colleagues 
(2000), who compared self-reports using the Addiction Severity Index (a semi-structured 
interview assessing frequency of drug use (opiates, cocaine) in the past 30 days) (McLellan et al., 
1992) and urinalysis. The authors found conditional k’s (cond. k) for opiates were closer to 
chance agreement (cond. k’s ranging from 0.07 to 0.24), suggesting that urinalysis tests were 
likely unable to identify drug use for a large proportion of the 30-day time interval assessed by 
the ASI. However, Chermack et al., (2000) compared self-reports to urinalysis among patients 
enrolled in methadone treatment, and comparisons across study should be made with caution 
regarding the degree of under-reporting under naturalistic conditions versus research conditions.  
Furthermore, while the present study found overall high concordance across substance, 
nearly all of the concordance in this study was attributable to participants who indicated non-use 
on the TLFB and whose UDS results were negative. The low value of the (cond. k’s) indicates 
that concordance positive rates were poor, with the exception of marijuana and cocaine (cond. k 
> 0.50) and suggests that results were likely influenced by the combination of patient 
underreporting and infrequent urinalysis tests. 
Differences in results could also be related to different study populations. In particular, 
nonmedical use of prescription opioids and heroin is a growing problem in the U.S. (Compton, 
Jones, & Baldwin, 2016), and the stigma associated with opioid use may be more apparent in 
healthcare settings (Olsen & Sharfstein, 2014; Yang et al., 2017). Also, Black individuals in the 
U.S. have been subject to discrimination, and addiction to opioids is seen as a condition largely 
affecting these disadvantaged minorities (Carliner et al., 2016; SAMHSA, 2020b). The present 
study’s sample consisted largely of Blacks (78%), and the intersectionality of race and stigma 
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could have contributed to the low concordant opioid self-report and urinalysis (White et al., 
2014).  
Overall concordance rates in the present study were somewhat lower compared to a 
recent study by Nordeck and colleagues (2020), who examined concordance of self-reported 
substance use using a past 30-day TLFB but compared to oral fluid testing (OFT). The study was 
conducted under research-confidential conditions in a sample of primary care patients. 
Specifically, the authors found overall concordance rates between TLFB and OFT were 94.9% or 
higher for each substance. Other research has also identified lower levels of agreement between 
biological testing and self-report (e.g., Preston et al., 1997; Rendon et al., 2017), and in his 
review of studies investigating treatment and non-treatment samples of drug users, Darke 
(1998) reported that concordance between urine testing and self-report data varied from 71% to 
95%, similar to the present study.  
Unlike the present study, Nordeck and colleagues (2020) conducted the TLFB prior to 
informing participants of the opportunity to provide an OFT, with the aim to prevent biased 
responses, and this may have affected the validity findings (Wish et al., 1997). For 
example, Hamid et al. (1999) demonstrated that agreement between urine test results and self-
report of opiate and cocaine use increased from 58% to 93% when the urine tests were performed 
before the self-report interview. Nordeck and colleagues (2000) also limited TLFB data to the 
time period that aligned with the OFT detection window, which ranged from 1 to 3 days 
depending on the substance. 
Interesting, Nordeck and colleagues (2020) found that marijuana had lower detection on 
OFT than self-report (27.6 % OFT-positive only vs 32.2 % TLFB-positive only), similar to the 
present study (30% UDS-positive only vs. 33 % TLFB-positive only). While it is unclear why 
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participants who self-reported recent marijuana use had a negative UDS, one possible 
explanation could be related to false negative UDS results. Research has also demonstrated that 
for marijuana, adherence (i.e., THC compounds migrating to non-aqueous surfaces such as the 
sides of bottles) may reduce the concentration of the drug in the urine specimen, perhaps below 
positive cut-off levels (Riley, Lu, & Taylor, 2000). It is possible that adherence may have 
occurred. Further, participants may be more willing to disclose marijuana use given its 
increasing prevalence and acceptance among the general public (Hasin, 2018); as a result, their 
use could have been inadvertently misreported.  
In the present study, rates of heroin / opiate use were also higher by self-report (24%) 
compared to UDS (20%), though, the difference was modest. Possible explanations for this 
discrepancy could relate to length of recall or cross-reactivity with other substances as well as 
other factors associated with the UDS detection window (e.g., dosing, metabolism, body mass, 
urine pH, duration of use, drug pharmacokinetics, etc.) (Riley et al., 2000). 
Present study findings were also fairly consistent with those of Neale and Robertson 
(2003), who reported a concordance rate of 85% across multiple substances (e.g., opiates, 
benzodiazepines, methadone and cannabis), and to Cone (2012) who reported a concordance rate 
of 95% for cocaine, but only slightly more than 50% for heroin use. However, in studies by 
Neale and Robertson (2003) and Cone (2012), data were collected via standardized 
questionnaires relating to drug use in the past 3 (Neale & Robertson, 2003) and 7 (Cone, 2012) 
days preceding baseline interview, self-report results were compared to OFT, and samples 
included participants from drug treatment facilities. While the present study included a non-
treatment sample, study eligibility required endorsement of heavy/problem alcohol and/or drug 
use. 
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In general, findings suggest that relying solely on self-report would have missed a 
number of participants with evidence of cocaine, heroin, opiate, benzodiazepine, and 
amphetamine use as indicated by positive UDS results. Conversely, relying solely on UDS 
results would also miss evidence of substance use via self-disclosure (e.g., marijuana; heroin / 
opiates), which might vary markedly depending on the substance (Fendrich et al., 2003). Of note, 
the present study only included those who reported prescription drug misuse by TLFB. UDS 
testing does not discriminate between reasons for prescription drug use, and thus participants 
who did not report prescription drug misuse may be positive for prescription medications. This is 
one likely reason for the stark difference between TLFB-positive only (4%) and UDS-positive 
only benzodiazepine (16%) results.   
Although it is not known what the cause of inconsistencies between patients self-reported 
illicit drug use and UDS was in this study, there are several possible explanations. Self-report 
data of recent illicit drug use can be flawed for numerous reasons including faulty memory 
(Darke, 1998), imprecise knowledge of the amount and purity of the drug, and fear of the 
consequences of admission of drug use despite assurances of confidentiality. Moreover, some 
substances are detectable in biological samples for periods that may exceed the detection 
window for TLFB, potentially leading to the classification of true-negative TLFB reports as false 
negatives. Conversely, some substances are detectable in biological samples only briefly, with 
true-positive TLFB reports being classified as false positives.   
Since these findings compare with the results of similar studies based on urine testing, it 
seems reasonable to argue that TLFB is both a valuable tool for detecting recent drug use and a 
useful independent indicator of the validity and reliability of drug users’ self-report data. That 
said, substance use behavior should ideally be measured by a combination of self-report and 
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biological indicators (Donovan et al., 2012). Also, future research should focus on replicating 
these results in primary care populations as well as further examining the variations in levels of 
concordance and discordance between the drug categories. 
Exploratory Analyses 
There were several differences observed in psychosocial correlates of self-reported 
substance use across each assessment. While there was no specific pattern, the most common 
psychosocial correlate for recent (past 30-day) alcohol use on the CAHS was being from a 
minority group; for the CARA it was being female and having government insurance, and for the 
IARA, it was having >12 years of education. The most common psychosocial correlates for 
recent illicit drug use on the CAHS were being older and endorsing moderate-severe 
psychological distress; on the CARA, they were trouble staying asleep in the past 30 days, being 
older and female, and endorsing moderate-severe psychological distress. On the IARA, only 
being older was the most commonly associated correlate with any recent illicit drug use. Taking 
sleep aids in the past 30 days and having 2+ medical conditions were the most common 
correlates associated with prescription drug misuse on the CAHS; on the CARA, trouble falling 
asleep in the past 30 days, being older age, and having 2+ medical conditions were most 
commonly associated with recent prescription drug misuse, while endorsing symptoms of 
anxiety was the most common correlate associated with prescription drug misuse on the IARA.   
Much of the existing literature focuses on correlates of SUDs in primary care 
populations. While the present sample included heavy alcohol and other drug users, diagnosing 
with a formal instrument was not completed. As a result, the generalizability of present study 
findings to other primary care populations must be made with caution. Further, methodological 
differences (setting, interview mode, contextual effect) complicate the comparison of our results 
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with those from other survey or clinical trial samples. However, discussing present study results 
in the context of the existing literature provides opportunities to inform research in primary care 
patients at-risk for substance use disorders.  
Present study findings are somewhat inconsistent with previous research (John et al., 
2018; Wu et al., 2017). In a primary care sample of past-year substance users, John and 
colleagues (2017) found that individuals who were male, white, less educated, disabled, or not 
married had increased odds of having a single SUD, while participants who were male, ages 26–
34, less educated, and unemployed had increased odds of multiple SUDs compared to one SUD.  
In a similar sample of 2000 adults, younger age (18-25), male sex, and low education were 
associated with increased odds of having a SUD (Wu et al., 2017). These results were despite a 
relatively large distribution of females, older adults, and blacks, similar to the present study. 
However, samples for these studies included primary care patients regardless of substance use 
while the present study included only those with heavy/problem alcohol and/or other drug use. 
The psychosocial characteristic comparison between the present study and the latter findings is 
important, however, since these results provide initial evidence that psychosocial differences 
exist between general primary care populations and heavy/problem substance users in primary 
care, which could impact other clinical outcomes (Rohn et al., 2017). 
Other research has found that SUDs are associated with major medical conditions. For 
example, in a study of participants from a large integrative health care system, patients with 
SUDs had higher prevalence of 19 major health problems, with chronic pain, chronic obstructive 
pulmonary disease, congestive heart failure, and hepatitis C being among the most elevated 
(Bahorik et al., 2017). In another study of patients with co-occurring diabetes and hypertension, 
1.9% of patients also had opioid use disorder, 2.2% had cocaine use disorder, 1.1% had cannabis 
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use disorder, and 8.8% had alcohol use disorder (Winhusen et al., 2019), and in a sample of adult 
patients with high risk diabetes, 48.3% had a comorbid SUD (Wu et al., 2018). Although these 
studies used data that were based on electronic health record (EHR) documented diagnoses that 
were provider identified, rather than comprehensively screened for or assessed. EHR data can be 
influenced by biases (e.g., misclassification, severity of medical conditions, provider specialty), 
and the recency of EHR-based diagnoses cannot be precisely defined (Wu et al., 2013).  
Largely consistent with present study findings, previous research by members of our 
research team found present study-RCT consenters reported experiencing a larger number of 
psychosocial and medical comorbidities than non-consenters. In particular, older age, being 
unemployed or on disability, endorsing problems with anxiety and depression, and trouble falling 
asleep (past 30 days) were all associated with consenting to participate in the SBIRT RCT. 
Participants with ≤ high school degree, as well as those who were employed or retired was 
associated with declining study participation (Kelpin et al., 2018). In general, these patterns 
could be a result of SUD-related health problems requiring treatment (Pilowsky & Wu, 2012), 
and that participants were more ready to identify they are in need of services due to their 
comorbidities. Interestingly, recent research has also found that nontreatment seekers for alcohol 
use (compared to treatment-seekers), were more ethnically diverse, less educated, single, and 
working part-time or unemployed (p’s < 0.05) (Haass-Koffler et al., 2020). 
Comorbid substance use and mental health disorders have been shown to be associated 
with greater substance use severity (Gorfinkel et al., 2020; Grant et al., 2016). Interestingly, 
screening for substance use can also lead to the potential identification of these comorbid 
disorders. For example, Khan and colleagues (2020) found that within a sample of Veterans 
Health Administration patients, an AUDIT score of 20 or higher (vs <8, the reference) was 
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associated with symptoms of depression and anxiety. This highlights how alcohol screening 
alone has potential to convey substantial information regarding the likely presence of alcohol-
clustering conditions, particularly for depression and anxiety, and inform decisions about 
additional assessment. Taken together, these findings reinforce the importance of promoting the 
integration of evidence-based mental health and substance use screening in routine medical 
settings, which currently are not used consistently (Bazzi & Satz, 2018; Edelman, & Tetrault, 
2019).   
It is also important to note that patients with SUDs may face stigma or other barriers to 
engaging with primary care (van Boekel et al., 2013), which can contribute to disparities in 
preventive care (Hirsh et al., 2020; Hoggatt et al., 2019). Despite considerable study on 
disparities in health care experiences by race/ethnicity and gender (Jones et al., 2016), continuing 
to explore other correlates of substance use and identify disparities is important for ensuring 
health care equity for all vulnerable groups. Furthermore, research on the driving forces 
contributing to these disparities is needed. 
Study Implications and Applications 
 
This study has a number of important implications. First, it provides benchmark data on 
comparing computerized anonymous and confidential surveys to a confidential, interviewer-
administered assessment across alcohol and illicit drug use as well as prescription drug misuse. 
Overall, participants self-reported higher rates of substance use on the computerized, anonymous 
health survey (CAHS), including any recent (past 30-day) alcohol use, binge drinking, and 
problems associated with alcohol use. While rates of any recent (past 30-day) illicit drug use 
were higher on the CARA, this tool provided more in-depth assessment of use across several 
classes of illicit and prescription drugs and included a window of past 3-months. For quantity-
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frequency of alcohol use as well as frequency of illicit drug and prescription drug misuse, self-
reported use was highest on the IARA (i.e., the TLFB). While the CAHS had good sensitivity, 
specificity, acceptable agreement and reliability for identifying alcohol and illicit drug use and 
associated problems, for substances that are less frequently encountered in primary care, 
sensitivity and specificity estimates were lower and less precise. Nevertheless, research suggests 
that increased reporting of substance use is a sign of improved validity in the methodology since 
these behaviors are typically underreported (Beck et al., 2014). 
Thus, while screening for recent alcohol and other drug use by the CAHS provides the 
most parsimonious method to screen for substance use and related behaviors in primary care, 
collecting the most accurate data on the substance(s) can be improved with additional follow-up 
using a confidential TLFB. This approach will help provide sufficient information to inform 
clinical practice and looks separately at difference substances (Gryczynski et al., 2017; Smith et 
al., 20010; Saitz et al., 2014b; Tiet et al., 2015), and follows the current recommended guidelines 
which suggest starting with brief screening (1-2 questions) with follow-up on cases where 
substance use was detected to collect diagnostic data (Sayre et al., 2020). It’s important to note 
that the CAHS utilized CIAS and was avatar guided. This practice is becoming more relevant 
within the larger alcohol-SBIRT literature where several trials embed alcohol questions in a 
broader health and lifestyle assessment survey to reduce social stigma of substance use and 
tendency to under-report use (Blow et al., 2006; Cucciare et al., 2013; Dimeff et al., 2000; 
Haskins et al., 2017; Montag et al., 2015; Neumann, et al., 2006; Ondersma et al., 2016; Tzilos et 
al., 2011). Anonymous surveys should take this into consideration for future research and clinical 
applications.  
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Studies have shown that allowing people to answer questionnaires completely 
anonymously yields more reports of socially inappropriate attitudes, beliefs, and behaviors, 
however, anonymous research designs do not allow for longitudinal follow-up with linking of 
data across observations. Another challenge implementing anonymous surveys is connecting 
patient data to their medical record. Therefore, it may be impractical to try and ensure absolute 
anonymity, especially when the goal is translation to clinical practice. As such, one way to utilize 
an anonymous survey limit any privacy risk of data is by ensuring confidentiality and controlling 
access to the data (Beatty et al., 2014; Wayal et al., 2018).   
This study also further documents and strengthens the evidence supporting the construct 
validity of the TLFB. While utilizing a CAHS followed by an interviewer-administered TLFB 
may be a useful way to capture sensitive and accurate data about substance use in primary care 
from a research perspective (Bobak et al., 2004; Rehm et al., 2001; Russell et al., 2004), it may 
not be the best clinical practice. For example, length of administration and other limitations (e.g., 
availability of clinic and research team resources) are major disadvantages of the TLFB. 
However, if the goal of a research study lies in comparing two groups in their volume of alcohol 
consumption, such level of detail may not be accurately captured by a CAHS. Therefore, 
continuing to utilize the TLFB to capture accurate data related to quantity and frequency remains 
best research practice. 
Additionally, present study findings are similar with others comparing self-report with 
urine testing. While the TLFB can be a useful independent indicator of the validity and reliability 
of drug users’ self-report data, the present study found that the TLFB and UDS showed disparate 
detection of different substances. These findings suggest that using a combination of self-report 
and biological indicators may improve detection of drug use (Donovan et al., 2012).   
  
 
135 
 
 
The economic implications of present study findings warrant consideration. Research 
shows that the cost of substance abuse treatment is substantial (Florence et al., 2018), and the 
presence of a substance use disorder often doubles the odds that a person will develop another 
chronic and costly medical illness (Scott et al., 2016). Further, recent examination of healthcare 
spending shows that individuals who have comorbid mental health and substance use disorders 
account for almost half of the annual total healthcare costs (Davenport et al., 2020). Primary care 
settings have been at the forefront of delivering substance use disorder services in mainstream 
health care, resulting in significant health-care savings (Babor et al., 2007; HHS, 2016). While 
primary care providers may utilize brief screeners for alcohol and other drug use, interviewer-
administered screening approaches can be challenging to implement because they require staff 
time and training, and the cost of using a skilled interviewer for the TLFB is considerable 
(Maisto et al., 2008). Moreover, implementation cost estimates for screening in primary care 
indicate that other key cost drivers are service support costs for screening (Zarkin et al., 2015). 
This has prompted the development of alternative administration methods, in particular, 
computerized methods (Delker et al., 2016; McNeely et al., 2016a; McNeely et al., 2016b). 
Embedding standardized, validated clinical assessments of substance use, including the TLFB 
(Martin-Willett et al., 2020), into self-administered electronic platforms may not only facilitate 
the assessment of substance use as part of the routine clinical workflow and may also be cost-
effective (Gryczynski et al., 2017; Tai et al., 2012). Further, because the TLFB produces a valid 
description of patterns and amounts of illicit substance use, it holds practical cost advantages 
over the use of biological measures such as samples of urine, blood, or hair.  
Lastly, several studies have focused on computerized modes of administration to 
counteract substance use-related stigma and address confidentiality concerns, demonstrating that 
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computerized self-administered instruments generate higher rates of self-reported substance use 
(Beck et al., 2014; Lessler et al., 2000; McNeely et al., 2016a; NIMH, 2008; Perlis et al., 2004; 
van Griensven et al., 2006), consistent with the present study. While attitudes within the clinical 
treatment system of individuals with substance use disorders are shifting, sociocultural factors 
associated with problematic drug-using populations, such as fear, lack of information and 
education, general physical and mental health problems, homelessness, and incarceration further 
stigmatizes people who use drugs, making it more difficult to engage people in health care and 
other services (American Public Health Association [APHA], 2013). Consequently, focusing on 
computerized screening and assessment will likely decrease stigma associated with alcohol and 
other drug use, enable widespread reach and scalability of evidence-based practices, and provide 
a more equitable distribution of health resources and existing racial and class-based inequities 
(Marsch et al., 2020).  
Addressing the Dual Challenges of Substance Use Disorders and COVID-19.  
The U.S. is currently facing an opioid epidemic (SAMHSA, 2019), and the Coronavirus 
disease 2019 (COVID-19) pandemic is projected to be the largest mass casualty event in U.S. 
history. The COVID-19 pandemic is having a wide range of negative impacts on people affected 
by a variety of health conditions, namely those with mental health and substance use disorders. 
Recent analysis of nationwide surveillance data found that drug overdoses rose by 18% in 
March, 29% in April, and 42 percent in May compared to the same months in 2019 (ODMAP; 
Alter & Yeager, 2020). This increase in opioid overdoses has been observed locally as well, 
where the total number of opioid overdose visits at VCUHS increased from 102 to 227 in the 
first four months of the COVID-19 pandemic compared to the same time period in 2019 
(Ochalek et al., 2020). Additionally, a recent study examining alcohol consumption in the U.S. 
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during COVID-19 found an increase in adult consumption by 14% between spring of 2019 and 
spring of 2020. Also, heavy drinking episodes by women increased by 41% (Pollard et al., 2020). 
Further, symptoms of anxiety and depression increased considerably during April-June of 
2020, compared with the same period in 2019 (Czeisler et al., 2020). Again, this reinforces the 
importance of promoting evidence-based screening in routine medical care. Fortunately, the 
Centers for Medicare and Medicaid Serves have issued sweeping changes to make telehealth 
services easier to access as the COVID-19 crisis has made routine care more difficult to deliver. 
With the increase in health and telehealth communication strategies (Pierce et al., 2020), 
incorporating clinically meaningful screening tools into telehealth systems will likely help 
address these conditions associated with the COVID-19 pandemic. 
Study Strengths, Limitations, and Future Directions 
Strengths. The present study had a number of strengths. First, whenever possible, the 
CAHS used reliable and valid measures to assess for problems in each domain of interest. To 
avoid practitioner bias, every patient was asked the same set of questions (Svikis & Reid-
Quiñones, 2003). Further, the format and delivery of the CAHS survey promoted patient 
anonymity and included many items irrelevant to substance use in an effort to mask the true 
purpose of the screener as well as to reduce the stigma associated with substance use. Also, the 
use of the self-administered electronic screener provided a comprehensive, reliable, private, and 
less biased approach to collecting data. Moreover, the Computerized Intervention Authoring 
System (CIAS) format was engaging and less intimidating than traditional health screeners. 
Lastly, the CAHS and CARA included branching logic that streamlined the screening tool and 
all answers were recorded by simply tapping responses from a list. This helped cut down on the 
overall time to complete the screener and limited missing data. 
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Second, the study included random assignment and produced approximately equal group 
assignments. 
Third, the different level of data protection as well as method of administration across the 
three substance abuse assessment measures allowed for a novel comparison within a primary 
care population. The present study provides benchmark data on frequency of other drug use, 
adding to the literature suggesting the TLFB is a useful tool for assessing other drug use 
frequency patterns.  
Fourth, the study included biological measures of substance use (e.g., urine drug screen), 
offering confirmatory measures of self-report data. Further, the study emphasized that the 
research study was independent of the patient’s treatment and would not be shared with VCUHS 
staff, supporting participant confidentiality and overall comfort with study participation. 
Limitations: Despite these strengths, the study also had a number of limitations. First, 
sampling was only from on primary care clinic in Eastern U.S. and included participants who 
only spoke English language. The clinic also serves predominately low-income, ethnic 
minorities. Hence, findings may not generalize to other parts of the U.S., to other countries, or be 
representative of patients seen in all primary care settings. Additionally, while RCT eligibility 
had few exclusion criteria, the present study sample only included those who met criteria for 
heavy/problem alcohol and/or drug use. Moreover, of those who met RCT criteria only half 
consented, and differences were found between those who did and did not consent to the RCT 
(Kelpin et al., 2018). For example, consenters were more likely than nonconsenters to report 
recent and more frequent drug use, prescription drug misuse and binge drinking; consenters also 
reported a greater number and more severe psychosocial and mental health problems than those 
who declined study participation. Taken together, the present study’s sample is less 
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representative of not only general primary care populations but also less representative of the 
overall clinical population as well.  
Second, the extent to which the instruments would perform equally well when delivered 
by primary care staff and entered into the patient’s medical record is not known. It should also be 
noted that methodological differences including setting, interview mode, and contextual effects 
make comparisons difficult between other healthcare settings. 
Third, while self-administered help promote disclosure of substance use, this format may 
not be feasible in all practice settings. Self-administration on a tablet could be problematic in 
patients with low literacy or poor vision, though the audio guidance can help to address these 
barriers. Elderly patients may also have difficulty using a tablet. Further, tablet computers in 
primary care settings would require considerations for workflow, security, and hygiene. 
Lastly, despite efforts to mask the primary purpose of the screener, it relied solely on 
self-report information. Also, this study relied on secondary analysis of existing data and was 
limited by available items. Additionally, participants completed the computerized health survey 
prior to being offered research participation and there was a consistent order effect, which may 
have resulted in practical issues (e.g., cumulative time for research at one visit) and may have 
influenced response rates. 
Future Directions: The present study expanded on the current research supporting 
screening and assessment for substance use in primary care settings. However, further 
examination of the stability and consistency of self-report of substance use is important. Future 
research can further evaluate different versions of standardized measures across different levels 
of data protection and confirm their accuracy in identifying unhealthy alcohol and other drug use 
in various populations. Future research should also focus on the optimal screening interval and 
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assessment window for detecting unhealthy alcohol and drug use. The accuracy of screening 
tools for detecting nonmedical use of prescription drugs, including opioids, should also be 
expanded upon. Going forward, research on how to best integrate multiple substance components 
into primary care-based screening assessments and interventions for problem substance use is 
also needed.  
More evidence on important clinical outcomes is also needed, such as longer-term 
morbidity, mortality, health care utilization, and social and legal outcomes. Further, trials 
designed to report subgroup effects in diverse populations (e.g., by age, race/ethnicity, sexual 
identity, or baseline severity) will be important. In particular, research focused on gender-
specific screening will be advantageous, especially since research has demonstrated women have 
increased vulnerability for adverse medical and social consequences associated with substance 
use (e.g., Polak et al., 2015). Research also suggests that women are more vulnerable to social 
desirability bias than men (Delker et al., 2016; Durant et al., 2002), as women may be more 
concerned about judgment or about reporting substance use in a face-to-face interviews due to 
fear of losing custody of their children. Also, continued research on comorbid mental health and 
substance abuse disorders will be beneficial. A recent study secondary analysis of the same 
sample as the present study found that patients who consented to the RCT reported a greater 
number and more severe psychosocial and mental health problems than those who declined study 
participation, which has important implications regarding generalizability to other clinic samples 
(Kelpin et al., 2018). 
Future research should also focus on differences of substance use rates at follow-up 
intervals. Historically, collection of comprehensive baseline assessment data from experimental 
as well as control group participants has been integral to RCT research. Studies that have begun 
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to dismantle the components of clinical trial research have found that simply participating in a 
baseline assessment of substance use behaviors can produce positive changes in subsequent 
quantity and frequency of alcohol and other drug use. This is important as it highlights the 
importance of more systematically examining the extent to which simple attention to the problem 
of heavy/problem substance use may be therapeutic. This most parsimonious interpretation can 
explain much of the existing data and raises the possibility that remarkably simple approaches 
might be efficacious.  
Finally, future research should build on present study findings and continue to replicate 
these findings in primary care samples and other samples and across additional substance use 
outcomes. Also, utilizing a test-retest approach, in which the same instrument(s) are used in both 
shorter and longer over-lapping timeframes to determine whether the pattern of use is shown to 
be similar across measures will be important. This will be especially helpful to support their 
reliability for longitudinal examination of self-reported alcohol and other drug use. 
Moreover, while computerized versions of TLFB measures have been developed (Rueger 
et al., 2012; Sobell et al., 1996) little research exists on how these measures compare to 
interviewer-administered TLFB or other ACASI procedures; future studies in this area would 
offer useful information. Further, the comparative performance of the TLFB and ACASI to 
measure more complex aspects of substance use could be studied.  
Conclusions 
To our knowledge, this study represents the first examination of computerized 
anonymous and confidential surveys to a confidential, interviewer-administered assessment 
across alcohol and illicit drug use as well as prescription drug misuse. Having information on the 
most parsimonious methods to collect the most sensitive and accurate data possible about 
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substance use and related behaviors is essential for ensuring the quality and safety of medical 
care and has the potential to improve medical and psychosocial outcomes. This study supports 
the use of an anonymous computerized health survey in screening primary care patients for 
problem substance use. It may also detect alcohol and other drug use problems. However, 
additional assessment via confidential, interviewer-administered TLFB is needed to capture 
specific details of use. With advancements in technology, incorporating a confidential, 
computerized version of the TLFB has the potential to ease barriers and improve cost-
effectiveness to incorporating substance screening into busy clinical environments. The United 
States Preventive Services Task Force (USPSTF) recommends screening for unhealthy alcohol 
use and recently has recommended screening for unhealthy drug use, in primary care settings in 
adults 18 years or older. Continued focus on best practices to identify substance use and related 
problems should remain a core clinical quality measure for primary care settings. 
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Appendix A 
 
TIMELINE FOLLOWBACK CALENDAR: 2018 
 
 
 
 
 
 
 
 
 
 
2018 SUN MON TUES WED THURS FRI SAT 
  1 
New Year’s
 2 3 4 5 6 
    J 7 8 9 10 11 12 13 
A 14
 
 15
 M. Luther King
 16 17 18 19 20 
N 21 22
 
 23 24 25 26 27 
 28 29 30 31 1 2 3 
F 4 5 6 7 8 9 10 
E 11 12 13 14
 Valentine
 15 16 17 
B 18
 
 19
 Pres. Day
 20 21
 Ash Wednesday
 22 23 24 
 25 26 27 28 1 2 3 
M 4 5 6 7 8 9 10 
A 11 12 13 14 15 16 17
 St. Patrick
 
R 18
 
 19 20 21 22 23 24 
 25 26 27 28 29 30 31 
A 1 2 3
 Passover
 4 5 6
 Good Friday
 7 
P 8 
Easter
 9 10 11 12 13  14 
R 15  16 17 18 19 20 21 
 22 23 24 25 26 27 28 
 29 30 1 2 3 4 5 
M 6 7 8 9 10 11 12 
A 13
 Mother’s Day
 14 15 16 17 18 19 
Y 20 21 
 
 22 23 24 25 26 
 27 28 
Memorial Day
 29 30 31   
Complete the Following 
Start Date (Day 1):         End Date (yesterday):     
MO                  DY                  YR             MO                  DY                  YR  
 
One 5 oz glass of 
regular (12%) 
wine 
1 ½ oz of hard liquor 
(e.g. rum, vodka, 
whiskey) 
1 mixed or straight 
drink with 1 ½ oz 
hard liquor  
1 Standard Drink is Equal to 
One 12 oz 
can/bottle 
of beer 
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2018 SUN MON TUES WED THURS FRI SAT 
      1 2 
    J 3 4 5 6 7 8 9 
U 10 11 12 13 14 15 16 
N 17
 Father’s Day
 18 19 20 21 22 23 
 24 25 26 27 28 29 30 
J 1  2 3 4 
Independence Day
 5 6 7 
U 8 9 10 11 12 13 14 
L 15 16 17 18 19 20 21 
 22 23 24 25 26 27 28 
 29 30 31 1 2 3 4 
A 5 6 7 8 9 10 11 
U 12 13 14 15 16 17 18 
G 19 20
 
 21 22 23 24 25 
 26 27 28 29 30 31 1 
S 2 3
 Labor Day
 4 5 6 7 8 
E 9 10 11 12 13
 Rosh Hashanah
 14 15 
P 16 17 18  19 20 21 22 
Yom Kippur
 
 23 24 25 26 27
 
 28 29 
 30 1 2 3 4 5 6 
O 7 8 
Columbus Day
 9 10 11 12 13 
C 14 15 16 17 18 19 20 
T 21 22 23 24 25 26 27 
 28 29 30 31 
Halloween
 1 2 3 
N 4 5  6
 Election Day
 7 8 9 10 
O 11  12 
Veterans Day Obsv
 13 14 15 16 17 
V 18
 
 19 20 21 22
Thanksgiving
 23 24 
 25 26 27 28 29 30 1 
D 2 3 4 5 
Hanukkah
 6 7 8 
E 9 10  11 12 13 14 15 
C 16 17 18 19 20 21 22 
 23 24 25 
Christmas
 26 27
 
 28 29 
 30 31
 New Yea’s Eve
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